<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00209274</url>
  </required_header>
  <id_info>
    <org_study_id>Protocol #0401</org_study_id>
    <secondary_id>Protocol #0401</secondary_id>
    <nct_id>NCT00209274</nct_id>
  </id_info>
  <brief_title>Pivotal Study of a Percutaneous Mitral Valve Repair System</brief_title>
  <acronym>EVERESTIIRCT</acronym>
  <official_title>Pivotal Study: A Study of the Evalve Cardiovascular Valve Repair System - Endovascular Valve Edge-to-Edge REpair STudy (EVERESTIIRCT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Evalve</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Evalve</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      EVEREST II Randomized Controlled Trial (RCT) is a prospective, multi-center, randomized study
      of the MitraClip® System in the treatment of mitral valve regurgitation, randomizing patients
      to MitraClip or mitral valve surgery. The EVEREST II High Risk Registry (HRR) study is a
      prospective multi-center study of the MitraClip System for the treatment of mitral valve
      regurgitation in high surgical risk patients. Enrollment in the RCT and HRR is closed. A
      continued access prospective, multi-center study (REALISM) of the MitraClip System in a
      surgical population (non-high risk arm) and a high surgical risk population (high risk arm)
      is ongoing. Enrollment in the non-high risk arm of REALISM is closed. Enrollment in the high
      risk arm of REALISM is ongoing. Patients enrolled in EVEREST II undergo 30-day, 6-month,
      12-month, 18-month and 24-month clinical and echocardiographic follow-up, and then annually
      for 5 years.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prospective, multi-center, randomized study of the safety and effectiveness of an
      endovascular approach to the treatment of mitral valve regurgitation using the Evalve
      Cardiovascular Valve Repair System (MitraClip® implant).

      A minimum of 279 evaluable patients randomized 2:1 to MitraClip or mitral valve surgery,
      respectively, are required to test the primary safety and effectiveness endpoints of the RCT.
      Enrollment in the RCT is now complete. 60 roll-in patients were enrolled under EVEREST II
      RCT.

      38 clinical sites throughout the US and Canada have participated in the RCT and HRR. 37 US
      sites are participating in REALISM.

      The RCT is powered to test the hypothesis MitraClip has both superiority of safety and
      non-inferiority of effectiveness compared to mitral valve repair or replacement surgery. The
      HRR is powered to show lower mortality at 30 days with the MitraClip than predicted surgical
      mortality.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2005</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">November 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Major Adverse Events (MAE)</measure>
    <time_frame>30 days</time_frame>
    <description>Defined as a combined clinical endpoint of death, myocardial infarction, reoperation for failed surgical repair or replacement, nonelective cardiovascular surgery for adverse events, stroke, renal failure, deep wound infection, ventilation for greater than 48 hours, gastrointestinal (GI) complication requiring surgery, new onset of permanent atrial fibrillation, septicemia, and transfusion of 2 or more units of blood.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Freedom From Surgery for Valve Dysfunction, Death, and Moderate to Severe (3+) or Severe (4+) Mitral Regurgitation (MR).</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Freedom From All-Cause Mortality</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom From All-Cause Mortality</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom From All-Cause Mortality</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom From All-Cause Mortality</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom From All-Cause Mortality</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Freedom From Surgery for Valve Dysfunction, Death, and Moderate to Severe (3+) or Severe (4+) Mitral Regurgitation.</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Freedom From Surgery for Valve Dysfunction, Death, and Moderate to Severe (3+) or Severe (4+) Mitral Regurgitation (MR).</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Freedom From Surgery for Valve Dysfunction, Death, and Moderate to Severe (3+) or Severe (4+) Mitral Regurgitation (MR) in Intention to Treat Strategy Cohort</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left Ventricular Ejection Fraction (LVEF)</measure>
    <time_frame>At discharge (≤ 14 days following index procedure) or 30 days</time_frame>
    <description>LVEF as determined by the core echo laboratory at 30 days or hospital discharge, whichever is longer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left Ventricular Ejection Fraction (LVEF)</measure>
    <time_frame>12 months</time_frame>
    <description>LVEF as determined by the core echo laboratory.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left Ventricular Ejection Fraction (LVEF)</measure>
    <time_frame>24 months</time_frame>
    <description>LVEF as determined by the core echo laboratory.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left Ventricular Ejection Fraction (LVEF)</measure>
    <time_frame>3 years</time_frame>
    <description>LVEF as determined by the core echo laboratory.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left Ventricular Ejection Fraction (LVEF)</measure>
    <time_frame>4 years</time_frame>
    <description>LVEF as determined by the core echo laboratory.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left Ventricular Ejection Fraction (LVEF)</measure>
    <time_frame>5 years</time_frame>
    <description>LVEF as determined by the core echo laboratory.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left Ventricular Status- Left Ventricular End-diastolic Volume (LVEDV), Left Ventricular End-systolic Volume (LVESV)</measure>
    <time_frame>30 days</time_frame>
    <description>Left Ventricular Status includes Left ventricular (LV) end-diastolic volume (LVEDV), LV end-systolic volume (LVESV), as determined by the core echo laboratory at 30 days or hospital discharge, whichever is longer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left Ventricular Status- LVEDV, LVESV</measure>
    <time_frame>12 months</time_frame>
    <description>Left Ventricular Status includes LV end-diastolic volume (LVEDV), LV end-systolic volume (LVESV),as determined by the core echo laboratory at 12 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left Ventricular Status- LVEDV, LVESV</measure>
    <time_frame>24 months</time_frame>
    <description>Left Ventricular Status includes LV end-diastolic volume (LVEDV), LV end-systolic volume (LVESV), as determined by the core echo laboratory at 24 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left Ventricular Status- LVEDV, LVESV</measure>
    <time_frame>3 years</time_frame>
    <description>Left Ventricular Status includes LV end-diastolic volume (LVEDV), LV end-systolic volume (LVESV), as determined by the core echo laboratory at 3 years.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left Ventricular Status- LVEDV, LVESV</measure>
    <time_frame>4 years</time_frame>
    <description>Left Ventricular Status includes LV end-diastolic volume (LVEDV), LV end-systolic volume (LVESV), as determined by the core echo laboratory at 4 years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left Ventricular Status- LVEDV, LVESV</measure>
    <time_frame>5 years</time_frame>
    <description>Left Ventricular Status includes LV end-diastolic volume (LVEDV), LV end-systolic volume (LVESV), as determined by the core echo laboratory at 5 years.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left Ventricular Internal Dimension Systole (LVIDs)</measure>
    <time_frame>30 days</time_frame>
    <description>Left Ventricular internal dimension systole (LVIDs) as determined by the core echo laboratory.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left Ventricular Internal Dimension Systole (LVIDs)</measure>
    <time_frame>12 months</time_frame>
    <description>Left Ventricular internal dimension systole (LVIDs) as determined by the core echo laboratory.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left Ventricular Internal Dimension Systole (LVIDs)</measure>
    <time_frame>2 years</time_frame>
    <description>Left Ventricular internal dimension systole (LVIDs) as determined by the core echo laboratory.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left Ventricular Internal Dimension Systole (LVIDs)</measure>
    <time_frame>3 years</time_frame>
    <description>Left Ventricular internal dimension systole (LVIDs) as determined by the core echo laboratory.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left Ventricular Internal Dimension Systole (LVIDs)</measure>
    <time_frame>4 years</time_frame>
    <description>Left Ventricular internal dimension systole (LVIDs) as determined by the core echo laboratory.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left Ventricular Internal Dimension Systole (LVIDs)</measure>
    <time_frame>5 years</time_frame>
    <description>Left Ventricular internal dimension systole (LVIDs) as determined by the core echo laboratory.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left Ventricular Internal Dimension Diastole (LVIDd)</measure>
    <time_frame>30 days</time_frame>
    <description>Left Ventricular internal dimension diastole (LVIDd) as determined by the core echo laboratory.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left Ventricular Internal Dimension Diastole (LVIDd)</measure>
    <time_frame>12 months</time_frame>
    <description>Left Ventricular internal dimension diastole (LVIDd) as determined by the core echo laboratory at 12 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left Ventricular Internal Dimension Diastole (LVIDd)</measure>
    <time_frame>24 months</time_frame>
    <description>Left Ventricular internal dimension diastole (LVIDd) as determined by the core echo laboratory at 24 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left Ventricular Internal Dimension Diastole (LVIDd)</measure>
    <time_frame>3 years</time_frame>
    <description>Left Ventricular internal dimension diastole (LVIDd) as determined by the core echo laboratory at 3 years.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left Ventricular Internal Dimension Diastole (LVIDd)</measure>
    <time_frame>4 years</time_frame>
    <description>Left Ventricular internal dimension diastole (LVIDd) as determined by the core echo laboratory at 4 years.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left Ventricular Internal Dimension Diastole (LVIDd)</measure>
    <time_frame>5 years</time_frame>
    <description>Left Ventricular internal dimension diastole (LVIDd) as determined by the core echo laboratory at 5 years.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With New York Heart Association (NYHA) Functional Class Cardiac Disease.</measure>
    <time_frame>Baseline</time_frame>
    <description>Class I: Patients with cardiac disease but without resulting limitations of physical activity.
Class II: Patients with cardiac disease resulting in slight limitation of physical activity. Patients are comfortable at rest. Ordinary physical activity results in fatigue, palpitation, dyspnea, or anginal pain.
Class III: Patients with cardiac disease resulting in marked limitation of physical activity. They are comfortable at rest. Less than ordinary physical activity causes fatigue, palpitation dyspnea, or anginal pain.
Class IV: Patients with cardiac disease resulting in inability to carry on any physical activity without discomfort. Symptoms of cardiac insufficiency or of the anginal syndrome may be present even at rest. If any physical activity is undertaken, discomfort is increased.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With New York Heart Association (NYHA) Functional Class Cardiac Disease.</measure>
    <time_frame>30 days</time_frame>
    <description>Class I: Patients with cardiac disease but without resulting limitations of physical activity.
Class II: Patients with cardiac disease resulting in slight limitation of physical activity. Patients are comfortable at rest. Ordinary physical activity results in fatigue, palpitation, dyspnea, or anginal pain.
Class III: Patients with cardiac disease resulting in marked limitation of physical activity. They are comfortable at rest. Less than ordinary physical activity causes fatigue, palpitation dyspnea, or anginal pain.
Class IV: Patients with cardiac disease resulting in inability to carry on any physical activity without discomfort. Symptoms of cardiac insufficiency or of the anginal syndrome may be present even at rest. If any physical activity is undertaken, discomfort is increased.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With New York Heart Association (NYHA) Functional Class Cardiac Disease.</measure>
    <time_frame>12 months</time_frame>
    <description>Class I: Patients with cardiac disease but without resulting limitations of physical activity.
Class II: Patients with cardiac disease resulting in slight limitation of physical activity. Patients are comfortable at rest. Ordinary physical activity results in fatigue, palpitation, dyspnea, or anginal pain.
Class III: Patients with cardiac disease resulting in marked limitation of physical activity. They are comfortable at rest. Less than ordinary physical activity causes fatigue, palpitation dyspnea, or anginal pain.
Class IV: Patients with cardiac disease resulting in inability to carry on any physical activity without discomfort. Symptoms of cardiac insufficiency or of the anginal syndrome may be present even at rest. If any physical activity is undertaken, discomfort is increased.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With New York Heart Association (NYHA) Functional Class Cardiac Disease.</measure>
    <time_frame>24 months</time_frame>
    <description>Class I: Patients with cardiac disease but without resulting limitations of physical activity.
Class II: Patients with cardiac disease resulting in slight limitation of physical activity. Patients are comfortable at rest. Ordinary physical activity results in fatigue, palpitation, dyspnea, or anginal pain.
Class III: Patients with cardiac disease resulting in marked limitation of physical activity. They are comfortable at rest. Less than ordinary physical activity causes fatigue, palpitation dyspnea, or anginal pain.
Class IV: Patients with cardiac disease resulting in inability to carry on any physical activity without discomfort. Symptoms of cardiac insufficiency or of the anginal syndrome may be present even at rest. If any physical activity is undertaken, discomfort is increased.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With New York Heart Association (NYHA) Functional Class Cardiac Disease.</measure>
    <time_frame>3 years</time_frame>
    <description>Class I: Patients with cardiac disease but without resulting limitations of physical activity.
Class II: Patients with cardiac disease resulting in slight limitation of physical activity. Patients are comfortable at rest. Ordinary physical activity results in fatigue, palpitation, dyspnea, or anginal pain.
Class III: Patients with cardiac disease resulting in marked limitation of physical activity. They are comfortable at rest. Less than ordinary physical activity causes fatigue, palpitation dyspnea, or anginal pain.
Class IV: Patients with cardiac disease resulting in inability to carry on any physical activity without discomfort. Symptoms of cardiac insufficiency or of the anginal syndrome may be present even at rest. If any physical activity is undertaken, discomfort is increased.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With New York Heart Association (NYHA) Functional Class Cardiac Disease.</measure>
    <time_frame>4 years</time_frame>
    <description>Class I: Patients with cardiac disease but without resulting limitations of physical activity.
Class II: Patients with cardiac disease resulting in slight limitation of physical activity. Patients are comfortable at rest. Ordinary physical activity results in fatigue, palpitation, dyspnea, or anginal pain.
Class III: Patients with cardiac disease resulting in marked limitation of physical activity. They are comfortable at rest. Less than ordinary physical activity causes fatigue, palpitation dyspnea, or anginal pain.
Class IV: Patients with cardiac disease resulting in inability to carry on any physical activity without discomfort. Symptoms of cardiac insufficiency or of the anginal syndrome may be present even at rest. If any physical activity is undertaken, discomfort is increased.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With New York Heart Association (NYHA) Functional Class Cardiac Disease.</measure>
    <time_frame>5 years</time_frame>
    <description>Class I: Patients with cardiac disease but without resulting limitations of physical activity.
Class II: Patients with cardiac disease resulting in slight limitation of physical activity. Patients are comfortable at rest. Ordinary physical activity results in fatigue, palpitation, dyspnea, or anginal pain.
Class III: Patients with cardiac disease resulting in marked limitation of physical activity. They are comfortable at rest. Less than ordinary physical activity causes fatigue, palpitation dyspnea, or anginal pain.
Class IV: Patients with cardiac disease resulting in inability to carry on any physical activity without discomfort. Symptoms of cardiac insufficiency or of the anginal syndrome may be present even at rest. If any physical activity is undertaken, discomfort is increased.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>New York Heart Association (NYHA) Functional Class Cardiac Disease: NYHA Functional Class III or IV</measure>
    <time_frame>30 days</time_frame>
    <description>Class I: Patients with cardiac disease but without resulting limitations of physical activity.
Class II: Patients with cardiac disease resulting in slight limitation of physical activity. Patients are comfortable at rest. Ordinary physical activity results in fatigue, palpitation, dyspnea, or anginal pain.
Class III: Patients with cardiac disease resulting in marked limitation of physical activity. They are comfortable at rest. Less than ordinary physical activity causes fatigue, palpitation dyspnea, or anginal pain.
Class IV: Patients with cardiac disease resulting in inability to carry on any physical activity without discomfort. Symptoms of cardiac insufficiency or of the anginal syndrome may be present even at rest. If any physical activity is undertaken, discomfort is increased.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With New York Heart Association (NYHA) Functional Class Cardiac Disease: NYHA Functional Class III or IV</measure>
    <time_frame>12 months</time_frame>
    <description>Class I: Patients with cardiac disease but without resulting limitations of physical activity.
Class II: Patients with cardiac disease resulting in slight limitation of physical activity. Patients are comfortable at rest. Ordinary physical activity results in fatigue, palpitation, dyspnea, or anginal pain.
Class III: Patients with cardiac disease resulting in marked limitation of physical activity. They are comfortable at rest. Less than ordinary physical activity causes fatigue, palpitation dyspnea, or anginal pain.
Class IV: Patients with cardiac disease resulting in inability to carry on any physical activity without discomfort. Symptoms of cardiac insufficiency or of the anginal syndrome may be present even at rest. If any physical activity is undertaken, discomfort is increased.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With New York Heart Association (NYHA) Functional Class Cardiac Disease: NYHA Functional Class III or IV</measure>
    <time_frame>2 years</time_frame>
    <description>Class I: Patients with cardiac disease but without resulting limitations of physical activity.
Class II: Patients with cardiac disease resulting in slight limitation of physical activity. Patients are comfortable at rest. Ordinary physical activity results in fatigue, palpitation, dyspnea, or anginal pain.
Class III: Patients with cardiac disease resulting in marked limitation of physical activity. They are comfortable at rest. Less than ordinary physical activity causes fatigue, palpitation dyspnea, or anginal pain.
Class IV: Patients with cardiac disease resulting in inability to carry on any physical activity without discomfort. Symptoms of cardiac insufficiency or of the anginal syndrome may be present even at rest. If any physical activity is undertaken, discomfort is increased.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With New York Heart Association (NYHA) Functional Class Cardiac Disease: NYHA Functional Class III or IV</measure>
    <time_frame>3 years</time_frame>
    <description>Class I: Patients with cardiac disease but without resulting limitations of physical activity.
Class II: Patients with cardiac disease resulting in slight limitation of physical activity. Patients are comfortable at rest. Ordinary physical activity results in fatigue, palpitation, dyspnea, or anginal pain.
Class III: Patients with cardiac disease resulting in marked limitation of physical activity. They are comfortable at rest. Less than ordinary physical activity causes fatigue, palpitation dyspnea, or anginal pain.
Class IV: Patients with cardiac disease resulting in inability to carry on any physical activity without discomfort. Symptoms of cardiac insufficiency or of the anginal syndrome may be present even at rest. If any physical activity is undertaken, discomfort is increased.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With New York Heart Association (NYHA) Functional Class Cardiac Disease: NYHA Functional Class III or IV</measure>
    <time_frame>4 years</time_frame>
    <description>Class I: Patients with cardiac disease but without resulting limitations of physical activity.
Class II: Patients with cardiac disease resulting in slight limitation of physical activity. Patients are comfortable at rest. Ordinary physical activity results in fatigue, palpitation, dyspnea, or anginal pain.
Class III: Patients with cardiac disease resulting in marked limitation of physical activity. They are comfortable at rest. Less than ordinary physical activity causes fatigue, palpitation dyspnea, or anginal pain.
Class IV: Patients with cardiac disease resulting in inability to carry on any physical activity without discomfort. Symptoms of cardiac insufficiency or of the anginal syndrome may be present even at rest. If any physical activity is undertaken, discomfort is increased.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With New York Heart Association (NYHA) Functional Class Cardiac Disease: NYHA Functional Class III or IV</measure>
    <time_frame>5 years</time_frame>
    <description>Class I: Patients with cardiac disease but without resulting limitations of physical activity.
Class II: Patients with cardiac disease resulting in slight limitation of physical activity. Patients are comfortable at rest. Ordinary physical activity results in fatigue, palpitation, dyspnea, or anginal pain.
Class III: Patients with cardiac disease resulting in marked limitation of physical activity. They are comfortable at rest. Less than ordinary physical activity causes fatigue, palpitation dyspnea, or anginal pain.
Class IV: Patients with cardiac disease resulting in inability to carry on any physical activity without discomfort. Symptoms of cardiac insufficiency or of the anginal syndrome may be present even at rest. If any physical activity is undertaken, discomfort is increased.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Short Form (SF)-36 Quality of Life Questionnaire.</measure>
    <time_frame>30 days</time_frame>
    <description>The SF-36 is a multidimensional, patient-reported survey containing 36 questions on a 0-100 scale measuring physical (Physical Component Score) &amp; mental health status (Mental Component Score) in relation to 8 health concepts: physical functioning, role limitations due to physical or emotional health, bodily pain, general health perceptions, vitality, social functioning, &amp; general mental health. Responses to each of the SF-36 items are scored and expressed as a score on a 0-100 scale (0% in a domain represents the poorest possible QOL&amp;100% indicates full QOL).Higher scores represent better self-perceived health.
The physical &amp; mental functions were assessed by the Physical Component Summary (PCS) score &amp; Mental Component Summary (MCS) score. Normal PCS and MCS scores vary depending on the demographics of the population studied. The PCS&amp;MCS norms for 65-75 year old are 44 &amp; 52, respectively while the norms for CHF population are 31 &amp; 46, respectively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Short Form (SF)-36 Quality of Life Questionnaire.</measure>
    <time_frame>12 months</time_frame>
    <description>The SF-36 is a multidimensional, patient-reported survey containing 36 questions on a 0-100 scale measuring physical (Physical Component Score) &amp; mental health status (Mental Component Score) in relation to 8 health concepts: physical functioning, role limitations due to physical or emotional health, bodily pain, general health perceptions, vitality, social functioning, &amp; general mental health. Responses to each of the SF-36 items are scored and expressed as a score on a 0-100 scale (0% in a domain represents the poorest possible QOL&amp;100% indicates full QOL).Higher scores represent better self-perceived health.
The physical &amp; mental functions were assessed by the Physical Component Summary (PCS) score &amp; Mental Component Summary (MCS) score. Normal PCS and MCS scores vary depending on the demographics of the population studied. The PCS&amp;MCS norms for 65-75 year old are 44 &amp; 52, respectively while the norms for CHF population are 31 &amp; 46, respectively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac Output</measure>
    <time_frame>30 days</time_frame>
    <description>Cardiac output as measured by core lab echocardiography.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac Output</measure>
    <time_frame>12 months</time_frame>
    <description>Cardiac output as measured by core lab echocardiography.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac Output</measure>
    <time_frame>24 months</time_frame>
    <description>Cardiac output as measured by core lab echocardiography.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac Index</measure>
    <time_frame>30 days</time_frame>
    <description>Defined as cardiac output divided by body surface area, as measured by core lab echocardiography.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac Index (CI)</measure>
    <time_frame>12 months</time_frame>
    <description>Defined as cardiac output divided by body surface area as measured by core lab echocardiography. CI is a normalization of cardiac output to take into account the effect of body size on cardiac output requirements.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac Index</measure>
    <time_frame>24 months</time_frame>
    <description>Defined as cardiac output divided by body surface area, as measured by core lab echocardiography.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Regurgitant Volume</measure>
    <time_frame>30 Days</time_frame>
    <description>Regurgitant volume as determined by the core echo laboratory. In the presence of regurgitation of one valve, without any intracardiac shunt, the flow through the affected valve is larger than through other competent valves. The difference between the two represents the regurgitant volume.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Regurgitant Volume</measure>
    <time_frame>12 months</time_frame>
    <description>Regurgitant volume as determined by the core echo laboratory.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Regurgitant Volume</measure>
    <time_frame>24 months</time_frame>
    <description>Regurgitant volume as determined by the core echo laboratory.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Regurgitant Fraction (RF)</measure>
    <time_frame>30 Days</time_frame>
    <description>RF is defined as the percentage of the left ventricular (LV) stroke volume that regurgitates into the left atrium.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Regurgitant Fraction</measure>
    <time_frame>12 months</time_frame>
    <description>Regurgitant fraction is defined as the percentage of the left ventricular (LV) stroke volume that regurgitates into the left atrium.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Regurgitant Fraction</measure>
    <time_frame>24 months</time_frame>
    <description>Regurgitant fraction is defined as the percentage of the left ventricular (LV) stroke volume that regurgitates into the left atrium.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Clip Implant Rate</measure>
    <time_frame>Day 0</time_frame>
    <description>Defined as the rate of successful implantation of MitraClip(s).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Acute Procedural Success</measure>
    <time_frame>30 Days</time_frame>
    <description>Defined as successful MitraClip implantation with resulting MR of 2+ or less.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Acute Surgical Success</measure>
    <time_frame>30 Days</time_frame>
    <description>Defined as successful mitral valve repair or replacement surgery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Successful Clip Implant and Acute Procedural Success</measure>
    <time_frame>30 days</time_frame>
    <description>Acute procedural success is defined as MR severity ≤ 2 at discharge or 1 grade MR reduction at discharge accompanied by 1 level NYHA reduction.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Mitral Valve Repair Success.</measure>
    <time_frame>12 months</time_frame>
    <description>Defined as freedom from mitral valve replacement surgery for Valve Dysfunction, death, re-operation, and MR &gt; 2+ at 12 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Mitral Valve Repair Success.</measure>
    <time_frame>24 months</time_frame>
    <description>Defined as freedom from mitral valve replacement surgery for Valve Dysfunction, death, re-operation, and MR &gt; 2+ at 12 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Procedural Freedom From In-hospital MAE.</measure>
    <time_frame>Day 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Procedural Freedom From In-hospital MAE</measure>
    <time_frame>Day 30</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With MAE: Surgery After Device and First Time Surgery Control</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Major Vascular Complications</measure>
    <time_frame>30 days</time_frame>
    <description>Vascular Complications defined as the occurrence of any of the following resulting through 30 days or hospital discharge, whichever is longer:
Hematoma at access site &gt;6 cm;
Retroperitoneal hematoma;
Arteriovenous (AV) fistula;
Symptomatic peripheral ischemia / nerve injury or the clinical signs or symptoms lasting &gt;48 hours;
Vascular Surgical Repair at catheter access sites;
Pulmonary embolism;
Ipsilateral deep vein thrombus; or
Access site-related infection requiring intravenous antibiotics and/or extended hospitalization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Major Vascular Complications</measure>
    <time_frame>12 months</time_frame>
    <description>Vascular Complications defined as the occurrence of any of the following resulting through 30 days or hospital discharge, whichever is longer:
Hematoma at access site &gt;6 cm;
Retroperitoneal hematoma;
Arteriovenous (AV) fistula;
Symptomatic peripheral ischemia / nerve injury or the clinical signs or symptoms lasting &gt;48 hours;
Vascular Surgical Repair at catheter access sites;
Pulmonary embolism;
Ipsilateral deep vein thrombus; or
Access site-related infection requiring intravenous antibiotics and/or extended hospitalization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Major Bleeding Complications.</measure>
    <time_frame>30 days</time_frame>
    <description>Major Bleeding Complications defined as procedure related bleeding that requires a transfusion of ≥2 units of blood products and/or surgical intervention at 30 days or hospital discharge, whichever is longer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Major Bleeding Complications.</measure>
    <time_frame>12 months</time_frame>
    <description>Major Bleeding Complications defined as procedure related bleeding that requires a transfusion of ≥2 units of blood products and/or surgical intervention at 12 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Major Adverse Events (MAE)</measure>
    <time_frame>12 months.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With MAE in Patients Over 75 Years of Age.</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With MAE in Patients Over 75 Years of Age.</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Dysrhythmia</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Dysrhythmia</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Endocarditis.</measure>
    <time_frame>30 days</time_frame>
    <description>Defined as a diagnosis of endocarditis based on the Duke criteria. Infection in the lining of the heart, of the valves, or of the muscles of the heart. Signs of endocarditis may include persistent positive blood cultures and/or valvular structural abnormality and vegetations as seen using echocardiography.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Endocarditis.</measure>
    <time_frame>12 months</time_frame>
    <description>Defined as a diagnosis of endocarditis based on the Duke criteria. Infection in the lining of the heart, of the valves, or of the muscles of the heart. Signs of endocarditis may include persistent positive blood cultures and/or valvular structural abnormality and vegetations as seen using echocardiography.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Thrombosis.</measure>
    <time_frame>30 days</time_frame>
    <description>Defined as evidence of the formation of an independently moving thrombus on any part of the MitraClip or any commercially available implant used during surgery by echocardiography or fluoroscopy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Thrombosis.</measure>
    <time_frame>12 months</time_frame>
    <description>Defined as evidence of the formation of an independently moving thrombus on any part of the MitraClip or any commercially available implant used during surgery by echocardiography or fluoroscopy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Hemolysis</measure>
    <time_frame>30 days</time_frame>
    <description>Defined as new onset of anemia associated with laboratory evidence of red cell destruction. Diagnosed when plasma free hemoglobin is greater than 40 mg/dL on repeat measures within 24 hours or on one measure if intervention is initiated based on other clinical symptoms. Reported as major or minor as defined below:
Major: Requires intervention with red blood cell transfusion or other hematocrit increasing measures in the absence of other obvious bleeding.
Minor: Does not require intervention.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Hemolysis</measure>
    <time_frame>12 months</time_frame>
    <description>Defined as new onset of anemia associated with laboratory evidence of red cell destruction. Diagnosed when plasma free hemoglobin is greater than 40 mg/dL on repeat measures within 24 hours or on one measure if intervention is initiated based on other clinical symptoms. Reported as major or minor as defined below:
Major: Requires intervention with red blood cell transfusion or other hematocrit increasing measures in the absence of other obvious bleeding.
Minor: Does not require intervention.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Clinically Significant Atrial Septal Defect (ASD).</measure>
    <time_frame>30 days</time_frame>
    <description>Defined as a significant residual atrial septal opening. Reported as clinically significant if intervention is performed for the primary purpose of repairing the ASD. If cardiac surgery is indicated for reasons other than residual ASD (e.g., residual MR) and the ASD is repaired at the same time, this does not meet the definition of clinically significant ASD.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Clinically Significant Atrial Septal Defect (ASD)</measure>
    <time_frame>12 months</time_frame>
    <description>Defined as a significant residual atrial septal opening. Reported as clinically significant if intervention is performed for the primary purpose of repairing the ASD. If cardiac surgery is indicated for reasons other than residual ASD (e.g., residual MR) and the ASD is repaired at the same time, this does not meet the definition of clinically significant ASD.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Mitral Valve Stenosis</measure>
    <time_frame>30 days</time_frame>
    <description>Defined as a mitral valve planimetered orifice area of less than 1.5 cm^2 as measured by echocardiography.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Mitral Valve Stenosis</measure>
    <time_frame>12 months</time_frame>
    <description>Defined as a mitral valve planimetered orifice area of less than 1.5 cm^2 as measured by echocardiography.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Mitral Valve Stenosis</measure>
    <time_frame>24 months</time_frame>
    <description>Defined as a mitral valve planimetered orifice area of less than 1.5 cm^2 as measured by echocardiography.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Mitral Valve Stenosis</measure>
    <time_frame>3 years</time_frame>
    <description>Defined as a mitral valve (MV) planimetered orifice area of less than 1.5 cm^2 as measured by echocardiography. A &quot;confirmed&quot; case of MV stenosis is defined as Echocardiography Core Lab (ECL) measured mitral valve orifice area &lt; 1.5 cm^2. A &quot;conservative&quot; case of MV stenosis is defined as stenosis suspected by the site, based on hemodynamic measurements or clinical symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Mitral Valve Stenosis</measure>
    <time_frame>4 years</time_frame>
    <description>Defined as a mitral valve (MV) planimetered orifice area of less than 1.5 cm^2 as measured by echocardiography. A &quot;confirmed&quot; case of MV stenosis is defined as Echocardiography Core Lab (ECL) measured mitral valve orifice area &lt; 1.5 cm^2. A &quot;conservative&quot; case of MV stenosis is defined as stenosis suspected by the site, based on hemodynamic measurements or clinical symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Mitral Valve Stenosis</measure>
    <time_frame>5 years</time_frame>
    <description>Defined as a mitral valve (MV) planimetered orifice area of less than 1.5 cm^2 as measured by echocardiography. A &quot;confirmed&quot; case of MV stenosis is defined as Echocardiography Core Lab (ECL) measured mitral valve orifice area &lt; 1.5 cm^2. A &quot;conservative&quot; case of MV stenosis is defined as stenosis suspected by the site, based on hemodynamic measurements or clinical symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mitral Valve Area by Planimetry</measure>
    <time_frame>At Discharge (≤14 days of index procedure)</time_frame>
    <description>Mitral valve area as measured by core lab echocardiography.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mitral Valve Area by Planimetry</measure>
    <time_frame>30 Days</time_frame>
    <description>Mitral valve area as measured by core lab echocardiography.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mitral Valve Area by Planimetry</measure>
    <time_frame>12 months</time_frame>
    <description>Mitral valve area as measured by core lab echocardiography.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mitral Valve Area by Planimetry</measure>
    <time_frame>24 months</time_frame>
    <description>Mitral valve area as measured by core lab echocardiography.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mitral Valve Area by Planimetry</measure>
    <time_frame>3 years</time_frame>
    <description>Mitral valve area as measured by core lab echocardiography.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mitral Valve Area by Planimetry</measure>
    <time_frame>4 years</time_frame>
    <description>Mitral valve area as measured by core lab echocardiography.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mitral Valve Area by Planimetry</measure>
    <time_frame>5 years</time_frame>
    <description>Mitral valve area as measured by core lab echocardiography.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mitral Valve Area by Planimetry Index</measure>
    <time_frame>30 Days</time_frame>
    <description>Defined as mitral valve area divided by body surface area as measured by core lab echocardiography.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mitral Valve Area by Planimetry Index</measure>
    <time_frame>12 months</time_frame>
    <description>Defined as mitral valve area divided by body surface area as measured by core lab echocardiography.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mitral Valve Area by Planimetry Index</measure>
    <time_frame>24 months</time_frame>
    <description>Defined as mitral valve area divided by body surface area as measured by core lab echocardiography.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mitral Valve Area by Pressure Half-time</measure>
    <time_frame>At Discharge (≤14 days of index procedure)</time_frame>
    <description>Mitral valve area as measured by core lab echocardiography.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mitral Valve Area by Pressure Half-time</measure>
    <time_frame>30 days</time_frame>
    <description>Mitral valve area as measured by core lab echocardiography.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mitral Valve Area by Pressure Half-time</measure>
    <time_frame>12 months</time_frame>
    <description>Mitral valve area as measured by core lab echocardiography.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mitral Valve Area by Pressure Half-time</measure>
    <time_frame>24 months</time_frame>
    <description>Mitral valve area as measured by core lab echocardiography.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mitral Valve Area by Pressure Half-time</measure>
    <time_frame>3 years</time_frame>
    <description>Mitral valve area as measured by core lab echocardiography.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mitral Valve Area by Pressure Half-time</measure>
    <time_frame>4 years</time_frame>
    <description>Mitral valve area as measured by core lab echocardiography.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mitral Valve Area by Pressure Half-time</measure>
    <time_frame>5 years</time_frame>
    <description>Mitral valve area as measured by core lab echocardiography.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mitral Valve Area by Pressure Half-time Index</measure>
    <time_frame>30 Days</time_frame>
    <description>Defined as mitral valve area divided by body surface area as measured by core lab echocardiography.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mitral Valve Area by Pressure Half-time Index</measure>
    <time_frame>12 months</time_frame>
    <description>Defined as mitral valve area divided by body surface area as measured by core lab echocardiography.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mitral Valve Area by Pressure Half-time Index</measure>
    <time_frame>24 months</time_frame>
    <description>Defined as mitral valve area divided by body surface area as measured by core lab echocardiography.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transvalvular Mitral Valve Gradient</measure>
    <time_frame>At Discharge (≤ 14 days following index procedure)</time_frame>
    <description>Defined as the mean pressure gradient across the mitral valve as measured by echocardiography.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transvalvular Mitral Mean Pressure Gradient (Mean MVG)</measure>
    <time_frame>12 months</time_frame>
    <description>Defined as the mean pressure gradient across the mitral valve as measured by Echocardiography Core Laboratory (ECL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transvalvular Mitral Mean Pressure Gradient (Mean MVG)</measure>
    <time_frame>24 months</time_frame>
    <description>Defined as the mean pressure gradient across the mitral valve as measured by echocardiography.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transvalvular Mitral Mean Pressure Gradient (Mean MVG)</measure>
    <time_frame>3 year</time_frame>
    <description>Defined as the mean pressure gradient across the mitral valve as measured by echocardiography.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transvalvular Mitral Mean Pressure Gradient (Mean MVG)</measure>
    <time_frame>4 year</time_frame>
    <description>Defined as the mean pressure gradient across the mitral valve as measured by echocardiography.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transvalvular Mitral Mean Pressure Gradient (Mean MVG)</measure>
    <time_frame>5 years</time_frame>
    <description>Defined as the mean pressure gradient across the mitral valve as measured by echocardiography.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-procedure Length of Hospital Stay</measure>
    <time_frame>30 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-procedure Intensive Care Unit (ICU) / Critical Care Unit (CCU) Duration</measure>
    <time_frame>30 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Hospital Re-admissions</measure>
    <time_frame>30 days</time_frame>
    <description>Defined as re-admission to the hospital for any reason. The endpoint was intended to capture each time a patient was re-admitted to the hospital for any reason and was to be reported as a rate through 30 days for both the Device and Control groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Incidence of Discharge to a Nursing Home or Skilled Nursing Facility/Hospital</measure>
    <time_frame>30 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Incidence of Hospital Readmissions for Congestive Heart Failure (CHF).</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With New Coumadin (Warfarin) Usage</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With New Coumadin (Warfarin) Usage</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Durability of the MitraClip Device and Surgery.</measure>
    <time_frame>12 months</time_frame>
    <description>Device group: Freedom from death, surgery for mitral valve dysfunction and MR &gt; 2+ at the end of each follow-up interval.
Control group: Freedom from death, re-operation for mitral valve dysfunction and MR &gt; 2+ at the end of each follow-up interval.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Durability of the MitraClip Device and Surgery.</measure>
    <time_frame>12-18 months</time_frame>
    <description>Device group: Freedom from death, surgery for mitral valve dysfunction and MR &gt; 2+ at the end of each follow-up interval.
Control group: Freedom from death, re-operation for mitral valve dysfunction and MR &gt; 2+ at the end of each follow-up interval.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Durability of the MitraClip Device and Surgery.</measure>
    <time_frame>18-24 months</time_frame>
    <description>Device group: Freedom from death, surgery for mitral valve dysfunction and MR &gt; 2+ at the end of each follow-up interval.
Control group: Freedom from death, re-operation for mitral valve dysfunction and MR &gt; 2+ at the end of each follow-up interval.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Durability of the MitraClip Device and Surgery.</measure>
    <time_frame>24 months-3 year</time_frame>
    <description>Device group: Freedom from death, surgery for mitral valve dysfunction and MR &gt; 2+ at the end of each follow-up interval.
Control group: Freedom from death, re-operation for mitral valve dysfunction and MR &gt; 2+ at the end of each follow-up interval.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Freedom From Death, Mitral Valve Surgery/Re-operation and MR &gt; 2+</measure>
    <time_frame>12 months</time_frame>
    <description>Durability estimates: Freedom from Death, Mitral Valve Surgery/Re-operation and MR &gt; 2+</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Freedom From Death, Mitral Valve Surgery/Re-operation and MR &gt; 2+</measure>
    <time_frame>24 months</time_frame>
    <description>Durability estimates: Freedom from Death, Mitral Valve Surgery/Re-operation and MR &gt; 2+</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Freedom From Death, Mitral Valve Surgery/Re-operation and MR &gt; 2+</measure>
    <time_frame>3 years</time_frame>
    <description>Durability estimates: Freedom from Death, Mitral Valve Surgery/Re-operation and MR &gt; 2+</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Freedom From Mitral Valve Surgery/Re-operation</measure>
    <time_frame>12 months</time_frame>
    <description>Durability estimates: Freedom from Mitral Valve Surgery/Re-operation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Freedom From Mitral Valve Surgery/Re-operation</measure>
    <time_frame>24 months</time_frame>
    <description>Durability estimates: Freedom from Mitral Valve Surgery/Re-operation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Freedom From Mitral Valve Surgery/Re-operation</measure>
    <time_frame>3 years</time_frame>
    <description>Durability estimates: Freedom from Mitral Valve Surgery/Re-operation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Freedom From Mitral Valve Surgery/Re-operation</measure>
    <time_frame>4 years</time_frame>
    <description>Durability estimates: Freedom from Mitral Valve Surgery/Re-operation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Freedom From Mitral Valve Surgery/Re-operation</measure>
    <time_frame>5 years</time_frame>
    <description>Durability estimates: Freedom from Mitral Valve Surgery/Re-operation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Freedom From Death and Mitral Valve Surgery/Re-operation</measure>
    <time_frame>12 months</time_frame>
    <description>Durability estimates: Freedom from Death and Mitral Valve Surgery/Re-operation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Freedom From Death and Mitral Valve Surgery/Re-operation</measure>
    <time_frame>24 months</time_frame>
    <description>Durability estimates: Freedom from Death and Mitral Valve Surgery/Re-operation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Freedom From Death and Mitral Valve Surgery/Re-operation</measure>
    <time_frame>3 years</time_frame>
    <description>Durability estimates: Freedom from Death and Mitral Valve Surgery/Re-operation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Freedom From Death and Mitral Valve Surgery/Re-operation</measure>
    <time_frame>4 years</time_frame>
    <description>Durability estimates: Freedom from Death and Mitral Valve Surgery/Re-operation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Freedom From Death and Mitral Valve Surgery/Re-operation</measure>
    <time_frame>5 years</time_frame>
    <description>Durability estimates: Freedom from Death and Mitral Valve Surgery/Re-operation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With MitraClip Device Embolization/Single Leaflet Device Attachment</measure>
    <time_frame>12 months</time_frame>
    <description>Device Embolization is defined as the complete detachment of the MitraClip Device from one or both mitral leaflets. Single leaflet device attachment (SLDA) is defined as attachment of one mitral valve leaflet to the MitraClip device. The control group did not receive the MitraClip device.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With MitraClip Device Embolization/Single Leaflet Device Attachment</measure>
    <time_frame>12 months to 3 years</time_frame>
    <description>Device Embolization is defined as the complete detachment of the MitraClip Device from one or both mitral leaflets. Single leaflet device attachment (SLDA) is defined as attachment of one mitral valve leaflet to the MitraClip device. The control group did not receive the MitraClip device</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With MitraClip Device Embolization/Single Leaflet Device Attachment</measure>
    <time_frame>12 months to 4 years</time_frame>
    <description>Device Embolization is defined as the complete detachment of the MitraClip Device from one or both mitral leaflets. Single leaflet device attachment (SLDA) is defined as attachment of one mitral valve leaflet to the MitraClip device. The control group did not receive the MitraClip device</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With MitraClip Device Embolization/Single Leaflet Device Attachment</measure>
    <time_frame>12 months to 5 years</time_frame>
    <description>Device Embolization is defined as the complete detachment of the MitraClip Device from one or both mitral leaflets. Single leaflet device attachment (SLDA) is defined as attachment of one mitral valve leaflet to the MitraClip device. The control group did not receive the MitraClip device</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Non-cerebral Thromboembolism.</measure>
    <time_frame>12 months</time_frame>
    <description>Defined as any thrombus or thromboembolism in the vasculature (excluding central nervous system events) or on the investigational device or any commercially available implant used during surgery confirmed by standard clinical and laboratory testing and which requires treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With MR Severity</measure>
    <time_frame>30 days</time_frame>
    <description>MR Severity of 0: None,1+: Mild, 2+: Moderate, 3+: Moderate-to-Severe, 4+: Severe.
&quot;Discharge&quot; refers to each individual patient's date of hospital discharge. The discharge date varies for each patient, but in general, discharge occurs before 30-days follow-up. A 30-day echocardiogram will be used if the discharge echocardiogram is unavailable or otherwise uninterpretable.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With MR Severity</measure>
    <time_frame>12 months</time_frame>
    <description>MR Severity of 0: None,1+: Mild, 2+: Moderate, 3+: Moderate-to-Severe, 4+: Severe</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With MR Severity</measure>
    <time_frame>24 months</time_frame>
    <description>MR Severity of 0: None,1+: Mild, 2+: Moderate, 3+: Moderate-to-Severe, 4+: Severe</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With MR Severity</measure>
    <time_frame>3 years</time_frame>
    <description>MR Severity of 0: None,1+: Mild, 2+: Moderate, 3+: Moderate-to-Severe, 4+: Severe</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With MR Severity</measure>
    <time_frame>4 years</time_frame>
    <description>MR Severity of 0: None,1+: Mild, 2+: Moderate, 3+: Moderate-to-Severe, 4+: Severe</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With MR Severity</measure>
    <time_frame>5 years</time_frame>
    <description>MR Severity of 0: None,1+: Mild, 2+: Moderate, 3+: Moderate-to-Severe, 4+: Severe</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Non-cerebral Thromboembolism.</measure>
    <time_frame>30 days</time_frame>
    <description>Defined as any thrombus or thromboembolism in the vasculature (excluding central nervous system events) or on the investigational device or any commercially available implant used during surgery confirmed by standard clinical and laboratory testing and which requires treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Incidence of Mitral Valve Replacement</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Incidence of Mitral Valve Replacement</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">279</enrollment>
  <condition>Mitral Valve Insufficiency</condition>
  <condition>Mitral Valve Regurgitation</condition>
  <condition>Mitral Valve Incompetence</condition>
  <condition>Mitral Regurgitation</condition>
  <condition>Mitral Insufficiency</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Percutaneous mitral valve repair using MitraClip implant. The calculated sample size was 186 patients in the device arm</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Mitral valve repair or replacement surgery. The calculated sample size was 93 patients in the control arm.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Percutaneous mitral valve repair using MitraClip implant</intervention_name>
    <description>MitraClip Implant</description>
    <arm_group_label>1</arm_group_label>
    <other_name>MitraClip</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Mitral valve repair or replacement surgery</intervention_name>
    <description>Repair or replacement of mitral valve</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion/Exclusion Criteria:

        Patients with Grade 3 (moderate to severe) or Grade 4 (severe) mitral regurgitation (MR)
        based on American Society of Echocardiography guidelines:

          -  Are 18 years or older.

          -  Symptomatic

          -  If asymptomatic, must have new onset of atrial fibrillation, pulmonary hypertension,
             or evidence of left ventricular dysfunction

          -  Are candidates for mitral valve surgery

          -  Are candidates for transseptal catheterization

          -  Primary regurgitant jet must originate from malcoaptation of the A2 and P2 scallops of
             the mitral valve

          -  Appropriate valve anatomy for MitraClip

          -  Does not need other cardiac surgery or any emergency surgery

          -  Did not experience myocardial infarction in prior 12 weeks or endovascular procedure
             in prior 30 days

          -  Mitral valve orifice area ≥ 4 cm2

          -  Do not have renal insufficiency

          -  Echocardiographic evidence of intracardiac mass, thrombus or vegetation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ted Feldman, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>NorthShore University HealthSystem Research Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Donald G Glower Jr., MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University Medical Center, Department of Surgery</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Evanston Northwestern Healthcare</name>
      <address>
        <city>Evanston</city>
        <state>Illinois</state>
        <zip>60201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Fann JI, St Goar FG, Komtebedde J, Oz MC, Block PC, Foster E, Butany J, Feldman T, Burdon TA. Beating heart catheter-based edge-to-edge mitral valve procedure in a porcine model: efficacy and healing response. Circulation. 2004 Aug 24;110(8):988-93. Epub 2004 Aug 9.</citation>
    <PMID>15302782</PMID>
  </reference>
  <reference>
    <citation>St Goar FG, Fann JI, Komtebedde J, Foster E, Oz MC, Fogarty TJ, Feldman T, Block PC. Endovascular edge-to-edge mitral valve repair: short-term results in a porcine model. Circulation. 2003 Oct 21;108(16):1990-3. Epub 2003 Oct 6.</citation>
    <PMID>14530193</PMID>
  </reference>
  <reference>
    <citation>Borgia F, Di Mario C, Franzen O. Adenosine-induced asystole to facilitate MitraClip placement in a patient with adverse mitral valve morphology. Heart. 2011 May;97(10):864. doi: 10.1136/hrt.2010.208132. Epub 2010 Oct 29.</citation>
    <PMID>21036802</PMID>
  </reference>
  <reference>
    <citation>Tamburino C, Immè S, Barbanti M, Mulè M, Pistritto AM, Aruta P, Cammalleri V, Scarabelli M, Mangiafico S, Scandura S, Ussia GP. Reduction of mitral valve regurgitation with Mitraclip® percutaneous system. Minerva Cardioangiol. 2010 Oct;58(5):589-98.</citation>
    <PMID>20948505</PMID>
  </reference>
  <reference>
    <citation>Lim DS, Kunjummen BJ, Smalling R. Mitral valve repair with the MitraClip device after prior surgical mitral annuloplasty. Catheter Cardiovasc Interv. 2010 Sep 1;76(3):455-9. doi: 10.1002/ccd.22547.</citation>
    <PMID>20839359</PMID>
  </reference>
  <reference>
    <citation>Tamburino C, Ussia GP, Maisano F, Capodanno D, La Canna G, Scandura S, Colombo A, Giacomini A, Michev I, Mangiafico S, Cammalleri V, Barbanti M, Alfieri O. Percutaneous mitral valve repair with the MitraClip system: acute results from a real world setting. Eur Heart J. 2010 Jun;31(11):1382-9. doi: 10.1093/eurheartj/ehq051. Epub 2010 Mar 18.</citation>
    <PMID>20299349</PMID>
  </reference>
  <reference>
    <citation>Argenziano M, Skipper E, Heimansohn D, Letsou GV, Woo YJ, Kron I, Alexander J, Cleveland J, Kong B, Davidson M, Vassiliades T, Krieger K, Sako E, Tibi P, Galloway A, Foster E, Feldman T, Glower D; EVEREST Investigators. Surgical revision after percutaneous mitral repair with the MitraClip device. Ann Thorac Surg. 2010 Jan;89(1):72-80; discussion p 80. doi: 10.1016/j.athoracsur.2009.08.063.</citation>
    <PMID>20103209</PMID>
  </reference>
  <reference>
    <citation>Rogers JH, Yeo KK, Carroll JD, Cleveland J, Reece TB, Gillinov AM, Rodriguez L, Whitlow P, Woo YJ, Herrmann HC, Young JN. Late surgical mitral valve repair after percutaneous repair with the MitraClip system. J Card Surg. 2009 Nov-Dec;24(6):677-81. doi: 10.1111/j.1540-8191.2009.00901.x. Epub 2009 Jul 24.</citation>
    <PMID>19682161</PMID>
  </reference>
  <reference>
    <citation>Feldman T, Kar S, Rinaldi M, Fail P, Hermiller J, Smalling R, Whitlow PL, Gray W, Low R, Herrmann HC, Lim S, Foster E, Glower D; EVEREST Investigators. Percutaneous mitral repair with the MitraClip system: safety and midterm durability in the initial EVEREST (Endovascular Valve Edge-to-Edge REpair Study) cohort. J Am Coll Cardiol. 2009 Aug 18;54(8):686-94. doi: 10.1016/j.jacc.2009.03.077.</citation>
    <PMID>19679246</PMID>
  </reference>
  <reference>
    <citation>Herrmann HC, Kar S, Siegel R, Fail P, Loghin C, Lim S, Hahn R, Rogers JH, Bommer WJ, Wang A, Berke A, Lerakis S, Kramer P, Wong SC, Foster E, Glower D, Feldman T; EVEREST Investigators. Effect of percutaneous mitral repair with the MitraClip device on mitral valve area and gradient. EuroIntervention. 2009 Jan;4(4):437-42.</citation>
    <PMID>19284064</PMID>
  </reference>
  <reference>
    <citation>Luk A, Butany J, Ahn E, Fann JI, St Goar F, Thornton T, McDermott L, Madayag C, Komtebedde J. Mitral repair with the Evalve MitraClip device: histopathologic findings in the porcine model. Cardiovasc Pathol. 2009 Sep-Oct;18(5):279-85. doi: 10.1016/j.carpath.2008.07.001. Epub 2008 Aug 13.</citation>
    <PMID>18703359</PMID>
  </reference>
  <reference>
    <citation>Pope NH, Lim S, Ailawadi G. Late calcific mitral stenosis after MitraClip procedure in a dialysis-dependent patient. Ann Thorac Surg. 2013 May;95(5):e113-4. doi: 10.1016/j.athoracsur.2012.10.067.</citation>
    <PMID>23608290</PMID>
  </reference>
  <reference>
    <citation>Cikirikcioglu M, Cherian S, Schussler O, Kalangos A. Regarding &quot;The EVEREST II Trial: design and rationale for a randomized study of the Evalve MitraClip system compared with mitral valve surgery for mitral regurgitation&quot;. Am Heart J. 2011 Jul;162(1):e11-2; author reply e13. doi: 10.1016/j.ahj.2011.04.004. Epub 2011 Jun 12.</citation>
    <PMID>21742074</PMID>
  </reference>
  <reference>
    <citation>Condado JA, Vélez-Gimón M. Catheter-based approach to mitral regurgitation. J Interv Cardiol. 2003 Dec;16(6):523-34. Review.</citation>
    <PMID>14632950</PMID>
  </reference>
  <reference>
    <citation>Fann JI, St Goar FG. Percutaneous aortic valve replacement and mitral valve repair. Future Cardiol. 2005 May;1(3):393-403. doi: 10.1517/14796678.1.3.393.</citation>
    <PMID>19804122</PMID>
  </reference>
  <reference>
    <citation>Cohn LH. Percutaneous mitral valve repair with the edge-to-edge technique: a surgeon's perspective. J Am Coll Cardiol. 2005 Dec 6;46(11):2141-2. Epub 2005 Oct 17.</citation>
    <PMID>16325054</PMID>
  </reference>
  <reference>
    <citation>Condado JA, Acquatella H, Rodriguez L, Whitlow P, Vélez-Gimo M, St Goar FG. Percutaneous edge-to-edge mitral valve repair: 2-year follow-up in the first human case. Catheter Cardiovasc Interv. 2006 Feb;67(2):323-5.</citation>
    <PMID>16419054</PMID>
  </reference>
  <reference>
    <citation>Feldman T, Glower D. Patient selection for percutaneous mitral valve repair: insight from early clinical trial applications. Nat Clin Pract Cardiovasc Med. 2008 Feb;5(2):84-90. doi: 10.1038/ncpcardio1068. Review.</citation>
    <PMID>18223540</PMID>
  </reference>
  <reference>
    <citation>Biner S, Siegel RJ, Feldman T, Rafique AM, Trento A, Whitlow P, Rogers J, Moon M, Lindman B, Zajarias A, Glower D, Kar S; EVEREST investigators. Acute effect of percutaneous MitraClip therapy in patients with haemodynamic decompensation. Eur J Heart Fail. 2012 Aug;14(8):939-45. Epub 2012 May 14.</citation>
    <PMID>22588322</PMID>
  </reference>
  <results_reference>
    <citation>Dang NC, Aboodi MS, Sakaguchi T, Wasserman HS, Argenziano M, Cosgrove DM, Rosengart TK, Feldman T, Block PC, Oz MC. Surgical revision after percutaneous mitral valve repair with a clip: initial multicenter experience. Ann Thorac Surg. 2005 Dec;80(6):2338-42.</citation>
    <PMID>16305903</PMID>
  </results_reference>
  <results_reference>
    <citation>Feldman T, Wasserman HS, Herrmann HC, Gray W, Block PC, Whitlow P, St Goar F, Rodriguez L, Silvestry F, Schwartz A, Sanborn TA, Condado JA, Foster E. Percutaneous mitral valve repair using the edge-to-edge technique: six-month results of the EVEREST Phase I Clinical Trial. J Am Coll Cardiol. 2005 Dec 6;46(11):2134-40. Epub 2005 Oct 19.</citation>
    <PMID>16325053</PMID>
  </results_reference>
  <results_reference>
    <citation>Herrmann HC, Rohatgi S, Wasserman HS, Block P, Gray W, Hamilton A, Zunamon A, Homma S, Di Tullio MR, Kraybill K, Merlino J, Martin R, Rodriguez L, Stewart WJ, Whitlow P, Wiegers SE, Silvestry FE, Foster E, Feldman T. Mitral valve hemodynamic effects of percutaneous edge-to-edge repair with the MitraClip device for mitral regurgitation. Catheter Cardiovasc Interv. 2006 Dec;68(6):821-8.</citation>
    <PMID>17080467</PMID>
  </results_reference>
  <results_reference>
    <citation>Silvestry FE, Rodriguez LL, Herrmann HC, Rohatgi S, Weiss SJ, Stewart WJ, Homma S, Goyal N, Pulerwitz T, Zunamon A, Hamilton A, Merlino J, Martin R, Krabill K, Block PC, Whitlow P, Tuzcu EM, Kapadia S, Gray WA, Reisman M, Wasserman H, Schwartz A, Foster E, Feldman T, Wiegers SE. Echocardiographic guidance and assessment of percutaneous repair for mitral regurgitation with the Evalve MitraClip: lessons learned from EVEREST I. J Am Soc Echocardiogr. 2007 Oct;20(10):1131-40. Epub 2007 Jun 13.</citation>
    <PMID>17570634</PMID>
  </results_reference>
  <results_reference>
    <citation>Mauri L, Garg P, Massaro JM, Foster E, Glower D, Mehoudar P, Powell F, Komtebedde J, McDermott E, Feldman T. The EVEREST II Trial: design and rationale for a randomized study of the evalve mitraclip system compared with mitral valve surgery for mitral regurgitation. Am Heart J. 2010 Jul;160(1):23-9. doi: 10.1016/j.ahj.2010.04.009.</citation>
    <PMID>20598968</PMID>
  </results_reference>
  <results_reference>
    <citation>Whitlow PL, Feldman T, Pedersen WR, Lim DS, Kipperman R, Smalling R, Bajwa T, Herrmann HC, Lasala J, Maddux JT, Tuzcu M, Kapadia S, Trento A, Siegel RJ, Foster E, Glower D, Mauri L, Kar S; EVEREST II Investigators. Acute and 12-month results with catheter-based mitral valve leaflet repair: the EVEREST II (Endovascular Valve Edge-to-Edge Repair) High Risk Study. J Am Coll Cardiol. 2012 Jan 10;59(2):130-9. doi: 10.1016/j.jacc.2011.08.067.</citation>
    <PMID>22222076</PMID>
  </results_reference>
  <results_reference>
    <citation>Herrmann HC, Gertz ZM, Silvestry FE, Wiegers SE, Woo YJ, Hermiller J, Segar D, Heimansohn D, Gray W, Homma S, Argenziano M, Wang A, Jollis J, Lampert MB, Alexander J, Mauri L, Foster E, Glower D, Feldman T. Effects of atrial fibrillation on treatment of mitral regurgitation in the EVEREST II (Endovascular Valve Edge-to-Edge Repair Study) randomized trial. J Am Coll Cardiol. 2012 Apr 3;59(14):1312-9. doi: 10.1016/j.jacc.2011.12.023.</citation>
    <PMID>22464260</PMID>
  </results_reference>
  <results_reference>
    <citation>Glower D, Ailawadi G, Argenziano M, Mack M, Trento A, Wang A, Lim DS, Gray W, Grayburn P, Dent J, Gillam L, Sethuraman B, Feldman T, Foster E, Mauri L, Kron I; EVEREST II Investigators. EVEREST II randomized clinical trial: predictors of mitral valve replacement in de novo surgery or after the MitraClip procedure. J Thorac Cardiovasc Surg. 2012 Apr;143(4 Suppl):S60-3. doi: 10.1016/j.jtcvs.2012.01.047.</citation>
    <PMID>22423604</PMID>
  </results_reference>
  <results_reference>
    <citation>Smith T, McGinty P, Bommer W, Low RI, Lim S, Fail P, Rogers JH. Prevalence and echocardiographic features of iatrogenic atrial septal defect after catheter-based mitral valve repair with the MitraClip system. Catheter Cardiovasc Interv. 2012 Oct 1;80(4):678-85. doi: 10.1002/ccd.23485. Epub 2012 Mar 15.</citation>
    <PMID>22422577</PMID>
  </results_reference>
  <results_reference>
    <citation>Mauri L, Foster E, Glower DD, Apruzzese P, Massaro JM, Herrmann HC, Hermiller J, Gray W, Wang A, Pedersen WR, Bajwa T, Lasala J, Low R, Grayburn P, Feldman T; EVEREST II Investigators. 4-year results of a randomized controlled trial of percutaneous repair versus surgery for mitral regurgitation. J Am Coll Cardiol. 2013 Jul 23;62(4):317-28. doi: 10.1016/j.jacc.2013.04.030. Epub 2013 May 9.</citation>
    <PMID>23665364</PMID>
  </results_reference>
  <results_reference>
    <citation>Foster E, Kwan D, Feldman T, Weissman NJ, Grayburn PA, Schwartz A, Rogers JH, Kar S, Rinaldi MJ, Fail PS, Hermiller J, Whitlow PL, Herrmann HC, Lim DS, Glower DD; EVEREST Investigators. Percutaneous mitral valve repair in the initial EVEREST cohort: evidence of reverse left ventricular remodeling. Circ Cardiovasc Imaging. 2013 Jul;6(4):522-30. doi: 10.1161/CIRCIMAGING.112.000098. Epub 2013 Apr 30.</citation>
    <PMID>23633132</PMID>
  </results_reference>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2005</study_first_posted>
  <results_first_submitted>December 6, 2013</results_first_submitted>
  <results_first_submitted_qc>August 2, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">September 5, 2017</results_first_posted>
  <disposition_first_submitted>July 31, 2013</disposition_first_submitted>
  <disposition_first_submitted_qc>September 17, 2013</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">September 18, 2013</disposition_first_posted>
  <last_update_submitted>March 5, 2018</last_update_submitted>
  <last_update_submitted_qc>March 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Mitral Valve Insufficiency</keyword>
  <keyword>Mitral Valve Regurgitation</keyword>
  <keyword>Mitral Valve Incompetence</keyword>
  <keyword>Mitral Regurgitation</keyword>
  <keyword>Mitral Insufficiency</keyword>
  <keyword>Mitral Valve</keyword>
  <keyword>MR</keyword>
  <keyword>Mitral Valve Prolapse</keyword>
  <keyword>Edge to Edge (E2E)</keyword>
  <keyword>Alfieri Technique</keyword>
  <keyword>MitraClip</keyword>
  <keyword>Functional MR</keyword>
  <keyword>Degenerative MR</keyword>
  <keyword>Echocardiogram</keyword>
  <keyword>CAD - Coronary Artery Disease</keyword>
  <keyword>Heart Failure</keyword>
  <keyword>Heart Attack</keyword>
  <keyword>EVEREST</keyword>
  <keyword>EVEREST I</keyword>
  <keyword>EVEREST II</keyword>
  <keyword>REALISM</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mitral Valve Insufficiency</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The EVEREST II RCT was conducted in patients who were indicated for and could undergo mitral valve surgery. A total of 279 patients were enrolled at United States &amp; Canada investigational sites between Aug 5,2005 to Sep 17,2008 time period. The subjects were randomized to Device group (n=184; MitraClip) &amp;Control group (n=95;Mitral Valve Surgery).</recruitment_details>
      <pre_assignment_details>The EVEREST II RCT enrolled 279 patients (184 Device and 95 Control), of whom 21 patients (6 Device and 15 Control) did not undergo treatment per their randomized assignment, and are reported as “randomized not treated” (RNT). All RNT patients except one withdrew from the trial.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Device Group (MitraClip Device)</title>
          <description>Percutaneous mitral valve repair using MitraClip implant.</description>
        </group>
        <group group_id="P2">
          <title>Control Group (Mitral Valve Surgery)</title>
          <description>Mitral valve repair or replacement surgery.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="184"/>
                <participants group_id="P2" count="95"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="113"/>
                <participants group_id="P2" count="48"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="71"/>
                <participants group_id="P2" count="47"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Missed visit</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Randomized not treated (RNT)</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Device Group (MitraClip Device)</title>
          <description>Percutaneous mitral valve repair using MitraClip implant.</description>
        </group>
        <group group_id="B2">
          <title>Control Group (Mitral Valve Surgery)</title>
          <description>Mitral valve repair or replacement surgery.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="184"/>
            <count group_id="B2" value="95"/>
            <count group_id="B3" value="279"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67.3" spread="12.8"/>
                    <measurement group_id="B2" value="65.7" spread="12.9"/>
                    <measurement group_id="B3" value="66.7" spread="12.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>18-75 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="129"/>
                    <measurement group_id="B2" value="69"/>
                    <measurement group_id="B3" value="198"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;75 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="69"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="101"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="115"/>
                    <measurement group_id="B2" value="63"/>
                    <measurement group_id="B3" value="178"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="177"/>
                    <measurement group_id="B2" value="93"/>
                    <measurement group_id="B3" value="270"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>NYHA Functional Class</title>
          <description>Class I: Patients with cardiac disease but without resulting limitations of physical activity. Class II: Patients with cardiac disease resulting in slight limitation of physical activity. Patients are comfortable at rest. Class III: Patients with cardiac disease resulting in marked limitation of physical activity. They are comfortable at rest. Class IV: Patients with cardiac disease resulting in inability to carry on any physical activity without discomfort. Symptoms of cardiac insufficiency or anginal syndrome may be present even at rest &amp; discomfort is increased with physical activity.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>NYHA Functional Class I</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NYHA Functional Class II</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="73"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="104"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NYHA Functional Class III</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="82"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="123"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NYHA Functional Class IV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Mitral regurgitation (MR)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>0: None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1+: Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2+: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3+: Moderate-to-Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="130"/>
                    <measurement group_id="B2" value="67"/>
                    <measurement group_id="B3" value="197"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4+: Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Left Ventricular (LV) Measurement</title>
          <units>mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>LV End Diastolic Volume (LVEDV)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="156.5" spread="39.0"/>
                    <measurement group_id="B2" value="159.6" spread="46.3"/>
                    <measurement group_id="B3" value="158.05" spread="42.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LV End Systolic Volume (LVESV)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.5" spread="25.5"/>
                    <measurement group_id="B2" value="63.8" spread="28.9"/>
                    <measurement group_id="B3" value="63.65" spread="27.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Left Ventricular (LV) Measurement</title>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>LV internal dimension diastole (LVIDd)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.5" spread="0.7"/>
                    <measurement group_id="B2" value="5.5" spread="0.7"/>
                    <measurement group_id="B3" value="5.5" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LV internal dimension systole (LVIDs)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.7" spread="0.9"/>
                    <measurement group_id="B2" value="3.5" spread="0.8"/>
                    <measurement group_id="B3" value="3.6" spread="0.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>36-Item Short Form Health Survey (SF-36) Quality of Life (QOL)</title>
          <description>The SF-36 is a multidimensional, patient-reported survey containing 36 questions on a 0-100 scale measuring physical (Physical Component Score PCS) &amp; mental health status (Mental Component Score MCS) in relation to 8 health concepts: physical functioning, role limitations due to physical or emotional health, bodily pain, general health perceptions, vitality, social functioning, &amp; general mental health. Higher scores represent better self-perceived health. The PCS &amp; MCS norms for 65-75 year olds are 44 and 52, while the norms for CHF population are 31 and 46, respectively.</description>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Physical Component Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41.1" spread="10.0"/>
                    <measurement group_id="B2" value="41.9" spread="11.1"/>
                    <measurement group_id="B3" value="41.4" spread="10.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mental Component Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47.1" spread="11.9"/>
                    <measurement group_id="B2" value="46.6" spread="12.5"/>
                    <measurement group_id="B3" value="46.9" spread="12.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Major Adverse Events (MAE)</title>
        <description>Defined as a combined clinical endpoint of death, myocardial infarction, reoperation for failed surgical repair or replacement, nonelective cardiovascular surgery for adverse events, stroke, renal failure, deep wound infection, ventilation for greater than 48 hours, gastrointestinal (GI) complication requiring surgery, new onset of permanent atrial fibrillation, septicemia, and transfusion of 2 or more units of blood.</description>
        <time_frame>30 days</time_frame>
        <population>Per-protocol cohort. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Device Group (MitraClip Device)</title>
            <description>Percutaneous mitral valve repair using MitraClip implant.</description>
          </group>
          <group group_id="O2">
            <title>Control Group (Mitral Valve Surgery)</title>
            <description>Mitral valve repair or replacement surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Major Adverse Events (MAE)</title>
          <description>Defined as a combined clinical endpoint of death, myocardial infarction, reoperation for failed surgical repair or replacement, nonelective cardiovascular surgery for adverse events, stroke, renal failure, deep wound infection, ventilation for greater than 48 hours, gastrointestinal (GI) complication requiring surgery, new onset of permanent atrial fibrillation, septicemia, and transfusion of 2 or more units of blood.</description>
          <population>Per-protocol cohort. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="136"/>
                <count group_id="O2" value="79"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Freedom From Surgery for Valve Dysfunction, Death, and Moderate to Severe (3+) or Severe (4+) Mitral Regurgitation (MR).</title>
        <time_frame>12 months</time_frame>
        <population>Per-protocol cohort. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Device Group (MitraClip Device)</title>
            <description>Percutaneous mitral valve repair using MitraClip implant.</description>
          </group>
          <group group_id="O2">
            <title>Control Group (Mitral Valve Surgery)</title>
            <description>Mitral valve repair or replacement surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Freedom From Surgery for Valve Dysfunction, Death, and Moderate to Severe (3+) or Severe (4+) Mitral Regurgitation (MR).</title>
          <population>Per-protocol cohort. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="134"/>
                <count group_id="O2" value="74"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97"/>
                    <measurement group_id="O2" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Freedom From All-Cause Mortality</title>
        <time_frame>12 months</time_frame>
        <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Device Group (MitraClip Device)</title>
            <description>Percutaneous mitral valve repair using MitraClip implant.</description>
          </group>
          <group group_id="O2">
            <title>Control Group (Mitral Valve Surgery)</title>
            <description>Mitral valve repair or replacement surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Freedom From All-Cause Mortality</title>
          <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="158"/>
                <count group_id="O2" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.7"/>
                    <measurement group_id="O2" value="92.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Freedom From All-Cause Mortality</title>
        <time_frame>24 months</time_frame>
        <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Device Group (MitraClip Device)</title>
            <description>Percutaneous mitral valve repair using MitraClip implant.</description>
          </group>
          <group group_id="O2">
            <title>Control Group (Mitral Valve Surgery)</title>
            <description>Mitral valve repair or replacement surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Freedom From All-Cause Mortality</title>
          <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="143"/>
                <count group_id="O2" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.0"/>
                    <measurement group_id="O2" value="89.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Freedom From All-Cause Mortality</title>
        <time_frame>3 years</time_frame>
        <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Device Group (MitraClip Device)</title>
            <description>Percutaneous mitral valve repair using MitraClip implant.</description>
          </group>
          <group group_id="O2">
            <title>Control Group (Mitral Valve Surgery)</title>
            <description>Mitral valve repair or replacement surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Freedom From All-Cause Mortality</title>
          <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="133"/>
                <count group_id="O2" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.5"/>
                    <measurement group_id="O2" value="85.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Freedom From All-Cause Mortality</title>
        <time_frame>4 years</time_frame>
        <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Device Group (MitraClip Device)</title>
            <description>Percutaneous mitral valve repair using MitraClip implant.</description>
          </group>
          <group group_id="O2">
            <title>Control Group (Mitral Valve Surgery)</title>
            <description>Mitral valve repair or replacement surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Freedom From All-Cause Mortality</title>
          <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="119"/>
                <count group_id="O2" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.4"/>
                    <measurement group_id="O2" value="82.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Freedom From All-Cause Mortality</title>
        <time_frame>5 years</time_frame>
        <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Device Group (MitraClip Device)</title>
            <description>Percutaneous mitral valve repair using MitraClip implant.</description>
          </group>
          <group group_id="O2">
            <title>Control Group (Mitral Valve Surgery)</title>
            <description>Mitral valve repair or replacement surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Freedom From All-Cause Mortality</title>
          <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.2"/>
                    <measurement group_id="O2" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Freedom From Surgery for Valve Dysfunction, Death, and Moderate to Severe (3+) or Severe (4+) Mitral Regurgitation.</title>
        <time_frame>12 months</time_frame>
        <population>Intent-to-treat (ITT) population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Device Group (MitraClip Device)</title>
            <description>Percutaneous mitral valve repair using MitraClip implant.</description>
          </group>
          <group group_id="O2">
            <title>Control Group (Mitral Valve Surgery)</title>
            <description>Mitral valve repair or replacement surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Freedom From Surgery for Valve Dysfunction, Death, and Moderate to Severe (3+) or Severe (4+) Mitral Regurgitation.</title>
          <population>Intent-to-treat (ITT) population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="175"/>
                <count group_id="O2" value="89"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="118"/>
                    <measurement group_id="O2" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Freedom From Surgery for Valve Dysfunction, Death, and Moderate to Severe (3+) or Severe (4+) Mitral Regurgitation (MR).</title>
        <time_frame>24 months</time_frame>
        <population>Per-protocol population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Device Group (MitraClip Device)</title>
            <description>Percutaneous mitral valve repair using MitraClip implant.</description>
          </group>
          <group group_id="O2">
            <title>Control Group (Mitral Valve Surgery)</title>
            <description>Mitral valve repair or replacement surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Freedom From Surgery for Valve Dysfunction, Death, and Moderate to Severe (3+) or Severe (4+) Mitral Regurgitation (MR).</title>
          <population>Per-protocol population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="126"/>
                <count group_id="O2" value="68"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87"/>
                    <measurement group_id="O2" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Freedom From Surgery for Valve Dysfunction, Death, and Moderate to Severe (3+) or Severe (4+) Mitral Regurgitation (MR) in Intention to Treat Strategy Cohort</title>
        <time_frame>24 months</time_frame>
        <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Device Group (MitraClip Device)</title>
            <description>Percutaneous mitral valve repair using MitraClip implant.</description>
          </group>
          <group group_id="O2">
            <title>Control Group (Mitral Valve Surgery)</title>
            <description>Mitral valve repair or replacement surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Freedom From Surgery for Valve Dysfunction, Death, and Moderate to Severe (3+) or Severe (4+) Mitral Regurgitation (MR) in Intention to Treat Strategy Cohort</title>
          <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="161"/>
                <count group_id="O2" value="83"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Left Ventricular Ejection Fraction (LVEF)</title>
        <description>LVEF as determined by the core echo laboratory at 30 days or hospital discharge, whichever is longer.</description>
        <time_frame>At discharge (≤ 14 days following index procedure) or 30 days</time_frame>
        <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Device Group (MitraClip Device)</title>
            <description>Percutaneous mitral valve repair using MitraClip implant.</description>
          </group>
          <group group_id="O2">
            <title>Control Group (Mitral Valve Surgery)</title>
            <description>Mitral valve repair or replacement surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Left Ventricular Ejection Fraction (LVEF)</title>
          <description>LVEF as determined by the core echo laboratory at 30 days or hospital discharge, whichever is longer.</description>
          <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Percentage of volume ejected</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="170"/>
                <count group_id="O2" value="77"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.9" spread="10.0"/>
                    <measurement group_id="O2" value="53.9" spread="10.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Left Ventricular Ejection Fraction (LVEF)</title>
        <description>LVEF as determined by the core echo laboratory.</description>
        <time_frame>12 months</time_frame>
        <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Device Group (MitraClip Device)</title>
            <description>Percutaneous mitral valve repair using MitraClip implant.</description>
          </group>
          <group group_id="O2">
            <title>Control Group (Mitral Valve Surgery)</title>
            <description>Mitral valve repair or replacement surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Left Ventricular Ejection Fraction (LVEF)</title>
          <description>LVEF as determined by the core echo laboratory.</description>
          <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Percentage of volume ejected</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="144"/>
                <count group_id="O2" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.0" spread="8.7"/>
                    <measurement group_id="O2" value="55.3" spread="10.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Left Ventricular Ejection Fraction (LVEF)</title>
        <description>LVEF as determined by the core echo laboratory.</description>
        <time_frame>24 months</time_frame>
        <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Device Group (MitraClip Device)</title>
            <description>Percutaneous mitral valve repair using MitraClip implant.</description>
          </group>
          <group group_id="O2">
            <title>Control Group (Mitral Valve Surgery)</title>
            <description>Mitral valve repair or replacement surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Left Ventricular Ejection Fraction (LVEF)</title>
          <description>LVEF as determined by the core echo laboratory.</description>
          <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Percentage of volume ejected</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="125"/>
                <count group_id="O2" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.9" spread="8.3"/>
                    <measurement group_id="O2" value="55.8" spread="8.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Left Ventricular Ejection Fraction (LVEF)</title>
        <description>LVEF as determined by the core echo laboratory.</description>
        <time_frame>3 years</time_frame>
        <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Device Group (MitraClip Device)</title>
            <description>Percutaneous mitral valve repair using MitraClip implant.</description>
          </group>
          <group group_id="O2">
            <title>Control Group (Mitral Valve Surgery)</title>
            <description>Mitral valve repair or replacement surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Left Ventricular Ejection Fraction (LVEF)</title>
          <description>LVEF as determined by the core echo laboratory.</description>
          <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Percentage of volume ejected</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="119"/>
                <count group_id="O2" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.0" spread="9.1"/>
                    <measurement group_id="O2" value="58.4" spread="9.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Left Ventricular Ejection Fraction (LVEF)</title>
        <description>LVEF as determined by the core echo laboratory.</description>
        <time_frame>4 years</time_frame>
        <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Device Group (MitraClip Device)</title>
            <description>Percutaneous mitral valve repair using MitraClip implant.</description>
          </group>
          <group group_id="O2">
            <title>Control Group (Mitral Valve Surgery)</title>
            <description>Mitral valve repair or replacement surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Left Ventricular Ejection Fraction (LVEF)</title>
          <description>LVEF as determined by the core echo laboratory.</description>
          <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Percentage of volume ejected</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.6" spread="9.9"/>
                    <measurement group_id="O2" value="58.9" spread="10.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Left Ventricular Ejection Fraction (LVEF)</title>
        <description>LVEF as determined by the core echo laboratory.</description>
        <time_frame>5 years</time_frame>
        <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Device Group (MitraClip Device)</title>
            <description>Percutaneous mitral valve repair using MitraClip implant.</description>
          </group>
          <group group_id="O2">
            <title>Control Group (Mitral Valve Surgery)</title>
            <description>Mitral valve repair or replacement surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Left Ventricular Ejection Fraction (LVEF)</title>
          <description>LVEF as determined by the core echo laboratory.</description>
          <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Percentage of volume ejected</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="105"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.5" spread="10.1"/>
                    <measurement group_id="O2" value="57" spread="9.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Left Ventricular Status- Left Ventricular End-diastolic Volume (LVEDV), Left Ventricular End-systolic Volume (LVESV)</title>
        <description>Left Ventricular Status includes Left ventricular (LV) end-diastolic volume (LVEDV), LV end-systolic volume (LVESV), as determined by the core echo laboratory at 30 days or hospital discharge, whichever is longer.</description>
        <time_frame>30 days</time_frame>
        <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Device Group (MitraClip Device)</title>
            <description>Percutaneous mitral valve repair using MitraClip implant.</description>
          </group>
          <group group_id="O2">
            <title>Control Group (Mitral Valve Surgery)</title>
            <description>Mitral valve repair or replacement surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Left Ventricular Status- Left Ventricular End-diastolic Volume (LVEDV), Left Ventricular End-systolic Volume (LVESV)</title>
          <description>Left Ventricular Status includes Left ventricular (LV) end-diastolic volume (LVEDV), LV end-systolic volume (LVESV), as determined by the core echo laboratory at 30 days or hospital discharge, whichever is longer.</description>
          <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="170"/>
                <count group_id="O2" value="77"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>LVEDV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="144.7" spread="40.0"/>
                    <measurement group_id="O2" value="130.8" spread="40.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LVESV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.7" spread="27.2"/>
                    <measurement group_id="O2" value="62.0" spread="29.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Left Ventricular Status- LVEDV, LVESV</title>
        <description>Left Ventricular Status includes LV end-diastolic volume (LVEDV), LV end-systolic volume (LVESV),as determined by the core echo laboratory at 12 months.</description>
        <time_frame>12 months</time_frame>
        <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Device Group (MitraClip Device)</title>
            <description>Percutaneous mitral valve repair using MitraClip implant.</description>
          </group>
          <group group_id="O2">
            <title>Control Group (Mitral Valve Surgery)</title>
            <description>Mitral valve repair or replacement surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Left Ventricular Status- LVEDV, LVESV</title>
          <description>Left Ventricular Status includes LV end-diastolic volume (LVEDV), LV end-systolic volume (LVESV),as determined by the core echo laboratory at 12 months.</description>
          <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="144"/>
                <count group_id="O2" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>LVEDV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="133.7" spread="35.5"/>
                    <measurement group_id="O2" value="120.9" spread="44.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LVESV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.5" spread="24.0"/>
                    <measurement group_id="O2" value="56.2" spread="31.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Left Ventricular Status- LVEDV, LVESV</title>
        <description>Left Ventricular Status includes LV end-diastolic volume (LVEDV), LV end-systolic volume (LVESV), as determined by the core echo laboratory at 24 months.</description>
        <time_frame>24 months</time_frame>
        <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Device Group (MitraClip Device)</title>
            <description>Percutaneous mitral valve repair using MitraClip implant.</description>
          </group>
          <group group_id="O2">
            <title>Control Group (Mitral Valve Surgery)</title>
            <description>Mitral valve repair or replacement surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Left Ventricular Status- LVEDV, LVESV</title>
          <description>Left Ventricular Status includes LV end-diastolic volume (LVEDV), LV end-systolic volume (LVESV), as determined by the core echo laboratory at 24 months.</description>
          <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="125"/>
                <count group_id="O2" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>LVEDV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="123.4" spread="35.0"/>
                    <measurement group_id="O2" value="110.5" spread="40.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LVESV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.7" spread="24.7"/>
                    <measurement group_id="O2" value="50.4" spread="26.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Left Ventricular Status- LVEDV, LVESV</title>
        <description>Left Ventricular Status includes LV end-diastolic volume (LVEDV), LV end-systolic volume (LVESV), as determined by the core echo laboratory at 3 years.</description>
        <time_frame>3 years</time_frame>
        <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Device Group (MitraClip Device)</title>
            <description>Percutaneous mitral valve repair using MitraClip implant.</description>
          </group>
          <group group_id="O2">
            <title>Control Group (Mitral Valve Surgery)</title>
            <description>Mitral valve repair or replacement surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Left Ventricular Status- LVEDV, LVESV</title>
          <description>Left Ventricular Status includes LV end-diastolic volume (LVEDV), LV end-systolic volume (LVESV), as determined by the core echo laboratory at 3 years.</description>
          <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="119"/>
                <count group_id="O2" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>LVEDV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="130.6" spread="32.6"/>
                    <measurement group_id="O2" value="112.7" spread="40.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LVESV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.7" spread="24.7"/>
                    <measurement group_id="O2" value="48.0" spread="24.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Left Ventricular Status- LVEDV, LVESV</title>
        <description>Left Ventricular Status includes LV end-diastolic volume (LVEDV), LV end-systolic volume (LVESV), as determined by the core echo laboratory at 4 years</description>
        <time_frame>4 years</time_frame>
        <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Device Group (MitraClip Device)</title>
            <description>Percutaneous mitral valve repair using MitraClip implant.</description>
          </group>
          <group group_id="O2">
            <title>Control Group (Mitral Valve Surgery)</title>
            <description>Mitral valve repair or replacement surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Left Ventricular Status- LVEDV, LVESV</title>
          <description>Left Ventricular Status includes LV end-diastolic volume (LVEDV), LV end-systolic volume (LVESV), as determined by the core echo laboratory at 4 years</description>
          <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>LVEDV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="126.6" spread="33.1"/>
                    <measurement group_id="O2" value="112.7" spread="40.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LVESV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.0" spread="24.4"/>
                    <measurement group_id="O2" value="48.1" spread="26.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Left Ventricular Status- LVEDV, LVESV</title>
        <description>Left Ventricular Status includes LV end-diastolic volume (LVEDV), LV end-systolic volume (LVESV), as determined by the core echo laboratory at 5 years.</description>
        <time_frame>5 years</time_frame>
        <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Device Group (MitraClip Device)</title>
            <description>Percutaneous mitral valve repair using MitraClip implant.</description>
          </group>
          <group group_id="O2">
            <title>Control Group (Mitral Valve Surgery)</title>
            <description>Mitral valve repair or replacement surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Left Ventricular Status- LVEDV, LVESV</title>
          <description>Left Ventricular Status includes LV end-diastolic volume (LVEDV), LV end-systolic volume (LVESV), as determined by the core echo laboratory at 5 years.</description>
          <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="105"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>LVEDV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="126.3" spread="32.5"/>
                    <measurement group_id="O2" value="112.9" spread="37.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LVESV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.1" spread="23"/>
                    <measurement group_id="O2" value="50.1" spread="26.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Left Ventricular Internal Dimension Systole (LVIDs)</title>
        <description>Left Ventricular internal dimension systole (LVIDs) as determined by the core echo laboratory.</description>
        <time_frame>30 days</time_frame>
        <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Device Group (MitraClip Device)</title>
            <description>Percutaneous mitral valve repair using MitraClip implant.</description>
          </group>
          <group group_id="O2">
            <title>Control Group (Mitral Valve Surgery)</title>
            <description>Mitral valve repair or replacement surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Left Ventricular Internal Dimension Systole (LVIDs)</title>
          <description>Left Ventricular internal dimension systole (LVIDs) as determined by the core echo laboratory.</description>
          <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="169"/>
                <count group_id="O2" value="77"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.6" spread="0.9"/>
                    <measurement group_id="O2" value="3.5" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Left Ventricular Internal Dimension Systole (LVIDs)</title>
        <description>Left Ventricular internal dimension systole (LVIDs) as determined by the core echo laboratory.</description>
        <time_frame>12 months</time_frame>
        <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Device Group (MitraClip Device)</title>
            <description>Percutaneous mitral valve repair using MitraClip implant.</description>
          </group>
          <group group_id="O2">
            <title>Control Group (Mitral Valve Surgery)</title>
            <description>Mitral valve repair or replacement surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Left Ventricular Internal Dimension Systole (LVIDs)</title>
          <description>Left Ventricular internal dimension systole (LVIDs) as determined by the core echo laboratory.</description>
          <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="146"/>
                <count group_id="O2" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.5" spread="0.8"/>
                    <measurement group_id="O2" value="3.3" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Left Ventricular Internal Dimension Systole (LVIDs)</title>
        <description>Left Ventricular internal dimension systole (LVIDs) as determined by the core echo laboratory.</description>
        <time_frame>2 years</time_frame>
        <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Device Group (MitraClip Device)</title>
            <description>Percutaneous mitral valve repair using MitraClip implant.</description>
          </group>
          <group group_id="O2">
            <title>Control Group (Mitral Valve Surgery)</title>
            <description>Mitral valve repair or replacement surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Left Ventricular Internal Dimension Systole (LVIDs)</title>
          <description>Left Ventricular internal dimension systole (LVIDs) as determined by the core echo laboratory.</description>
          <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="125"/>
                <count group_id="O2" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4" spread="0.8"/>
                    <measurement group_id="O2" value="3.2" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Left Ventricular Internal Dimension Systole (LVIDs)</title>
        <description>Left Ventricular internal dimension systole (LVIDs) as determined by the core echo laboratory.</description>
        <time_frame>3 years</time_frame>
        <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Device Group (MitraClip Device)</title>
            <description>Percutaneous mitral valve repair using MitraClip implant.</description>
          </group>
          <group group_id="O2">
            <title>Control Group (Mitral Valve Surgery)</title>
            <description>Mitral valve repair or replacement surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Left Ventricular Internal Dimension Systole (LVIDs)</title>
          <description>Left Ventricular internal dimension systole (LVIDs) as determined by the core echo laboratory.</description>
          <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="120"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.6" spread="0.9"/>
                    <measurement group_id="O2" value="3.2" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Left Ventricular Internal Dimension Systole (LVIDs)</title>
        <description>Left Ventricular internal dimension systole (LVIDs) as determined by the core echo laboratory.</description>
        <time_frame>4 years</time_frame>
        <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Device Group (MitraClip Device)</title>
            <description>Percutaneous mitral valve repair using MitraClip implant.</description>
          </group>
          <group group_id="O2">
            <title>Control Group (Mitral Valve Surgery)</title>
            <description>Mitral valve repair or replacement surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Left Ventricular Internal Dimension Systole (LVIDs)</title>
          <description>Left Ventricular internal dimension systole (LVIDs) as determined by the core echo laboratory.</description>
          <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
                <count group_id="O2" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.6" spread="0.9"/>
                    <measurement group_id="O2" value="3.3" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Left Ventricular Internal Dimension Systole (LVIDs)</title>
        <description>Left Ventricular internal dimension systole (LVIDs) as determined by the core echo laboratory.</description>
        <time_frame>5 years</time_frame>
        <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Device Group (MitraClip Device)</title>
            <description>Percutaneous mitral valve repair using MitraClip implant.</description>
          </group>
          <group group_id="O2">
            <title>Control Group (Mitral Valve Surgery)</title>
            <description>Mitral valve repair or replacement surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Left Ventricular Internal Dimension Systole (LVIDs)</title>
          <description>Left Ventricular internal dimension systole (LVIDs) as determined by the core echo laboratory.</description>
          <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="104"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.6" spread="0.9"/>
                    <measurement group_id="O2" value="3.3" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Left Ventricular Internal Dimension Diastole (LVIDd)</title>
        <description>Left Ventricular internal dimension diastole (LVIDd) as determined by the core echo laboratory.</description>
        <time_frame>30 days</time_frame>
        <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Device Group (MitraClip Device)</title>
            <description>Percutaneous mitral valve repair using MitraClip implant.</description>
          </group>
          <group group_id="O2">
            <title>Control Group (Mitral Valve Surgery)</title>
            <description>Mitral valve repair or replacement surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Left Ventricular Internal Dimension Diastole (LVIDd)</title>
          <description>Left Ventricular internal dimension diastole (LVIDd) as determined by the core echo laboratory.</description>
          <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="171"/>
                <count group_id="O2" value="77"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.3" spread="0.7"/>
                    <measurement group_id="O2" value="5.0" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Left Ventricular Internal Dimension Diastole (LVIDd)</title>
        <description>Left Ventricular internal dimension diastole (LVIDd) as determined by the core echo laboratory at 12 months.</description>
        <time_frame>12 months</time_frame>
        <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Device Group (MitraClip Device)</title>
            <description>Percutaneous mitral valve repair using MitraClip implant.</description>
          </group>
          <group group_id="O2">
            <title>Control Group (Mitral Valve Surgery)</title>
            <description>Mitral valve repair or replacement surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Left Ventricular Internal Dimension Diastole (LVIDd)</title>
          <description>Left Ventricular internal dimension diastole (LVIDd) as determined by the core echo laboratory at 12 months.</description>
          <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="148"/>
                <count group_id="O2" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.1" spread="0.7"/>
                    <measurement group_id="O2" value="4.8" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Left Ventricular Internal Dimension Diastole (LVIDd)</title>
        <description>Left Ventricular internal dimension diastole (LVIDd) as determined by the core echo laboratory at 24 months.</description>
        <time_frame>24 months</time_frame>
        <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Device Group (MitraClip Device)</title>
            <description>Percutaneous mitral valve repair using MitraClip implant.</description>
          </group>
          <group group_id="O2">
            <title>Control Group (Mitral Valve Surgery)</title>
            <description>Mitral valve repair or replacement surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Left Ventricular Internal Dimension Diastole (LVIDd)</title>
          <description>Left Ventricular internal dimension diastole (LVIDd) as determined by the core echo laboratory at 24 months.</description>
          <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="127"/>
                <count group_id="O2" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0" spread="0.7"/>
                    <measurement group_id="O2" value="4.7" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Left Ventricular Internal Dimension Diastole (LVIDd)</title>
        <description>Left Ventricular internal dimension diastole (LVIDd) as determined by the core echo laboratory at 3 years.</description>
        <time_frame>3 years</time_frame>
        <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Device Group (MitraClip Device)</title>
            <description>Percutaneous mitral valve repair using MitraClip implant.</description>
          </group>
          <group group_id="O2">
            <title>Control Group (Mitral Valve Surgery)</title>
            <description>Mitral valve repair or replacement surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Left Ventricular Internal Dimension Diastole (LVIDd)</title>
          <description>Left Ventricular internal dimension diastole (LVIDd) as determined by the core echo laboratory at 3 years.</description>
          <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="122"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.2" spread="0.7"/>
                    <measurement group_id="O2" value="4.8" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Left Ventricular Internal Dimension Diastole (LVIDd)</title>
        <description>Left Ventricular internal dimension diastole (LVIDd) as determined by the core echo laboratory at 4 years.</description>
        <time_frame>4 years</time_frame>
        <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Device Group (MitraClip Device)</title>
            <description>Percutaneous mitral valve repair using MitraClip implant.</description>
          </group>
          <group group_id="O2">
            <title>Control Group (Mitral Valve Surgery)</title>
            <description>Mitral valve repair or replacement surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Left Ventricular Internal Dimension Diastole (LVIDd)</title>
          <description>Left Ventricular internal dimension diastole (LVIDd) as determined by the core echo laboratory at 4 years.</description>
          <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
                <count group_id="O2" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.3" spread="0.6"/>
                    <measurement group_id="O2" value="4.8" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Left Ventricular Internal Dimension Diastole (LVIDd)</title>
        <description>Left Ventricular internal dimension diastole (LVIDd) as determined by the core echo laboratory at 5 years.</description>
        <time_frame>5 years</time_frame>
        <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Device Group (MitraClip Device)</title>
            <description>Percutaneous mitral valve repair using MitraClip implant.</description>
          </group>
          <group group_id="O2">
            <title>Control Group (Mitral Valve Surgery)</title>
            <description>Mitral valve repair or replacement surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Left Ventricular Internal Dimension Diastole (LVIDd)</title>
          <description>Left Ventricular internal dimension diastole (LVIDd) as determined by the core echo laboratory at 5 years.</description>
          <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="106"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.2" spread="0.6"/>
                    <measurement group_id="O2" value="4.9" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With New York Heart Association (NYHA) Functional Class Cardiac Disease.</title>
        <description>Class I: Patients with cardiac disease but without resulting limitations of physical activity.
Class II: Patients with cardiac disease resulting in slight limitation of physical activity. Patients are comfortable at rest. Ordinary physical activity results in fatigue, palpitation, dyspnea, or anginal pain.
Class III: Patients with cardiac disease resulting in marked limitation of physical activity. They are comfortable at rest. Less than ordinary physical activity causes fatigue, palpitation dyspnea, or anginal pain.
Class IV: Patients with cardiac disease resulting in inability to carry on any physical activity without discomfort. Symptoms of cardiac insufficiency or of the anginal syndrome may be present even at rest. If any physical activity is undertaken, discomfort is increased.</description>
        <time_frame>Baseline</time_frame>
        <population>ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>Device Group (MitraClip Device)</title>
            <description>Percutaneous mitral valve repair using MitraClip implant.</description>
          </group>
          <group group_id="O2">
            <title>Control Group (Mitral Valve Surgery)</title>
            <description>Mitral valve repair or replacement surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With New York Heart Association (NYHA) Functional Class Cardiac Disease.</title>
          <description>Class I: Patients with cardiac disease but without resulting limitations of physical activity.
Class II: Patients with cardiac disease resulting in slight limitation of physical activity. Patients are comfortable at rest. Ordinary physical activity results in fatigue, palpitation, dyspnea, or anginal pain.
Class III: Patients with cardiac disease resulting in marked limitation of physical activity. They are comfortable at rest. Less than ordinary physical activity causes fatigue, palpitation dyspnea, or anginal pain.
Class IV: Patients with cardiac disease resulting in inability to carry on any physical activity without discomfort. Symptoms of cardiac insufficiency or of the anginal syndrome may be present even at rest. If any physical activity is undertaken, discomfort is increased.</description>
          <population>ITT population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="184"/>
                <count group_id="O2" value="95"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>NYHA Functional Class I</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NYHA Functional Class II</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73"/>
                    <measurement group_id="O2" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NYHA Functional Class III</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82"/>
                    <measurement group_id="O2" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NYHA Functional Class IV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With New York Heart Association (NYHA) Functional Class Cardiac Disease.</title>
        <description>Class I: Patients with cardiac disease but without resulting limitations of physical activity.
Class II: Patients with cardiac disease resulting in slight limitation of physical activity. Patients are comfortable at rest. Ordinary physical activity results in fatigue, palpitation, dyspnea, or anginal pain.
Class III: Patients with cardiac disease resulting in marked limitation of physical activity. They are comfortable at rest. Less than ordinary physical activity causes fatigue, palpitation dyspnea, or anginal pain.
Class IV: Patients with cardiac disease resulting in inability to carry on any physical activity without discomfort. Symptoms of cardiac insufficiency or of the anginal syndrome may be present even at rest. If any physical activity is undertaken, discomfort is increased.</description>
        <time_frame>30 days</time_frame>
        <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Device Group (MitraClip Device)</title>
            <description>Percutaneous mitral valve repair using MitraClip implant.</description>
          </group>
          <group group_id="O2">
            <title>Control Group (Mitral Valve Surgery)</title>
            <description>Mitral valve repair or replacement surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With New York Heart Association (NYHA) Functional Class Cardiac Disease.</title>
          <description>Class I: Patients with cardiac disease but without resulting limitations of physical activity.
Class II: Patients with cardiac disease resulting in slight limitation of physical activity. Patients are comfortable at rest. Ordinary physical activity results in fatigue, palpitation, dyspnea, or anginal pain.
Class III: Patients with cardiac disease resulting in marked limitation of physical activity. They are comfortable at rest. Less than ordinary physical activity causes fatigue, palpitation dyspnea, or anginal pain.
Class IV: Patients with cardiac disease resulting in inability to carry on any physical activity without discomfort. Symptoms of cardiac insufficiency or of the anginal syndrome may be present even at rest. If any physical activity is undertaken, discomfort is increased.</description>
          <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="168"/>
                <count group_id="O2" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>NYHA Functional Class I</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84"/>
                    <measurement group_id="O2" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NYHA Functional Class II</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67"/>
                    <measurement group_id="O2" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NYHA Functional Class III</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NYHA Functional Class IV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With New York Heart Association (NYHA) Functional Class Cardiac Disease.</title>
        <description>Class I: Patients with cardiac disease but without resulting limitations of physical activity.
Class II: Patients with cardiac disease resulting in slight limitation of physical activity. Patients are comfortable at rest. Ordinary physical activity results in fatigue, palpitation, dyspnea, or anginal pain.
Class III: Patients with cardiac disease resulting in marked limitation of physical activity. They are comfortable at rest. Less than ordinary physical activity causes fatigue, palpitation dyspnea, or anginal pain.
Class IV: Patients with cardiac disease resulting in inability to carry on any physical activity without discomfort. Symptoms of cardiac insufficiency or of the anginal syndrome may be present even at rest. If any physical activity is undertaken, discomfort is increased.</description>
        <time_frame>12 months</time_frame>
        <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Device Group (MitraClip Device)</title>
            <description>Percutaneous mitral valve repair using MitraClip implant.</description>
          </group>
          <group group_id="O2">
            <title>Control Group (Mitral Valve Surgery)</title>
            <description>Mitral valve repair or replacement surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With New York Heart Association (NYHA) Functional Class Cardiac Disease.</title>
          <description>Class I: Patients with cardiac disease but without resulting limitations of physical activity.
Class II: Patients with cardiac disease resulting in slight limitation of physical activity. Patients are comfortable at rest. Ordinary physical activity results in fatigue, palpitation, dyspnea, or anginal pain.
Class III: Patients with cardiac disease resulting in marked limitation of physical activity. They are comfortable at rest. Less than ordinary physical activity causes fatigue, palpitation dyspnea, or anginal pain.
Class IV: Patients with cardiac disease resulting in inability to carry on any physical activity without discomfort. Symptoms of cardiac insufficiency or of the anginal syndrome may be present even at rest. If any physical activity is undertaken, discomfort is increased.</description>
          <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="151"/>
                <count group_id="O2" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>NYHA Functional Class I</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="104"/>
                    <measurement group_id="O2" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NYHA Functional Class II</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NYHA Functional Class III</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NYHA Functional Class IV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With New York Heart Association (NYHA) Functional Class Cardiac Disease.</title>
        <description>Class I: Patients with cardiac disease but without resulting limitations of physical activity.
Class II: Patients with cardiac disease resulting in slight limitation of physical activity. Patients are comfortable at rest. Ordinary physical activity results in fatigue, palpitation, dyspnea, or anginal pain.
Class III: Patients with cardiac disease resulting in marked limitation of physical activity. They are comfortable at rest. Less than ordinary physical activity causes fatigue, palpitation dyspnea, or anginal pain.
Class IV: Patients with cardiac disease resulting in inability to carry on any physical activity without discomfort. Symptoms of cardiac insufficiency or of the anginal syndrome may be present even at rest. If any physical activity is undertaken, discomfort is increased.</description>
        <time_frame>24 months</time_frame>
        <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Device Group (MitraClip Device)</title>
            <description>Percutaneous mitral valve repair using MitraClip implant.</description>
          </group>
          <group group_id="O2">
            <title>Control Group (Mitral Valve Surgery)</title>
            <description>Mitral valve repair or replacement surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With New York Heart Association (NYHA) Functional Class Cardiac Disease.</title>
          <description>Class I: Patients with cardiac disease but without resulting limitations of physical activity.
Class II: Patients with cardiac disease resulting in slight limitation of physical activity. Patients are comfortable at rest. Ordinary physical activity results in fatigue, palpitation, dyspnea, or anginal pain.
Class III: Patients with cardiac disease resulting in marked limitation of physical activity. They are comfortable at rest. Less than ordinary physical activity causes fatigue, palpitation dyspnea, or anginal pain.
Class IV: Patients with cardiac disease resulting in inability to carry on any physical activity without discomfort. Symptoms of cardiac insufficiency or of the anginal syndrome may be present even at rest. If any physical activity is undertaken, discomfort is increased.</description>
          <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="132"/>
                <count group_id="O2" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>NYHA Functional Class I</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89"/>
                    <measurement group_id="O2" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NYHA Functional Class II</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NYHA Functional Class III</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NYHA Functional Class IV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With New York Heart Association (NYHA) Functional Class Cardiac Disease.</title>
        <description>Class I: Patients with cardiac disease but without resulting limitations of physical activity.
Class II: Patients with cardiac disease resulting in slight limitation of physical activity. Patients are comfortable at rest. Ordinary physical activity results in fatigue, palpitation, dyspnea, or anginal pain.
Class III: Patients with cardiac disease resulting in marked limitation of physical activity. They are comfortable at rest. Less than ordinary physical activity causes fatigue, palpitation dyspnea, or anginal pain.
Class IV: Patients with cardiac disease resulting in inability to carry on any physical activity without discomfort. Symptoms of cardiac insufficiency or of the anginal syndrome may be present even at rest. If any physical activity is undertaken, discomfort is increased.</description>
        <time_frame>3 years</time_frame>
        <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Device Group (MitraClip Device)</title>
            <description>Percutaneous mitral valve repair using MitraClip implant.</description>
          </group>
          <group group_id="O2">
            <title>Control Group (Mitral Valve Surgery)</title>
            <description>Mitral valve repair or replacement surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With New York Heart Association (NYHA) Functional Class Cardiac Disease.</title>
          <description>Class I: Patients with cardiac disease but without resulting limitations of physical activity.
Class II: Patients with cardiac disease resulting in slight limitation of physical activity. Patients are comfortable at rest. Ordinary physical activity results in fatigue, palpitation, dyspnea, or anginal pain.
Class III: Patients with cardiac disease resulting in marked limitation of physical activity. They are comfortable at rest. Less than ordinary physical activity causes fatigue, palpitation dyspnea, or anginal pain.
Class IV: Patients with cardiac disease resulting in inability to carry on any physical activity without discomfort. Symptoms of cardiac insufficiency or of the anginal syndrome may be present even at rest. If any physical activity is undertaken, discomfort is increased.</description>
          <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="120"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>NYHA Functional Class I</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84"/>
                    <measurement group_id="O2" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NYHA Functional Class II</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NYHA Functional Class III</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NYHA Functional Class IV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With New York Heart Association (NYHA) Functional Class Cardiac Disease.</title>
        <description>Class I: Patients with cardiac disease but without resulting limitations of physical activity.
Class II: Patients with cardiac disease resulting in slight limitation of physical activity. Patients are comfortable at rest. Ordinary physical activity results in fatigue, palpitation, dyspnea, or anginal pain.
Class III: Patients with cardiac disease resulting in marked limitation of physical activity. They are comfortable at rest. Less than ordinary physical activity causes fatigue, palpitation dyspnea, or anginal pain.
Class IV: Patients with cardiac disease resulting in inability to carry on any physical activity without discomfort. Symptoms of cardiac insufficiency or of the anginal syndrome may be present even at rest. If any physical activity is undertaken, discomfort is increased.</description>
        <time_frame>4 years</time_frame>
        <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Device Group (MitraClip Device)</title>
            <description>Percutaneous mitral valve repair using MitraClip implant.</description>
          </group>
          <group group_id="O2">
            <title>Control Group (Mitral Valve Surgery)</title>
            <description>Mitral valve repair or replacement surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With New York Heart Association (NYHA) Functional Class Cardiac Disease.</title>
          <description>Class I: Patients with cardiac disease but without resulting limitations of physical activity.
Class II: Patients with cardiac disease resulting in slight limitation of physical activity. Patients are comfortable at rest. Ordinary physical activity results in fatigue, palpitation, dyspnea, or anginal pain.
Class III: Patients with cardiac disease resulting in marked limitation of physical activity. They are comfortable at rest. Less than ordinary physical activity causes fatigue, palpitation dyspnea, or anginal pain.
Class IV: Patients with cardiac disease resulting in inability to carry on any physical activity without discomfort. Symptoms of cardiac insufficiency or of the anginal syndrome may be present even at rest. If any physical activity is undertaken, discomfort is increased.</description>
          <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="105"/>
                <count group_id="O2" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>NYHA Functional Class I</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70"/>
                    <measurement group_id="O2" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NYHA Functional Class II</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NYHA Functional Class III</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NYHA Functional Class IV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With New York Heart Association (NYHA) Functional Class Cardiac Disease.</title>
        <description>Class I: Patients with cardiac disease but without resulting limitations of physical activity.
Class II: Patients with cardiac disease resulting in slight limitation of physical activity. Patients are comfortable at rest. Ordinary physical activity results in fatigue, palpitation, dyspnea, or anginal pain.
Class III: Patients with cardiac disease resulting in marked limitation of physical activity. They are comfortable at rest. Less than ordinary physical activity causes fatigue, palpitation dyspnea, or anginal pain.
Class IV: Patients with cardiac disease resulting in inability to carry on any physical activity without discomfort. Symptoms of cardiac insufficiency or of the anginal syndrome may be present even at rest. If any physical activity is undertaken, discomfort is increased.</description>
        <time_frame>5 years</time_frame>
        <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Device Group (MitraClip Device)</title>
            <description>Percutaneous mitral valve repair using MitraClip implant.</description>
          </group>
          <group group_id="O2">
            <title>Control Group (Mitral Valve Surgery)</title>
            <description>Mitral valve repair or replacement surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With New York Heart Association (NYHA) Functional Class Cardiac Disease.</title>
          <description>Class I: Patients with cardiac disease but without resulting limitations of physical activity.
Class II: Patients with cardiac disease resulting in slight limitation of physical activity. Patients are comfortable at rest. Ordinary physical activity results in fatigue, palpitation, dyspnea, or anginal pain.
Class III: Patients with cardiac disease resulting in marked limitation of physical activity. They are comfortable at rest. Less than ordinary physical activity causes fatigue, palpitation dyspnea, or anginal pain.
Class IV: Patients with cardiac disease resulting in inability to carry on any physical activity without discomfort. Symptoms of cardiac insufficiency or of the anginal syndrome may be present even at rest. If any physical activity is undertaken, discomfort is increased.</description>
          <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="106"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>NYHA Functional Class I</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70"/>
                    <measurement group_id="O2" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NYHA Functional Class II</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NYHA Functional Class III</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NYHA Functional Class IV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>New York Heart Association (NYHA) Functional Class Cardiac Disease: NYHA Functional Class III or IV</title>
        <description>Class I: Patients with cardiac disease but without resulting limitations of physical activity.
Class II: Patients with cardiac disease resulting in slight limitation of physical activity. Patients are comfortable at rest. Ordinary physical activity results in fatigue, palpitation, dyspnea, or anginal pain.
Class III: Patients with cardiac disease resulting in marked limitation of physical activity. They are comfortable at rest. Less than ordinary physical activity causes fatigue, palpitation dyspnea, or anginal pain.
Class IV: Patients with cardiac disease resulting in inability to carry on any physical activity without discomfort. Symptoms of cardiac insufficiency or of the anginal syndrome may be present even at rest. If any physical activity is undertaken, discomfort is increased.</description>
        <time_frame>30 days</time_frame>
        <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Device Group (MitraClip Device)</title>
            <description>Percutaneous mitral valve repair using MitraClip implant.</description>
          </group>
          <group group_id="O2">
            <title>Control Group (Mitral Valve Surgery)</title>
            <description>Mitral valve repair or replacement surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>New York Heart Association (NYHA) Functional Class Cardiac Disease: NYHA Functional Class III or IV</title>
          <description>Class I: Patients with cardiac disease but without resulting limitations of physical activity.
Class II: Patients with cardiac disease resulting in slight limitation of physical activity. Patients are comfortable at rest. Ordinary physical activity results in fatigue, palpitation, dyspnea, or anginal pain.
Class III: Patients with cardiac disease resulting in marked limitation of physical activity. They are comfortable at rest. Less than ordinary physical activity causes fatigue, palpitation dyspnea, or anginal pain.
Class IV: Patients with cardiac disease resulting in inability to carry on any physical activity without discomfort. Symptoms of cardiac insufficiency or of the anginal syndrome may be present even at rest. If any physical activity is undertaken, discomfort is increased.</description>
          <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="168"/>
                <count group_id="O2" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.1"/>
                    <measurement group_id="O2" value="9.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With New York Heart Association (NYHA) Functional Class Cardiac Disease: NYHA Functional Class III or IV</title>
        <description>Class I: Patients with cardiac disease but without resulting limitations of physical activity.
Class II: Patients with cardiac disease resulting in slight limitation of physical activity. Patients are comfortable at rest. Ordinary physical activity results in fatigue, palpitation, dyspnea, or anginal pain.
Class III: Patients with cardiac disease resulting in marked limitation of physical activity. They are comfortable at rest. Less than ordinary physical activity causes fatigue, palpitation dyspnea, or anginal pain.
Class IV: Patients with cardiac disease resulting in inability to carry on any physical activity without discomfort. Symptoms of cardiac insufficiency or of the anginal syndrome may be present even at rest. If any physical activity is undertaken, discomfort is increased.</description>
        <time_frame>12 months</time_frame>
        <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Device Group (MitraClip Device)</title>
            <description>Percutaneous mitral valve repair using MitraClip implant.</description>
          </group>
          <group group_id="O2">
            <title>Control Group (Mitral Valve Surgery)</title>
            <description>Mitral valve repair or replacement surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With New York Heart Association (NYHA) Functional Class Cardiac Disease: NYHA Functional Class III or IV</title>
          <description>Class I: Patients with cardiac disease but without resulting limitations of physical activity.
Class II: Patients with cardiac disease resulting in slight limitation of physical activity. Patients are comfortable at rest. Ordinary physical activity results in fatigue, palpitation, dyspnea, or anginal pain.
Class III: Patients with cardiac disease resulting in marked limitation of physical activity. They are comfortable at rest. Less than ordinary physical activity causes fatigue, palpitation dyspnea, or anginal pain.
Class IV: Patients with cardiac disease resulting in inability to carry on any physical activity without discomfort. Symptoms of cardiac insufficiency or of the anginal syndrome may be present even at rest. If any physical activity is undertaken, discomfort is increased.</description>
          <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="151"/>
                <count group_id="O2" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0"/>
                    <measurement group_id="O2" value="12.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With New York Heart Association (NYHA) Functional Class Cardiac Disease: NYHA Functional Class III or IV</title>
        <description>Class I: Patients with cardiac disease but without resulting limitations of physical activity.
Class II: Patients with cardiac disease resulting in slight limitation of physical activity. Patients are comfortable at rest. Ordinary physical activity results in fatigue, palpitation, dyspnea, or anginal pain.
Class III: Patients with cardiac disease resulting in marked limitation of physical activity. They are comfortable at rest. Less than ordinary physical activity causes fatigue, palpitation dyspnea, or anginal pain.
Class IV: Patients with cardiac disease resulting in inability to carry on any physical activity without discomfort. Symptoms of cardiac insufficiency or of the anginal syndrome may be present even at rest. If any physical activity is undertaken, discomfort is increased.</description>
        <time_frame>2 years</time_frame>
        <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Device Group (MitraClip Device)</title>
            <description>Percutaneous mitral valve repair using MitraClip implant.</description>
          </group>
          <group group_id="O2">
            <title>Control Group (Mitral Valve Surgery)</title>
            <description>Mitral valve repair or replacement surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With New York Heart Association (NYHA) Functional Class Cardiac Disease: NYHA Functional Class III or IV</title>
          <description>Class I: Patients with cardiac disease but without resulting limitations of physical activity.
Class II: Patients with cardiac disease resulting in slight limitation of physical activity. Patients are comfortable at rest. Ordinary physical activity results in fatigue, palpitation, dyspnea, or anginal pain.
Class III: Patients with cardiac disease resulting in marked limitation of physical activity. They are comfortable at rest. Less than ordinary physical activity causes fatigue, palpitation dyspnea, or anginal pain.
Class IV: Patients with cardiac disease resulting in inability to carry on any physical activity without discomfort. Symptoms of cardiac insufficiency or of the anginal syndrome may be present even at rest. If any physical activity is undertaken, discomfort is increased.</description>
          <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="132"/>
                <count group_id="O2" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8"/>
                    <measurement group_id="O2" value="10.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With New York Heart Association (NYHA) Functional Class Cardiac Disease: NYHA Functional Class III or IV</title>
        <description>Class I: Patients with cardiac disease but without resulting limitations of physical activity.
Class II: Patients with cardiac disease resulting in slight limitation of physical activity. Patients are comfortable at rest. Ordinary physical activity results in fatigue, palpitation, dyspnea, or anginal pain.
Class III: Patients with cardiac disease resulting in marked limitation of physical activity. They are comfortable at rest. Less than ordinary physical activity causes fatigue, palpitation dyspnea, or anginal pain.
Class IV: Patients with cardiac disease resulting in inability to carry on any physical activity without discomfort. Symptoms of cardiac insufficiency or of the anginal syndrome may be present even at rest. If any physical activity is undertaken, discomfort is increased.</description>
        <time_frame>3 years</time_frame>
        <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Device Group (MitraClip Device)</title>
            <description>Percutaneous mitral valve repair using MitraClip implant.</description>
          </group>
          <group group_id="O2">
            <title>Control Group (Mitral Valve Surgery)</title>
            <description>Mitral valve repair or replacement surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With New York Heart Association (NYHA) Functional Class Cardiac Disease: NYHA Functional Class III or IV</title>
          <description>Class I: Patients with cardiac disease but without resulting limitations of physical activity.
Class II: Patients with cardiac disease resulting in slight limitation of physical activity. Patients are comfortable at rest. Ordinary physical activity results in fatigue, palpitation, dyspnea, or anginal pain.
Class III: Patients with cardiac disease resulting in marked limitation of physical activity. They are comfortable at rest. Less than ordinary physical activity causes fatigue, palpitation dyspnea, or anginal pain.
Class IV: Patients with cardiac disease resulting in inability to carry on any physical activity without discomfort. Symptoms of cardiac insufficiency or of the anginal syndrome may be present even at rest. If any physical activity is undertaken, discomfort is increased.</description>
          <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="120"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3"/>
                    <measurement group_id="O2" value="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With New York Heart Association (NYHA) Functional Class Cardiac Disease: NYHA Functional Class III or IV</title>
        <description>Class I: Patients with cardiac disease but without resulting limitations of physical activity.
Class II: Patients with cardiac disease resulting in slight limitation of physical activity. Patients are comfortable at rest. Ordinary physical activity results in fatigue, palpitation, dyspnea, or anginal pain.
Class III: Patients with cardiac disease resulting in marked limitation of physical activity. They are comfortable at rest. Less than ordinary physical activity causes fatigue, palpitation dyspnea, or anginal pain.
Class IV: Patients with cardiac disease resulting in inability to carry on any physical activity without discomfort. Symptoms of cardiac insufficiency or of the anginal syndrome may be present even at rest. If any physical activity is undertaken, discomfort is increased.</description>
        <time_frame>4 years</time_frame>
        <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Device Group (MitraClip Device)</title>
            <description>Percutaneous mitral valve repair using MitraClip implant.</description>
          </group>
          <group group_id="O2">
            <title>Control Group (Mitral Valve Surgery)</title>
            <description>Mitral valve repair or replacement surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With New York Heart Association (NYHA) Functional Class Cardiac Disease: NYHA Functional Class III or IV</title>
          <description>Class I: Patients with cardiac disease but without resulting limitations of physical activity.
Class II: Patients with cardiac disease resulting in slight limitation of physical activity. Patients are comfortable at rest. Ordinary physical activity results in fatigue, palpitation, dyspnea, or anginal pain.
Class III: Patients with cardiac disease resulting in marked limitation of physical activity. They are comfortable at rest. Less than ordinary physical activity causes fatigue, palpitation dyspnea, or anginal pain.
Class IV: Patients with cardiac disease resulting in inability to carry on any physical activity without discomfort. Symptoms of cardiac insufficiency or of the anginal syndrome may be present even at rest. If any physical activity is undertaken, discomfort is increased.</description>
          <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="105"/>
                <count group_id="O2" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.7"/>
                    <measurement group_id="O2" value="6.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With New York Heart Association (NYHA) Functional Class Cardiac Disease: NYHA Functional Class III or IV</title>
        <description>Class I: Patients with cardiac disease but without resulting limitations of physical activity.
Class II: Patients with cardiac disease resulting in slight limitation of physical activity. Patients are comfortable at rest. Ordinary physical activity results in fatigue, palpitation, dyspnea, or anginal pain.
Class III: Patients with cardiac disease resulting in marked limitation of physical activity. They are comfortable at rest. Less than ordinary physical activity causes fatigue, palpitation dyspnea, or anginal pain.
Class IV: Patients with cardiac disease resulting in inability to carry on any physical activity without discomfort. Symptoms of cardiac insufficiency or of the anginal syndrome may be present even at rest. If any physical activity is undertaken, discomfort is increased.</description>
        <time_frame>5 years</time_frame>
        <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Device Group (MitraClip Device)</title>
            <description>Percutaneous mitral valve repair using MitraClip implant.</description>
          </group>
          <group group_id="O2">
            <title>Control Group (Mitral Valve Surgery)</title>
            <description>Mitral valve repair or replacement surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With New York Heart Association (NYHA) Functional Class Cardiac Disease: NYHA Functional Class III or IV</title>
          <description>Class I: Patients with cardiac disease but without resulting limitations of physical activity.
Class II: Patients with cardiac disease resulting in slight limitation of physical activity. Patients are comfortable at rest. Ordinary physical activity results in fatigue, palpitation, dyspnea, or anginal pain.
Class III: Patients with cardiac disease resulting in marked limitation of physical activity. They are comfortable at rest. Less than ordinary physical activity causes fatigue, palpitation dyspnea, or anginal pain.
Class IV: Patients with cardiac disease resulting in inability to carry on any physical activity without discomfort. Symptoms of cardiac insufficiency or of the anginal syndrome may be present even at rest. If any physical activity is undertaken, discomfort is increased.</description>
          <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="106"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.5"/>
                    <measurement group_id="O2" value="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Short Form (SF)-36 Quality of Life Questionnaire.</title>
        <description>The SF-36 is a multidimensional, patient-reported survey containing 36 questions on a 0-100 scale measuring physical (Physical Component Score) &amp; mental health status (Mental Component Score) in relation to 8 health concepts: physical functioning, role limitations due to physical or emotional health, bodily pain, general health perceptions, vitality, social functioning, &amp; general mental health. Responses to each of the SF-36 items are scored and expressed as a score on a 0–100 scale (0% in a domain represents the poorest possible QOL&amp;100% indicates full QOL).Higher scores represent better self-perceived health.
The physical &amp; mental functions were assessed by the Physical Component Summary (PCS) score &amp; Mental Component Summary (MCS) score. Normal PCS and MCS scores vary depending on the demographics of the population studied. The PCS&amp;MCS norms for 65-75 year old are 44 &amp; 52, respectively while the norms for CHF population are 31 &amp; 46, respectively.</description>
        <time_frame>30 days</time_frame>
        <population>The SF-36 questionnaire consists of 36 questions in relation to eight health concepts:
Physical functioning, role limitations due to physical health, bodily pain,general health perceptions,vitality (energy/fatigue),social functioning,role limitations due to emotional health and general mental health (psychological distress/wellbeing).</population>
        <group_list>
          <group group_id="O1">
            <title>Device Group (MitraClip Device)</title>
            <description>Percutaneous mitral valve repair using MitraClip implant.</description>
          </group>
          <group group_id="O2">
            <title>Control Group (Mitral Valve Surgery)</title>
            <description>Mitral valve repair or replacement surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Short Form (SF)-36 Quality of Life Questionnaire.</title>
          <description>The SF-36 is a multidimensional, patient-reported survey containing 36 questions on a 0-100 scale measuring physical (Physical Component Score) &amp; mental health status (Mental Component Score) in relation to 8 health concepts: physical functioning, role limitations due to physical or emotional health, bodily pain, general health perceptions, vitality, social functioning, &amp; general mental health. Responses to each of the SF-36 items are scored and expressed as a score on a 0–100 scale (0% in a domain represents the poorest possible QOL&amp;100% indicates full QOL).Higher scores represent better self-perceived health.
The physical &amp; mental functions were assessed by the Physical Component Summary (PCS) score &amp; Mental Component Summary (MCS) score. Normal PCS and MCS scores vary depending on the demographics of the population studied. The PCS&amp;MCS norms for 65-75 year old are 44 &amp; 52, respectively while the norms for CHF population are 31 &amp; 46, respectively.</description>
          <population>The SF-36 questionnaire consists of 36 questions in relation to eight health concepts:
Physical functioning, role limitations due to physical health, bodily pain,general health perceptions,vitality (energy/fatigue),social functioning,role limitations due to emotional health and general mental health (psychological distress/wellbeing).</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="159"/>
                <count group_id="O2" value="68"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Physical Component Summary</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.8" spread="9.8"/>
                    <measurement group_id="O2" value="36.9" spread="9.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mental Component Summary</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.8" spread="10.8"/>
                    <measurement group_id="O2" value="46.7" spread="12.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Short Form (SF)-36 Quality of Life Questionnaire.</title>
        <description>The SF-36 is a multidimensional, patient-reported survey containing 36 questions on a 0-100 scale measuring physical (Physical Component Score) &amp; mental health status (Mental Component Score) in relation to 8 health concepts: physical functioning, role limitations due to physical or emotional health, bodily pain, general health perceptions, vitality, social functioning, &amp; general mental health. Responses to each of the SF-36 items are scored and expressed as a score on a 0–100 scale (0% in a domain represents the poorest possible QOL&amp;100% indicates full QOL).Higher scores represent better self-perceived health.
The physical &amp; mental functions were assessed by the Physical Component Summary (PCS) score &amp; Mental Component Summary (MCS) score. Normal PCS and MCS scores vary depending on the demographics of the population studied. The PCS&amp;MCS norms for 65-75 year old are 44 &amp; 52, respectively while the norms for CHF population are 31 &amp; 46, respectively.</description>
        <time_frame>12 months</time_frame>
        <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Device Group (MitraClip Device)</title>
            <description>Percutaneous mitral valve repair using MitraClip implant.</description>
          </group>
          <group group_id="O2">
            <title>Control Group (Mitral Valve Surgery)</title>
            <description>Mitral valve repair or replacement surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Short Form (SF)-36 Quality of Life Questionnaire.</title>
          <description>The SF-36 is a multidimensional, patient-reported survey containing 36 questions on a 0-100 scale measuring physical (Physical Component Score) &amp; mental health status (Mental Component Score) in relation to 8 health concepts: physical functioning, role limitations due to physical or emotional health, bodily pain, general health perceptions, vitality, social functioning, &amp; general mental health. Responses to each of the SF-36 items are scored and expressed as a score on a 0–100 scale (0% in a domain represents the poorest possible QOL&amp;100% indicates full QOL).Higher scores represent better self-perceived health.
The physical &amp; mental functions were assessed by the Physical Component Summary (PCS) score &amp; Mental Component Summary (MCS) score. Normal PCS and MCS scores vary depending on the demographics of the population studied. The PCS&amp;MCS norms for 65-75 year old are 44 &amp; 52, respectively while the norms for CHF population are 31 &amp; 46, respectively.</description>
          <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="139"/>
                <count group_id="O2" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Physical Component Summary</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.8" spread="9.5"/>
                    <measurement group_id="O2" value="46.5" spread="10.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mental Component Summary</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.9" spread="8.0"/>
                    <measurement group_id="O2" value="50.4" spread="10.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cardiac Output</title>
        <description>Cardiac output as measured by core lab echocardiography.</description>
        <time_frame>30 days</time_frame>
        <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Device Group (MitraClip Device)</title>
            <description>Percutaneous mitral valve repair using MitraClip implant.</description>
          </group>
          <group group_id="O2">
            <title>Control Group (Mitral Valve Surgery)</title>
            <description>Mitral valve repair or replacement surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Cardiac Output</title>
          <description>Cardiac output as measured by core lab echocardiography.</description>
          <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>L/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="162"/>
                <count group_id="O2" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.2" spread="1.2"/>
                    <measurement group_id="O2" value="4.8" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cardiac Output</title>
        <description>Cardiac output as measured by core lab echocardiography.</description>
        <time_frame>12 months</time_frame>
        <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Device Group (MitraClip Device)</title>
            <description>Percutaneous mitral valve repair using MitraClip implant.</description>
          </group>
          <group group_id="O2">
            <title>Control Group (Mitral Valve Surgery)</title>
            <description>Mitral valve repair or replacement surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Cardiac Output</title>
          <description>Cardiac output as measured by core lab echocardiography.</description>
          <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>L/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="147"/>
                <count group_id="O2" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.4" spread="1.3"/>
                    <measurement group_id="O2" value="4.6" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cardiac Output</title>
        <description>Cardiac output as measured by core lab echocardiography.</description>
        <time_frame>24 months</time_frame>
        <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Device Group (MitraClip Device)</title>
            <description>Percutaneous mitral valve repair using MitraClip implant.</description>
          </group>
          <group group_id="O2">
            <title>Control Group (Mitral Valve Surgery)</title>
            <description>Mitral valve repair or replacement surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Cardiac Output</title>
          <description>Cardiac output as measured by core lab echocardiography.</description>
          <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>L/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="121"/>
                <count group_id="O2" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0" spread="1.1"/>
                    <measurement group_id="O2" value="4.1" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cardiac Index</title>
        <description>Defined as cardiac output divided by body surface area, as measured by core lab echocardiography.</description>
        <time_frame>30 days</time_frame>
        <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Device Group (MitraClip Device)</title>
            <description>Percutaneous mitral valve repair using MitraClip implant.</description>
          </group>
          <group group_id="O2">
            <title>Control Group (Mitral Valve Surgery)</title>
            <description>Mitral valve repair or replacement surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Cardiac Index</title>
          <description>Defined as cardiac output divided by body surface area, as measured by core lab echocardiography.</description>
          <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>L/min/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="158"/>
                <count group_id="O2" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2" spread="0.6"/>
                    <measurement group_id="O2" value="2.5" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cardiac Index (CI)</title>
        <description>Defined as cardiac output divided by body surface area as measured by core lab echocardiography. CI is a normalization of cardiac output to take into account the effect of body size on cardiac output requirements.</description>
        <time_frame>12 months</time_frame>
        <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Device Group (MitraClip Device)</title>
            <description>Percutaneous mitral valve repair using MitraClip implant.</description>
          </group>
          <group group_id="O2">
            <title>Control Group (Mitral Valve Surgery)</title>
            <description>Mitral valve repair or replacement surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Cardiac Index (CI)</title>
          <description>Defined as cardiac output divided by body surface area as measured by core lab echocardiography. CI is a normalization of cardiac output to take into account the effect of body size on cardiac output requirements.</description>
          <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>L/min/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="145"/>
                <count group_id="O2" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" spread="0.6"/>
                    <measurement group_id="O2" value="2.4" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cardiac Index</title>
        <description>Defined as cardiac output divided by body surface area, as measured by core lab echocardiography.</description>
        <time_frame>24 months</time_frame>
        <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Device Group (MitraClip Device)</title>
            <description>Percutaneous mitral valve repair using MitraClip implant.</description>
          </group>
          <group group_id="O2">
            <title>Control Group (Mitral Valve Surgery)</title>
            <description>Mitral valve repair or replacement surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Cardiac Index</title>
          <description>Defined as cardiac output divided by body surface area, as measured by core lab echocardiography.</description>
          <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>L/min/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="121"/>
                <count group_id="O2" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1" spread="0.5"/>
                    <measurement group_id="O2" value="2.1" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Regurgitant Volume</title>
        <description>Regurgitant volume as determined by the core echo laboratory. In the presence of regurgitation of one valve, without any intracardiac shunt, the flow through the affected valve is larger than through other competent valves. The difference between the two represents the regurgitant volume.</description>
        <time_frame>30 Days</time_frame>
        <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Device Group (MitraClip Device)</title>
            <description>Percutaneous mitral valve repair using MitraClip implant.</description>
          </group>
          <group group_id="O2">
            <title>Control Group (Mitral Valve Surgery)</title>
            <description>Mitral valve repair or replacement surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Regurgitant Volume</title>
          <description>Regurgitant volume as determined by the core echo laboratory. In the presence of regurgitation of one valve, without any intracardiac shunt, the flow through the affected valve is larger than through other competent valves. The difference between the two represents the regurgitant volume.</description>
          <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="131"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.7" spread="17.6"/>
                    <measurement group_id="O2" value="13.1" spread="10.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Regurgitant Volume</title>
        <description>Regurgitant volume as determined by the core echo laboratory.</description>
        <time_frame>12 months</time_frame>
        <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Device Group (MitraClip Device)</title>
            <description>Percutaneous mitral valve repair using MitraClip implant.</description>
          </group>
          <group group_id="O2">
            <title>Control Group (Mitral Valve Surgery)</title>
            <description>Mitral valve repair or replacement surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Regurgitant Volume</title>
          <description>Regurgitant volume as determined by the core echo laboratory.</description>
          <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="115"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.9" spread="14.4"/>
                    <measurement group_id="O2" value="14.6" spread="10.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Regurgitant Volume</title>
        <description>Regurgitant volume as determined by the core echo laboratory.</description>
        <time_frame>24 months</time_frame>
        <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Device Group (MitraClip Device)</title>
            <description>Percutaneous mitral valve repair using MitraClip implant.</description>
          </group>
          <group group_id="O2">
            <title>Control Group (Mitral Valve Surgery)</title>
            <description>Mitral valve repair or replacement surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Regurgitant Volume</title>
          <description>Regurgitant volume as determined by the core echo laboratory.</description>
          <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="85"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.4" spread="13.2"/>
                    <measurement group_id="O2" value="15.7" spread="10.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Regurgitant Fraction (RF)</title>
        <description>RF is defined as the percentage of the left ventricular (LV) stroke volume that regurgitates into the left atrium.</description>
        <time_frame>30 Days</time_frame>
        <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Device Group (MitraClip Device)</title>
            <description>Percutaneous mitral valve repair using MitraClip implant.</description>
          </group>
          <group group_id="O2">
            <title>Control Group (Mitral Valve Surgery)</title>
            <description>Mitral valve repair or replacement surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Regurgitant Fraction (RF)</title>
          <description>RF is defined as the percentage of the left ventricular (LV) stroke volume that regurgitates into the left atrium.</description>
          <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>percentage of LV stroke volume</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="131"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.4" spread="15.3"/>
                    <measurement group_id="O2" value="17.3" spread="13.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Regurgitant Fraction</title>
        <description>Regurgitant fraction is defined as the percentage of the left ventricular (LV) stroke volume that regurgitates into the left atrium.</description>
        <time_frame>12 months</time_frame>
        <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Device Group (MitraClip Device)</title>
            <description>Percutaneous mitral valve repair using MitraClip implant.</description>
          </group>
          <group group_id="O2">
            <title>Control Group (Mitral Valve Surgery)</title>
            <description>Mitral valve repair or replacement surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Regurgitant Fraction</title>
          <description>Regurgitant fraction is defined as the percentage of the left ventricular (LV) stroke volume that regurgitates into the left atrium.</description>
          <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Percentage of LV stroke volume</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="115"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.8" spread="13.8"/>
                    <measurement group_id="O2" value="19.2" spread="12.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Regurgitant Fraction</title>
        <description>Regurgitant fraction is defined as the percentage of the left ventricular (LV) stroke volume that regurgitates into the left atrium.</description>
        <time_frame>24 months</time_frame>
        <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Device Group (MitraClip Device)</title>
            <description>Percutaneous mitral valve repair using MitraClip implant.</description>
          </group>
          <group group_id="O2">
            <title>Control Group (Mitral Valve Surgery)</title>
            <description>Mitral valve repair or replacement surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Regurgitant Fraction</title>
          <description>Regurgitant fraction is defined as the percentage of the left ventricular (LV) stroke volume that regurgitates into the left atrium.</description>
          <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Percentage of LV stroke volume</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="85"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.5" spread="13.3"/>
                    <measurement group_id="O2" value="20.4" spread="10.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Clip Implant Rate</title>
        <description>Defined as the rate of successful implantation of MitraClip(s).</description>
        <time_frame>Day 0</time_frame>
        <population>The number of participants analyzed includes subjects who had available follow up data at that time frame. MitraClip was not implanted in control group, hence overall number of patients analyzed will remain 0.</population>
        <group_list>
          <group group_id="O1">
            <title>Device Group (MitraClip Device)</title>
            <description>Percutaneous mitral valve repair using MitraClip implant.</description>
          </group>
          <group group_id="O2">
            <title>Control Group (Mitral Valve Surgery)</title>
            <description>Mitral valve repair or replacement surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clip Implant Rate</title>
          <description>Defined as the rate of successful implantation of MitraClip(s).</description>
          <population>The number of participants analyzed includes subjects who had available follow up data at that time frame. MitraClip was not implanted in control group, hence overall number of patients analyzed will remain 0.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="178"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="158"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Acute Procedural Success</title>
        <description>Defined as successful MitraClip implantation with resulting MR of 2+ or less.</description>
        <time_frame>30 Days</time_frame>
        <population>ITT population. The number of participants analyzed in Device group includes subjects who had available follow up data at that time frame. Not applicable for Mitral valve surgery patients as device was not implanted.</population>
        <group_list>
          <group group_id="O1">
            <title>Device Group (MitraClip Device)</title>
            <description>Percutaneous mitral valve repair using MitraClip implant.</description>
          </group>
          <group group_id="O2">
            <title>Control Group (Mitral Valve Surgery)</title>
            <description>Mitral valve repair or replacement surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Acute Procedural Success</title>
          <description>Defined as successful MitraClip implantation with resulting MR of 2+ or less.</description>
          <population>ITT population. The number of participants analyzed in Device group includes subjects who had available follow up data at that time frame. Not applicable for Mitral valve surgery patients as device was not implanted.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="184"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="137"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Acute Surgical Success</title>
        <description>Defined as successful mitral valve repair or replacement surgery.</description>
        <time_frame>30 Days</time_frame>
        <population>The number of participants analyzed in control group includes subjects who had available follow up data at that time frame. Not applicable for Device group patients as device was not implanted. The population includes all patients who underwent the index surgical procedure and excludes 15 patients who were randomized, but not treated.</population>
        <group_list>
          <group group_id="O1">
            <title>Device Group (MitraClip Device)</title>
            <description>Percutaneous mitral valve repair using MitraClip implant.</description>
          </group>
          <group group_id="O2">
            <title>Control Group (Mitral Valve Surgery)</title>
            <description>Mitral valve repair or replacement surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Acute Surgical Success</title>
          <description>Defined as successful mitral valve repair or replacement surgery.</description>
          <population>The number of participants analyzed in control group includes subjects who had available follow up data at that time frame. Not applicable for Device group patients as device was not implanted. The population includes all patients who underwent the index surgical procedure and excludes 15 patients who were randomized, but not treated.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Successful Clip Implant and Acute Procedural Success</title>
        <description>Acute procedural success is defined as MR severity ≤ 2 at discharge or 1 grade MR reduction at discharge accompanied by 1 level NYHA reduction.</description>
        <time_frame>30 days</time_frame>
        <population>The number of participants analyzed in Device group includes subjects who had available follow up data at that time frame. Not applicable for Mitral valve surgery patients as device was not implanted.</population>
        <group_list>
          <group group_id="O1">
            <title>Device Group (MitraClip Device)</title>
            <description>Percutaneous mitral valve repair using MitraClip implant.</description>
          </group>
          <group group_id="O2">
            <title>Control Group (Mitral Valve Surgery)</title>
            <description>Mitral valve repair or replacement surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Successful Clip Implant and Acute Procedural Success</title>
          <description>Acute procedural success is defined as MR severity ≤ 2 at discharge or 1 grade MR reduction at discharge accompanied by 1 level NYHA reduction.</description>
          <population>The number of participants analyzed in Device group includes subjects who had available follow up data at that time frame. Not applicable for Mitral valve surgery patients as device was not implanted.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="178"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Device Implant Rate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="158"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Acute Procedural Success</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="137"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Mitral Valve Repair Success.</title>
        <description>Defined as freedom from mitral valve replacement surgery for Valve Dysfunction, death, re-operation, and MR &gt; 2+ at 12 months.</description>
        <time_frame>12 months</time_frame>
        <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Device Group (MitraClip Device)</title>
            <description>Percutaneous mitral valve repair using MitraClip implant.</description>
          </group>
          <group group_id="O2">
            <title>Control Group (Mitral Valve Surgery)</title>
            <description>Mitral valve repair or replacement surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Mitral Valve Repair Success.</title>
          <description>Defined as freedom from mitral valve replacement surgery for Valve Dysfunction, death, re-operation, and MR &gt; 2+ at 12 months.</description>
          <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="177"/>
                <count group_id="O2" value="91"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="114"/>
                    <measurement group_id="O2" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Mitral Valve Repair Success.</title>
        <description>Defined as freedom from mitral valve replacement surgery for Valve Dysfunction, death, re-operation, and MR &gt; 2+ at 12 months.</description>
        <time_frame>24 months</time_frame>
        <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Device Group (MitraClip Device)</title>
            <description>Percutaneous mitral valve repair using MitraClip implant.</description>
          </group>
          <group group_id="O2">
            <title>Control Group (Mitral Valve Surgery)</title>
            <description>Mitral valve repair or replacement surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Mitral Valve Repair Success.</title>
          <description>Defined as freedom from mitral valve replacement surgery for Valve Dysfunction, death, re-operation, and MR &gt; 2+ at 12 months.</description>
          <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="167"/>
                <count group_id="O2" value="84"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="103"/>
                    <measurement group_id="O2" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Procedural Freedom From In-hospital MAE.</title>
        <time_frame>Day 0</time_frame>
        <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Device Group (MitraClip Device)</title>
            <description>Percutaneous mitral valve repair using MitraClip implant.</description>
          </group>
          <group group_id="O2">
            <title>Control Group (Mitral Valve Surgery)</title>
            <description>Mitral valve repair or replacement surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Procedural Freedom From In-hospital MAE.</title>
          <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="178"/>
                <count group_id="O2" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="168"/>
                    <measurement group_id="O2" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Procedural Freedom From In-hospital MAE</title>
        <time_frame>Day 30</time_frame>
        <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Device Group (MitraClip Device)</title>
            <description>Percutaneous mitral valve repair using MitraClip implant.</description>
          </group>
          <group group_id="O2">
            <title>Control Group (Mitral Valve Surgery)</title>
            <description>Mitral valve repair or replacement surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Procedural Freedom From In-hospital MAE</title>
          <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="178"/>
                <count group_id="O2" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With MAE: Surgery After Device and First Time Surgery Control</title>
        <time_frame>30 days</time_frame>
        <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Device Group (MitraClip Device)</title>
            <description>Percutaneous mitral valve repair using MitraClip implant.</description>
          </group>
          <group group_id="O2">
            <title>Control Group (Mitral Valve Surgery)</title>
            <description>Mitral valve repair or replacement surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With MAE: Surgery After Device and First Time Surgery Control</title>
          <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Major Vascular Complications</title>
        <description>Vascular Complications defined as the occurrence of any of the following resulting through 30 days or hospital discharge, whichever is longer:
Hematoma at access site &gt;6 cm;
Retroperitoneal hematoma;
Arteriovenous (AV) fistula;
Symptomatic peripheral ischemia / nerve injury or the clinical signs or symptoms lasting &gt;48 hours;
Vascular Surgical Repair at catheter access sites;
Pulmonary embolism;
Ipsilateral deep vein thrombus; or
Access site-related infection requiring intravenous antibiotics and/or extended hospitalization.</description>
        <time_frame>30 days</time_frame>
        <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Device Group (MitraClip Device)</title>
            <description>Percutaneous mitral valve repair using MitraClip implant.</description>
          </group>
          <group group_id="O2">
            <title>Control Group (Mitral Valve Surgery)</title>
            <description>Mitral valve repair or replacement surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Major Vascular Complications</title>
          <description>Vascular Complications defined as the occurrence of any of the following resulting through 30 days or hospital discharge, whichever is longer:
Hematoma at access site &gt;6 cm;
Retroperitoneal hematoma;
Arteriovenous (AV) fistula;
Symptomatic peripheral ischemia / nerve injury or the clinical signs or symptoms lasting &gt;48 hours;
Vascular Surgical Repair at catheter access sites;
Pulmonary embolism;
Ipsilateral deep vein thrombus; or
Access site-related infection requiring intravenous antibiotics and/or extended hospitalization.</description>
          <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="184"/>
                <count group_id="O2" value="95"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Major Vascular Complications</title>
        <description>Vascular Complications defined as the occurrence of any of the following resulting through 30 days or hospital discharge, whichever is longer:
Hematoma at access site &gt;6 cm;
Retroperitoneal hematoma;
Arteriovenous (AV) fistula;
Symptomatic peripheral ischemia / nerve injury or the clinical signs or symptoms lasting &gt;48 hours;
Vascular Surgical Repair at catheter access sites;
Pulmonary embolism;
Ipsilateral deep vein thrombus; or
Access site-related infection requiring intravenous antibiotics and/or extended hospitalization.</description>
        <time_frame>12 months</time_frame>
        <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Device Group (MitraClip Device)</title>
            <description>Percutaneous mitral valve repair using MitraClip implant.</description>
          </group>
          <group group_id="O2">
            <title>Control Group (Mitral Valve Surgery)</title>
            <description>Mitral valve repair or replacement surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Major Vascular Complications</title>
          <description>Vascular Complications defined as the occurrence of any of the following resulting through 30 days or hospital discharge, whichever is longer:
Hematoma at access site &gt;6 cm;
Retroperitoneal hematoma;
Arteriovenous (AV) fistula;
Symptomatic peripheral ischemia / nerve injury or the clinical signs or symptoms lasting &gt;48 hours;
Vascular Surgical Repair at catheter access sites;
Pulmonary embolism;
Ipsilateral deep vein thrombus; or
Access site-related infection requiring intravenous antibiotics and/or extended hospitalization.</description>
          <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="184"/>
                <count group_id="O2" value="95"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Major Bleeding Complications.</title>
        <description>Major Bleeding Complications defined as procedure related bleeding that requires a transfusion of ≥2 units of blood products and/or surgical intervention at 30 days or hospital discharge, whichever is longer.</description>
        <time_frame>30 days</time_frame>
        <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Device Group (MitraClip Device)</title>
            <description>Percutaneous mitral valve repair using MitraClip implant.</description>
          </group>
          <group group_id="O2">
            <title>Control Group (Mitral Valve Surgery)</title>
            <description>Mitral valve repair or replacement surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Major Bleeding Complications.</title>
          <description>Major Bleeding Complications defined as procedure related bleeding that requires a transfusion of ≥2 units of blood products and/or surgical intervention at 30 days or hospital discharge, whichever is longer.</description>
          <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="184"/>
                <count group_id="O2" value="95"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Major Bleeding Complications.</title>
        <description>Major Bleeding Complications defined as procedure related bleeding that requires a transfusion of ≥2 units of blood products and/or surgical intervention at 12 months.</description>
        <time_frame>12 months</time_frame>
        <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Device Group (MitraClip Device)</title>
            <description>Percutaneous mitral valve repair using MitraClip implant.</description>
          </group>
          <group group_id="O2">
            <title>Control Group (Mitral Valve Surgery)</title>
            <description>Mitral valve repair or replacement surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Major Bleeding Complications.</title>
          <description>Major Bleeding Complications defined as procedure related bleeding that requires a transfusion of ≥2 units of blood products and/or surgical intervention at 12 months.</description>
          <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="184"/>
                <count group_id="O2" value="95"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Major Adverse Events (MAE)</title>
        <time_frame>12 months.</time_frame>
        <population>Intent to treat (ITT) population.</population>
        <group_list>
          <group group_id="O1">
            <title>Device Group (MitraClip Device)</title>
            <description>Percutaneous mitral valve repair using MitraClip implant.</description>
          </group>
          <group group_id="O2">
            <title>Control Group (Mitral Valve Surgery)</title>
            <description>Mitral valve repair or replacement surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Major Adverse Events (MAE)</title>
          <population>Intent to treat (ITT) population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="184"/>
                <count group_id="O2" value="95"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                    <measurement group_id="O2" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With MAE in Patients Over 75 Years of Age.</title>
        <time_frame>30 days</time_frame>
        <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Device Group (MitraClip Device)</title>
            <description>Percutaneous mitral valve repair using MitraClip implant.</description>
          </group>
          <group group_id="O2">
            <title>Control Group (Mitral Valve Surgery)</title>
            <description>Mitral valve repair or replacement surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With MAE in Patients Over 75 Years of Age.</title>
          <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With MAE in Patients Over 75 Years of Age.</title>
        <time_frame>12 months</time_frame>
        <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Device Group (MitraClip Device)</title>
            <description>Percutaneous mitral valve repair using MitraClip implant.</description>
          </group>
          <group group_id="O2">
            <title>Control Group (Mitral Valve Surgery)</title>
            <description>Mitral valve repair or replacement surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With MAE in Patients Over 75 Years of Age.</title>
          <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Dysrhythmia</title>
        <time_frame>30 days</time_frame>
        <population>ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>Device Group (MitraClip Device)</title>
            <description>Percutaneous mitral valve repair using MitraClip implant.</description>
          </group>
          <group group_id="O2">
            <title>Control Group (Mitral Valve Surgery)</title>
            <description>Mitral valve repair or replacement surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Dysrhythmia</title>
          <population>ITT population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="184"/>
                <count group_id="O2" value="95"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Dysrhythmia</title>
        <time_frame>12 months</time_frame>
        <population>ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>Device Group (MitraClip Device)</title>
            <description>Percutaneous mitral valve repair using MitraClip implant.</description>
          </group>
          <group group_id="O2">
            <title>Control Group (Mitral Valve Surgery)</title>
            <description>Mitral valve repair or replacement surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Dysrhythmia</title>
          <population>ITT population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="184"/>
                <count group_id="O2" value="95"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Endocarditis.</title>
        <description>Defined as a diagnosis of endocarditis based on the Duke criteria. Infection in the lining of the heart, of the valves, or of the muscles of the heart. Signs of endocarditis may include persistent positive blood cultures and/or valvular structural abnormality and vegetations as seen using echocardiography.</description>
        <time_frame>30 days</time_frame>
        <population>ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>Device Group (MitraClip Device)</title>
            <description>Percutaneous mitral valve repair using MitraClip implant.</description>
          </group>
          <group group_id="O2">
            <title>Control Group (Mitral Valve Surgery)</title>
            <description>Mitral valve repair or replacement surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Endocarditis.</title>
          <description>Defined as a diagnosis of endocarditis based on the Duke criteria. Infection in the lining of the heart, of the valves, or of the muscles of the heart. Signs of endocarditis may include persistent positive blood cultures and/or valvular structural abnormality and vegetations as seen using echocardiography.</description>
          <population>ITT population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="184"/>
                <count group_id="O2" value="95"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Endocarditis.</title>
        <description>Defined as a diagnosis of endocarditis based on the Duke criteria. Infection in the lining of the heart, of the valves, or of the muscles of the heart. Signs of endocarditis may include persistent positive blood cultures and/or valvular structural abnormality and vegetations as seen using echocardiography.</description>
        <time_frame>12 months</time_frame>
        <population>ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>Device Group (MitraClip Device)</title>
            <description>Percutaneous mitral valve repair using MitraClip implant.</description>
          </group>
          <group group_id="O2">
            <title>Control Group (Mitral Valve Surgery)</title>
            <description>Mitral valve repair or replacement surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Endocarditis.</title>
          <description>Defined as a diagnosis of endocarditis based on the Duke criteria. Infection in the lining of the heart, of the valves, or of the muscles of the heart. Signs of endocarditis may include persistent positive blood cultures and/or valvular structural abnormality and vegetations as seen using echocardiography.</description>
          <population>ITT population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="184"/>
                <count group_id="O2" value="95"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Thrombosis.</title>
        <description>Defined as evidence of the formation of an independently moving thrombus on any part of the MitraClip or any commercially available implant used during surgery by echocardiography or fluoroscopy.</description>
        <time_frame>30 days</time_frame>
        <population>ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>Device Group (MitraClip Device)</title>
            <description>Percutaneous mitral valve repair using MitraClip implant.</description>
          </group>
          <group group_id="O2">
            <title>Control Group (Mitral Valve Surgery)</title>
            <description>Mitral valve repair or replacement surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Thrombosis.</title>
          <description>Defined as evidence of the formation of an independently moving thrombus on any part of the MitraClip or any commercially available implant used during surgery by echocardiography or fluoroscopy.</description>
          <population>ITT population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="184"/>
                <count group_id="O2" value="95"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Thrombosis.</title>
        <description>Defined as evidence of the formation of an independently moving thrombus on any part of the MitraClip or any commercially available implant used during surgery by echocardiography or fluoroscopy.</description>
        <time_frame>12 months</time_frame>
        <population>ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>Device Group (MitraClip Device)</title>
            <description>Percutaneous mitral valve repair using MitraClip implant.</description>
          </group>
          <group group_id="O2">
            <title>Control Group (Mitral Valve Surgery)</title>
            <description>Mitral valve repair or replacement surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Thrombosis.</title>
          <description>Defined as evidence of the formation of an independently moving thrombus on any part of the MitraClip or any commercially available implant used during surgery by echocardiography or fluoroscopy.</description>
          <population>ITT population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="184"/>
                <count group_id="O2" value="95"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Hemolysis</title>
        <description>Defined as new onset of anemia associated with laboratory evidence of red cell destruction. Diagnosed when plasma free hemoglobin is greater than 40 mg/dL on repeat measures within 24 hours or on one measure if intervention is initiated based on other clinical symptoms. Reported as major or minor as defined below:
Major: Requires intervention with red blood cell transfusion or other hematocrit increasing measures in the absence of other obvious bleeding.
Minor: Does not require intervention.</description>
        <time_frame>30 days</time_frame>
        <population>ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>Device Group (MitraClip Device)</title>
            <description>Percutaneous mitral valve repair using MitraClip implant.</description>
          </group>
          <group group_id="O2">
            <title>Control Group (Mitral Valve Surgery)</title>
            <description>Mitral valve repair or replacement surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Hemolysis</title>
          <description>Defined as new onset of anemia associated with laboratory evidence of red cell destruction. Diagnosed when plasma free hemoglobin is greater than 40 mg/dL on repeat measures within 24 hours or on one measure if intervention is initiated based on other clinical symptoms. Reported as major or minor as defined below:
Major: Requires intervention with red blood cell transfusion or other hematocrit increasing measures in the absence of other obvious bleeding.
Minor: Does not require intervention.</description>
          <population>ITT population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="184"/>
                <count group_id="O2" value="95"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Hemolysis</title>
        <description>Defined as new onset of anemia associated with laboratory evidence of red cell destruction. Diagnosed when plasma free hemoglobin is greater than 40 mg/dL on repeat measures within 24 hours or on one measure if intervention is initiated based on other clinical symptoms. Reported as major or minor as defined below:
Major: Requires intervention with red blood cell transfusion or other hematocrit increasing measures in the absence of other obvious bleeding.
Minor: Does not require intervention.</description>
        <time_frame>12 months</time_frame>
        <population>ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>Device Group (MitraClip Device)</title>
            <description>Percutaneous mitral valve repair using MitraClip implant.</description>
          </group>
          <group group_id="O2">
            <title>Control Group (Mitral Valve Surgery)</title>
            <description>Mitral valve repair or replacement surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Hemolysis</title>
          <description>Defined as new onset of anemia associated with laboratory evidence of red cell destruction. Diagnosed when plasma free hemoglobin is greater than 40 mg/dL on repeat measures within 24 hours or on one measure if intervention is initiated based on other clinical symptoms. Reported as major or minor as defined below:
Major: Requires intervention with red blood cell transfusion or other hematocrit increasing measures in the absence of other obvious bleeding.
Minor: Does not require intervention.</description>
          <population>ITT population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="184"/>
                <count group_id="O2" value="95"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Clinically Significant Atrial Septal Defect (ASD).</title>
        <description>Defined as a significant residual atrial septal opening. Reported as clinically significant if intervention is performed for the primary purpose of repairing the ASD. If cardiac surgery is indicated for reasons other than residual ASD (e.g., residual MR) and the ASD is repaired at the same time, this does not meet the definition of clinically significant ASD.</description>
        <time_frame>30 days</time_frame>
        <population>ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>Device Group (MitraClip Device)</title>
            <description>Percutaneous mitral valve repair using MitraClip implant.</description>
          </group>
          <group group_id="O2">
            <title>Control Group (Mitral Valve Surgery)</title>
            <description>Mitral valve repair or replacement surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinically Significant Atrial Septal Defect (ASD).</title>
          <description>Defined as a significant residual atrial septal opening. Reported as clinically significant if intervention is performed for the primary purpose of repairing the ASD. If cardiac surgery is indicated for reasons other than residual ASD (e.g., residual MR) and the ASD is repaired at the same time, this does not meet the definition of clinically significant ASD.</description>
          <population>ITT population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="184"/>
                <count group_id="O2" value="95"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Clinically Significant Atrial Septal Defect (ASD)</title>
        <description>Defined as a significant residual atrial septal opening. Reported as clinically significant if intervention is performed for the primary purpose of repairing the ASD. If cardiac surgery is indicated for reasons other than residual ASD (e.g., residual MR) and the ASD is repaired at the same time, this does not meet the definition of clinically significant ASD.</description>
        <time_frame>12 months</time_frame>
        <population>ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>Device Group (MitraClip Device)</title>
            <description>Percutaneous mitral valve repair using MitraClip implant.</description>
          </group>
          <group group_id="O2">
            <title>Control Group (Mitral Valve Surgery)</title>
            <description>Mitral valve repair or replacement surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinically Significant Atrial Septal Defect (ASD)</title>
          <description>Defined as a significant residual atrial septal opening. Reported as clinically significant if intervention is performed for the primary purpose of repairing the ASD. If cardiac surgery is indicated for reasons other than residual ASD (e.g., residual MR) and the ASD is repaired at the same time, this does not meet the definition of clinically significant ASD.</description>
          <population>ITT population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="184"/>
                <count group_id="O2" value="95"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Mitral Valve Stenosis</title>
        <description>Defined as a mitral valve planimetered orifice area of less than 1.5 cm^2 as measured by echocardiography.</description>
        <time_frame>30 days</time_frame>
        <population>ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>Device Group (MitraClip Device)</title>
            <description>Percutaneous mitral valve repair using MitraClip implant.</description>
          </group>
          <group group_id="O2">
            <title>Control Group (Mitral Valve Surgery)</title>
            <description>Mitral valve repair or replacement surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Mitral Valve Stenosis</title>
          <description>Defined as a mitral valve planimetered orifice area of less than 1.5 cm^2 as measured by echocardiography.</description>
          <population>ITT population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="184"/>
                <count group_id="O2" value="95"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Mitral Valve Stenosis</title>
        <description>Defined as a mitral valve planimetered orifice area of less than 1.5 cm^2 as measured by echocardiography.</description>
        <time_frame>12 months</time_frame>
        <population>ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>Device Group (MitraClip Device)</title>
            <description>Percutaneous mitral valve repair using MitraClip implant.</description>
          </group>
          <group group_id="O2">
            <title>Control Group (Mitral Valve Surgery)</title>
            <description>Mitral valve repair or replacement surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Mitral Valve Stenosis</title>
          <description>Defined as a mitral valve planimetered orifice area of less than 1.5 cm^2 as measured by echocardiography.</description>
          <population>ITT population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="184"/>
                <count group_id="O2" value="95"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Mitral Valve Stenosis</title>
        <description>Defined as a mitral valve planimetered orifice area of less than 1.5 cm^2 as measured by echocardiography.</description>
        <time_frame>24 months</time_frame>
        <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Device Group (MitraClip Device)</title>
            <description>Percutaneous mitral valve repair using MitraClip implant.</description>
          </group>
          <group group_id="O2">
            <title>Control Group (Mitral Valve Surgery)</title>
            <description>Mitral valve repair or replacement surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Mitral Valve Stenosis</title>
          <description>Defined as a mitral valve planimetered orifice area of less than 1.5 cm^2 as measured by echocardiography.</description>
          <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="178"/>
                <count group_id="O2" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Mitral Valve Stenosis</title>
        <description>Defined as a mitral valve (MV) planimetered orifice area of less than 1.5 cm^2 as measured by echocardiography. A “confirmed” case of MV stenosis is defined as Echocardiography Core Lab (ECL) measured mitral valve orifice area &lt; 1.5 cm^2. A “conservative” case of MV stenosis is defined as stenosis suspected by the site, based on hemodynamic measurements or clinical symptoms.</description>
        <time_frame>3 years</time_frame>
        <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Device Group (MitraClip Device)</title>
            <description>Percutaneous mitral valve repair using MitraClip implant.</description>
          </group>
          <group group_id="O2">
            <title>Control Group (Mitral Valve Surgery)</title>
            <description>Mitral valve repair or replacement surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Mitral Valve Stenosis</title>
          <description>Defined as a mitral valve (MV) planimetered orifice area of less than 1.5 cm^2 as measured by echocardiography. A “confirmed” case of MV stenosis is defined as Echocardiography Core Lab (ECL) measured mitral valve orifice area &lt; 1.5 cm^2. A “conservative” case of MV stenosis is defined as stenosis suspected by the site, based on hemodynamic measurements or clinical symptoms.</description>
          <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="178"/>
                <count group_id="O2" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Conservative cases</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Confirmed cases</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Mitral Valve Stenosis</title>
        <description>Defined as a mitral valve (MV) planimetered orifice area of less than 1.5 cm^2 as measured by echocardiography. A “confirmed” case of MV stenosis is defined as Echocardiography Core Lab (ECL) measured mitral valve orifice area &lt; 1.5 cm^2. A “conservative” case of MV stenosis is defined as stenosis suspected by the site, based on hemodynamic measurements or clinical symptoms.</description>
        <time_frame>4 years</time_frame>
        <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Device Group (MitraClip Device)</title>
            <description>Percutaneous mitral valve repair using MitraClip implant.</description>
          </group>
          <group group_id="O2">
            <title>Control Group (Mitral Valve Surgery)</title>
            <description>Mitral valve repair or replacement surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Mitral Valve Stenosis</title>
          <description>Defined as a mitral valve (MV) planimetered orifice area of less than 1.5 cm^2 as measured by echocardiography. A “confirmed” case of MV stenosis is defined as Echocardiography Core Lab (ECL) measured mitral valve orifice area &lt; 1.5 cm^2. A “conservative” case of MV stenosis is defined as stenosis suspected by the site, based on hemodynamic measurements or clinical symptoms.</description>
          <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="178"/>
                <count group_id="O2" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Conservative cases</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Confirmed cases</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Mitral Valve Stenosis</title>
        <description>Defined as a mitral valve (MV) planimetered orifice area of less than 1.5 cm^2 as measured by echocardiography. A “confirmed” case of MV stenosis is defined as Echocardiography Core Lab (ECL) measured mitral valve orifice area &lt; 1.5 cm^2. A “conservative” case of MV stenosis is defined as stenosis suspected by the site, based on hemodynamic measurements or clinical symptoms.</description>
        <time_frame>5 years</time_frame>
        <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Device Group (MitraClip Device)</title>
            <description>Percutaneous mitral valve repair using MitraClip implant.</description>
          </group>
          <group group_id="O2">
            <title>Control Group (Mitral Valve Surgery)</title>
            <description>Mitral valve repair or replacement surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Mitral Valve Stenosis</title>
          <description>Defined as a mitral valve (MV) planimetered orifice area of less than 1.5 cm^2 as measured by echocardiography. A “confirmed” case of MV stenosis is defined as Echocardiography Core Lab (ECL) measured mitral valve orifice area &lt; 1.5 cm^2. A “conservative” case of MV stenosis is defined as stenosis suspected by the site, based on hemodynamic measurements or clinical symptoms.</description>
          <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="178"/>
                <count group_id="O2" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Conservative cases</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Confirmed cases</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mitral Valve Area by Planimetry</title>
        <description>Mitral valve area as measured by core lab echocardiography.</description>
        <time_frame>At Discharge (≤14 days of index procedure)</time_frame>
        <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Device Group (MitraClip Device)</title>
            <description>Percutaneous mitral valve repair using MitraClip implant.</description>
          </group>
          <group group_id="O2">
            <title>Control Group (Mitral Valve Surgery)</title>
            <description>Mitral valve repair or replacement surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Mitral Valve Area by Planimetry</title>
          <description>Mitral valve area as measured by core lab echocardiography.</description>
          <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>cm^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="140"/>
                <count group_id="O2" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.7" spread="1.4"/>
                    <measurement group_id="O2" value="3.6" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mitral Valve Area by Planimetry</title>
        <description>Mitral valve area as measured by core lab echocardiography.</description>
        <time_frame>30 Days</time_frame>
        <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Device Group (MitraClip Device)</title>
            <description>Percutaneous mitral valve repair using MitraClip implant.</description>
          </group>
          <group group_id="O2">
            <title>Control Group (Mitral Valve Surgery)</title>
            <description>Mitral valve repair or replacement surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Mitral Valve Area by Planimetry</title>
          <description>Mitral valve area as measured by core lab echocardiography.</description>
          <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>cm^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="121"/>
                <count group_id="O2" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.6" spread="1.1"/>
                    <measurement group_id="O2" value="3.9" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mitral Valve Area by Planimetry</title>
        <description>Mitral valve area as measured by core lab echocardiography.</description>
        <time_frame>12 months</time_frame>
        <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Device Group (MitraClip Device)</title>
            <description>Percutaneous mitral valve repair using MitraClip implant.</description>
          </group>
          <group group_id="O2">
            <title>Control Group (Mitral Valve Surgery)</title>
            <description>Mitral valve repair or replacement surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Mitral Valve Area by Planimetry</title>
          <description>Mitral valve area as measured by core lab echocardiography.</description>
          <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>cm^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
                <count group_id="O2" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2" spread="1.0"/>
                    <measurement group_id="O2" value="3.7" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mitral Valve Area by Planimetry</title>
        <description>Mitral valve area as measured by core lab echocardiography.</description>
        <time_frame>24 months</time_frame>
        <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Device Group (MitraClip Device)</title>
            <description>Percutaneous mitral valve repair using MitraClip implant.</description>
          </group>
          <group group_id="O2">
            <title>Control Group (Mitral Valve Surgery)</title>
            <description>Mitral valve repair or replacement surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Mitral Valve Area by Planimetry</title>
          <description>Mitral valve area as measured by core lab echocardiography.</description>
          <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>cm^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3" spread="0.9"/>
                    <measurement group_id="O2" value="3.3" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mitral Valve Area by Planimetry</title>
        <description>Mitral valve area as measured by core lab echocardiography.</description>
        <time_frame>3 years</time_frame>
        <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Device Group (MitraClip Device)</title>
            <description>Percutaneous mitral valve repair using MitraClip implant.</description>
          </group>
          <group group_id="O2">
            <title>Control Group (Mitral Valve Surgery)</title>
            <description>Mitral valve repair or replacement surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Mitral Valve Area by Planimetry</title>
          <description>Mitral valve area as measured by core lab echocardiography.</description>
          <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>cm^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="81"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3" spread="0.9"/>
                    <measurement group_id="O2" value="3.6" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mitral Valve Area by Planimetry</title>
        <description>Mitral valve area as measured by core lab echocardiography.</description>
        <time_frame>4 years</time_frame>
        <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Device Group (MitraClip Device)</title>
            <description>Percutaneous mitral valve repair using MitraClip implant.</description>
          </group>
          <group group_id="O2">
            <title>Control Group (Mitral Valve Surgery)</title>
            <description>Mitral valve repair or replacement surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Mitral Valve Area by Planimetry</title>
          <description>Mitral valve area as measured by core lab echocardiography.</description>
          <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>cm^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="82"/>
                <count group_id="O2" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2" spread="0.9"/>
                    <measurement group_id="O2" value="3.8" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mitral Valve Area by Planimetry</title>
        <description>Mitral valve area as measured by core lab echocardiography.</description>
        <time_frame>5 years</time_frame>
        <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Device Group (MitraClip Device)</title>
            <description>Percutaneous mitral valve repair using MitraClip implant.</description>
          </group>
          <group group_id="O2">
            <title>Control Group (Mitral Valve Surgery)</title>
            <description>Mitral valve repair or replacement surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Mitral Valve Area by Planimetry</title>
          <description>Mitral valve area as measured by core lab echocardiography.</description>
          <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>cm^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2" spread="1.0"/>
                    <measurement group_id="O2" value="3.7" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mitral Valve Area by Planimetry Index</title>
        <description>Defined as mitral valve area divided by body surface area as measured by core lab echocardiography.</description>
        <time_frame>30 Days</time_frame>
        <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Device Group (MitraClip Device)</title>
            <description>Percutaneous mitral valve repair using MitraClip implant.</description>
          </group>
          <group group_id="O2">
            <title>Control Group (Mitral Valve Surgery)</title>
            <description>Mitral valve repair or replacement surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Mitral Valve Area by Planimetry Index</title>
          <description>Defined as mitral valve area divided by body surface area as measured by core lab echocardiography.</description>
          <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>cm^2/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="118"/>
                <count group_id="O2" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" spread="0.6"/>
                    <measurement group_id="O2" value="2.0" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mitral Valve Area by Planimetry Index</title>
        <description>Defined as mitral valve area divided by body surface area as measured by core lab echocardiography.</description>
        <time_frame>12 months</time_frame>
        <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Device Group (MitraClip Device)</title>
            <description>Percutaneous mitral valve repair using MitraClip implant.</description>
          </group>
          <group group_id="O2">
            <title>Control Group (Mitral Valve Surgery)</title>
            <description>Mitral valve repair or replacement surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Mitral Valve Area by Planimetry Index</title>
          <description>Defined as mitral valve area divided by body surface area as measured by core lab echocardiography.</description>
          <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>cm^2/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="105"/>
                <count group_id="O2" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" spread="0.5"/>
                    <measurement group_id="O2" value="1.9" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mitral Valve Area by Planimetry Index</title>
        <description>Defined as mitral valve area divided by body surface area as measured by core lab echocardiography.</description>
        <time_frame>24 months</time_frame>
        <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Device Group (MitraClip Device)</title>
            <description>Percutaneous mitral valve repair using MitraClip implant.</description>
          </group>
          <group group_id="O2">
            <title>Control Group (Mitral Valve Surgery)</title>
            <description>Mitral valve repair or replacement surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Mitral Valve Area by Planimetry Index</title>
          <description>Defined as mitral valve area divided by body surface area as measured by core lab echocardiography.</description>
          <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>cm^2/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="92"/>
                <count group_id="O2" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" spread="0.4"/>
                    <measurement group_id="O2" value="1.8" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mitral Valve Area by Pressure Half-time</title>
        <description>Mitral valve area as measured by core lab echocardiography.</description>
        <time_frame>At Discharge (≤14 days of index procedure)</time_frame>
        <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Device Group (MitraClip Device)</title>
            <description>Percutaneous mitral valve repair using MitraClip implant.</description>
          </group>
          <group group_id="O2">
            <title>Control Group (Mitral Valve Surgery)</title>
            <description>Mitral valve repair or replacement surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Mitral Valve Area by Pressure Half-time</title>
          <description>Mitral valve area as measured by core lab echocardiography.</description>
          <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>cm^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="166"/>
                <count group_id="O2" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0" spread="1.1"/>
                    <measurement group_id="O2" value="3.3" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mitral Valve Area by Pressure Half-time</title>
        <description>Mitral valve area as measured by core lab echocardiography.</description>
        <time_frame>30 days</time_frame>
        <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Device Group (MitraClip Device)</title>
            <description>Percutaneous mitral valve repair using MitraClip implant.</description>
          </group>
          <group group_id="O2">
            <title>Control Group (Mitral Valve Surgery)</title>
            <description>Mitral valve repair or replacement surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Mitral Valve Area by Pressure Half-time</title>
          <description>Mitral valve area as measured by core lab echocardiography.</description>
          <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>cm^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="156"/>
                <count group_id="O2" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8" spread="1.0"/>
                    <measurement group_id="O2" value="3.5" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mitral Valve Area by Pressure Half-time</title>
        <description>Mitral valve area as measured by core lab echocardiography.</description>
        <time_frame>12 months</time_frame>
        <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Device Group (MitraClip Device)</title>
            <description>Percutaneous mitral valve repair using MitraClip implant.</description>
          </group>
          <group group_id="O2">
            <title>Control Group (Mitral Valve Surgery)</title>
            <description>Mitral valve repair or replacement surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Mitral Valve Area by Pressure Half-time</title>
          <description>Mitral valve area as measured by core lab echocardiography.</description>
          <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>cm^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="140"/>
                <count group_id="O2" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.9" spread="1.0"/>
                    <measurement group_id="O2" value="3.1" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mitral Valve Area by Pressure Half-time</title>
        <description>Mitral valve area as measured by core lab echocardiography.</description>
        <time_frame>24 months</time_frame>
        <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Device Group (MitraClip Device)</title>
            <description>Percutaneous mitral valve repair using MitraClip implant.</description>
          </group>
          <group group_id="O2">
            <title>Control Group (Mitral Valve Surgery)</title>
            <description>Mitral valve repair or replacement surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Mitral Valve Area by Pressure Half-time</title>
          <description>Mitral valve area as measured by core lab echocardiography.</description>
          <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>cm^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="121"/>
                <count group_id="O2" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7" spread="0.7"/>
                    <measurement group_id="O2" value="2.8" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mitral Valve Area by Pressure Half-time</title>
        <description>Mitral valve area as measured by core lab echocardiography.</description>
        <time_frame>3 years</time_frame>
        <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Device Group (MitraClip Device)</title>
            <description>Percutaneous mitral valve repair using MitraClip implant.</description>
          </group>
          <group group_id="O2">
            <title>Control Group (Mitral Valve Surgery)</title>
            <description>Mitral valve repair or replacement surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Mitral Valve Area by Pressure Half-time</title>
          <description>Mitral valve area as measured by core lab echocardiography.</description>
          <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>cm^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="120"/>
                <count group_id="O2" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7" spread="0.7"/>
                    <measurement group_id="O2" value="2.8" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mitral Valve Area by Pressure Half-time</title>
        <description>Mitral valve area as measured by core lab echocardiography.</description>
        <time_frame>4 years</time_frame>
        <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Device Group (MitraClip Device)</title>
            <description>Percutaneous mitral valve repair using MitraClip implant.</description>
          </group>
          <group group_id="O2">
            <title>Control Group (Mitral Valve Surgery)</title>
            <description>Mitral valve repair or replacement surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Mitral Valve Area by Pressure Half-time</title>
          <description>Mitral valve area as measured by core lab echocardiography.</description>
          <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>cm^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
                <count group_id="O2" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.9" spread="0.8"/>
                    <measurement group_id="O2" value="3.0" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mitral Valve Area by Pressure Half-time</title>
        <description>Mitral valve area as measured by core lab echocardiography.</description>
        <time_frame>5 years</time_frame>
        <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Device Group (MitraClip Device)</title>
            <description>Percutaneous mitral valve repair using MitraClip implant.</description>
          </group>
          <group group_id="O2">
            <title>Control Group (Mitral Valve Surgery)</title>
            <description>Mitral valve repair or replacement surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Mitral Valve Area by Pressure Half-time</title>
          <description>Mitral valve area as measured by core lab echocardiography.</description>
          <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>cm^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="101"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7" spread="0.7"/>
                    <measurement group_id="O2" value="2.8" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mitral Valve Area by Pressure Half-time Index</title>
        <description>Defined as mitral valve area divided by body surface area as measured by core lab echocardiography.</description>
        <time_frame>30 Days</time_frame>
        <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Device Group (MitraClip Device)</title>
            <description>Percutaneous mitral valve repair using MitraClip implant.</description>
          </group>
          <group group_id="O2">
            <title>Control Group (Mitral Valve Surgery)</title>
            <description>Mitral valve repair or replacement surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Mitral Valve Area by Pressure Half-time Index</title>
          <description>Defined as mitral valve area divided by body surface area as measured by core lab echocardiography.</description>
          <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>cm^2/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="153"/>
                <count group_id="O2" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" spread="0.6"/>
                    <measurement group_id="O2" value="1.9" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mitral Valve Area by Pressure Half-time Index</title>
        <description>Defined as mitral valve area divided by body surface area as measured by core lab echocardiography.</description>
        <time_frame>12 months</time_frame>
        <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Device Group (MitraClip Device)</title>
            <description>Percutaneous mitral valve repair using MitraClip implant.</description>
          </group>
          <group group_id="O2">
            <title>Control Group (Mitral Valve Surgery)</title>
            <description>Mitral valve repair or replacement surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Mitral Valve Area by Pressure Half-time Index</title>
          <description>Defined as mitral valve area divided by body surface area as measured by core lab echocardiography.</description>
          <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>cm^2/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="142"/>
                <count group_id="O2" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" spread="0.6"/>
                    <measurement group_id="O2" value="1.7" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mitral Valve Area by Pressure Half-time Index</title>
        <description>Defined as mitral valve area divided by body surface area as measured by core lab echocardiography.</description>
        <time_frame>24 months</time_frame>
        <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Device Group (MitraClip Device)</title>
            <description>Percutaneous mitral valve repair using MitraClip implant.</description>
          </group>
          <group group_id="O2">
            <title>Control Group (Mitral Valve Surgery)</title>
            <description>Mitral valve repair or replacement surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Mitral Valve Area by Pressure Half-time Index</title>
          <description>Defined as mitral valve area divided by body surface area as measured by core lab echocardiography.</description>
          <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>cm^2/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="123"/>
                <count group_id="O2" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" spread="0.4"/>
                    <measurement group_id="O2" value="1.5" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Transvalvular Mitral Valve Gradient</title>
        <description>Defined as the mean pressure gradient across the mitral valve as measured by echocardiography.</description>
        <time_frame>At Discharge (≤ 14 days following index procedure)</time_frame>
        <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Device Group (MitraClip Device)</title>
            <description>Percutaneous mitral valve repair using MitraClip implant.</description>
          </group>
          <group group_id="O2">
            <title>Control Group (Mitral Valve Surgery)</title>
            <description>Mitral valve repair or replacement surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Transvalvular Mitral Valve Gradient</title>
          <description>Defined as the mean pressure gradient across the mitral valve as measured by echocardiography.</description>
          <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="168"/>
                <count group_id="O2" value="73"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3" spread="1.9"/>
                    <measurement group_id="O2" value="3.1" spread="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Transvalvular Mitral Mean Pressure Gradient (Mean MVG)</title>
        <description>Defined as the mean pressure gradient across the mitral valve as measured by Echocardiography Core Laboratory (ECL).</description>
        <time_frame>12 months</time_frame>
        <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Device Group (MitraClip Device)</title>
            <description>Percutaneous mitral valve repair using MitraClip implant.</description>
          </group>
          <group group_id="O2">
            <title>Control Group (Mitral Valve Surgery)</title>
            <description>Mitral valve repair or replacement surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Transvalvular Mitral Mean Pressure Gradient (Mean MVG)</title>
          <description>Defined as the mean pressure gradient across the mitral valve as measured by Echocardiography Core Laboratory (ECL).</description>
          <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="140"/>
                <count group_id="O2" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2" spread="1.7"/>
                    <measurement group_id="O2" value="3.1" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Transvalvular Mitral Mean Pressure Gradient (Mean MVG)</title>
        <description>Defined as the mean pressure gradient across the mitral valve as measured by echocardiography.</description>
        <time_frame>24 months</time_frame>
        <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Device Group (MitraClip Device)</title>
            <description>Percutaneous mitral valve repair using MitraClip implant.</description>
          </group>
          <group group_id="O2">
            <title>Control Group (Mitral Valve Surgery)</title>
            <description>Mitral valve repair or replacement surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Transvalvular Mitral Mean Pressure Gradient (Mean MVG)</title>
          <description>Defined as the mean pressure gradient across the mitral valve as measured by echocardiography.</description>
          <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="121"/>
                <count group_id="O2" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8" spread="1.4"/>
                    <measurement group_id="O2" value="2.9" spread="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Transvalvular Mitral Mean Pressure Gradient (Mean MVG)</title>
        <description>Defined as the mean pressure gradient across the mitral valve as measured by echocardiography.</description>
        <time_frame>3 year</time_frame>
        <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Device Group (MitraClip Device)</title>
            <description>Percutaneous mitral valve repair using MitraClip implant.</description>
          </group>
          <group group_id="O2">
            <title>Control Group (Mitral Valve Surgery)</title>
            <description>Mitral valve repair or replacement surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Transvalvular Mitral Mean Pressure Gradient (Mean MVG)</title>
          <description>Defined as the mean pressure gradient across the mitral valve as measured by echocardiography.</description>
          <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="120"/>
                <count group_id="O2" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0" spread="1.5"/>
                    <measurement group_id="O2" value="2.8" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Transvalvular Mitral Mean Pressure Gradient (Mean MVG)</title>
        <description>Defined as the mean pressure gradient across the mitral valve as measured by echocardiography.</description>
        <time_frame>4 year</time_frame>
        <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Device Group (MitraClip Device)</title>
            <description>Percutaneous mitral valve repair using MitraClip implant.</description>
          </group>
          <group group_id="O2">
            <title>Control Group (Mitral Valve Surgery)</title>
            <description>Mitral valve repair or replacement surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Transvalvular Mitral Mean Pressure Gradient (Mean MVG)</title>
          <description>Defined as the mean pressure gradient across the mitral valve as measured by echocardiography.</description>
          <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
                <count group_id="O2" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0" spread="1.4"/>
                    <measurement group_id="O2" value="3.1" spread="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Transvalvular Mitral Mean Pressure Gradient (Mean MVG)</title>
        <description>Defined as the mean pressure gradient across the mitral valve as measured by echocardiography.</description>
        <time_frame>5 years</time_frame>
        <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Device Group (MitraClip Device)</title>
            <description>Percutaneous mitral valve repair using MitraClip implant.</description>
          </group>
          <group group_id="O2">
            <title>Control Group (Mitral Valve Surgery)</title>
            <description>Mitral valve repair or replacement surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Transvalvular Mitral Mean Pressure Gradient (Mean MVG)</title>
          <description>Defined as the mean pressure gradient across the mitral valve as measured by echocardiography.</description>
          <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="104"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0" spread="1.4"/>
                    <measurement group_id="O2" value="3.0" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Post-procedure Length of Hospital Stay</title>
        <time_frame>30 Days</time_frame>
        <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Device Group (MitraClip Device)</title>
            <description>Percutaneous mitral valve repair using MitraClip implant.</description>
          </group>
          <group group_id="O2">
            <title>Control Group (Mitral Valve Surgery)</title>
            <description>Mitral valve repair or replacement surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Post-procedure Length of Hospital Stay</title>
          <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="178"/>
                <count group_id="O2" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" spread="6.3"/>
                    <measurement group_id="O2" value="7.5" spread="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Post-procedure Intensive Care Unit (ICU) / Critical Care Unit (CCU) Duration</title>
        <time_frame>30 Days</time_frame>
        <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Device Group (MitraClip Device)</title>
            <description>Percutaneous mitral valve repair using MitraClip implant.</description>
          </group>
          <group group_id="O2">
            <title>Control Group (Mitral Valve Surgery)</title>
            <description>Mitral valve repair or replacement surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Post-procedure Intensive Care Unit (ICU) / Critical Care Unit (CCU) Duration</title>
          <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="176"/>
                <count group_id="O2" value="77"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.6" spread="135.9"/>
                    <measurement group_id="O2" value="82.3" spread="84.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Hospital Re-admissions</title>
        <description>Defined as re-admission to the hospital for any reason. The endpoint was intended to capture each time a patient was re-admitted to the hospital for any reason and was to be reported as a rate through 30 days for both the Device and Control groups.</description>
        <time_frame>30 days</time_frame>
        <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Device Group (MitraClip Device)</title>
            <description>Percutaneous mitral valve repair using MitraClip implant.</description>
          </group>
          <group group_id="O2">
            <title>Control Group (Mitral Valve Surgery)</title>
            <description>Mitral valve repair or replacement surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Hospital Re-admissions</title>
          <description>Defined as re-admission to the hospital for any reason. The endpoint was intended to capture each time a patient was re-admitted to the hospital for any reason and was to be reported as a rate through 30 days for both the Device and Control groups.</description>
          <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="171"/>
                <count group_id="O2" value="76"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Incidence of Discharge to a Nursing Home or Skilled Nursing Facility/Hospital</title>
        <time_frame>30 Days</time_frame>
        <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Device Group (MitraClip Device)</title>
            <description>Percutaneous mitral valve repair using MitraClip implant.</description>
          </group>
          <group group_id="O2">
            <title>Control Group (Mitral Valve Surgery)</title>
            <description>Mitral valve repair or replacement surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Incidence of Discharge to a Nursing Home or Skilled Nursing Facility/Hospital</title>
          <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="178"/>
                <count group_id="O2" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Incidence of Hospital Readmissions for Congestive Heart Failure (CHF).</title>
        <time_frame>30 days</time_frame>
        <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Device Group (MitraClip Device)</title>
            <description>Percutaneous mitral valve repair using MitraClip implant.</description>
          </group>
          <group group_id="O2">
            <title>Control Group (Mitral Valve Surgery)</title>
            <description>Mitral valve repair or replacement surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Incidence of Hospital Readmissions for Congestive Heart Failure (CHF).</title>
          <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="171"/>
                <count group_id="O2" value="76"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With New Coumadin (Warfarin) Usage</title>
        <time_frame>30 days</time_frame>
        <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Device Group (MitraClip Device)</title>
            <description>Percutaneous mitral valve repair using MitraClip implant.</description>
          </group>
          <group group_id="O2">
            <title>Control Group (Mitral Valve Surgery)</title>
            <description>Mitral valve repair or replacement surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With New Coumadin (Warfarin) Usage</title>
          <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="143"/>
                <count group_id="O2" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With New Coumadin (Warfarin) Usage</title>
        <time_frame>12 months</time_frame>
        <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Device Group (MitraClip Device)</title>
            <description>Percutaneous mitral valve repair using MitraClip implant.</description>
          </group>
          <group group_id="O2">
            <title>Control Group (Mitral Valve Surgery)</title>
            <description>Mitral valve repair or replacement surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With New Coumadin (Warfarin) Usage</title>
          <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="143"/>
                <count group_id="O2" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Durability of the MitraClip Device and Surgery.</title>
        <description>Device group: Freedom from death, surgery for mitral valve dysfunction and MR &gt; 2+ at the end of each follow-up interval.
Control group: Freedom from death, re-operation for mitral valve dysfunction and MR &gt; 2+ at the end of each follow-up interval.</description>
        <time_frame>12 months</time_frame>
        <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Device Group (MitraClip Device)</title>
            <description>Percutaneous mitral valve repair using MitraClip implant.</description>
          </group>
          <group group_id="O2">
            <title>Control Group (Mitral Valve Surgery)</title>
            <description>Mitral valve repair or replacement surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Durability of the MitraClip Device and Surgery.</title>
          <description>Device group: Freedom from death, surgery for mitral valve dysfunction and MR &gt; 2+ at the end of each follow-up interval.
Control group: Freedom from death, re-operation for mitral valve dysfunction and MR &gt; 2+ at the end of each follow-up interval.</description>
          <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="137"/>
                <count group_id="O2" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Deaths</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Surgeries</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patients with MR &gt; 2+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Withdrawn/ Censored</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Durability of the MitraClip Device and Surgery.</title>
        <description>Device group: Freedom from death, surgery for mitral valve dysfunction and MR &gt; 2+ at the end of each follow-up interval.
Control group: Freedom from death, re-operation for mitral valve dysfunction and MR &gt; 2+ at the end of each follow-up interval.</description>
        <time_frame>12-18 months</time_frame>
        <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Device Group (MitraClip Device)</title>
            <description>Percutaneous mitral valve repair using MitraClip implant.</description>
          </group>
          <group group_id="O2">
            <title>Control Group (Mitral Valve Surgery)</title>
            <description>Mitral valve repair or replacement surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Durability of the MitraClip Device and Surgery.</title>
          <description>Device group: Freedom from death, surgery for mitral valve dysfunction and MR &gt; 2+ at the end of each follow-up interval.
Control group: Freedom from death, re-operation for mitral valve dysfunction and MR &gt; 2+ at the end of each follow-up interval.</description>
          <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="97"/>
                <count group_id="O2" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Deaths</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Surgeries</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patients with MR &gt; 2+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Withdrawn/ Censored</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Durability of the MitraClip Device and Surgery.</title>
        <description>Device group: Freedom from death, surgery for mitral valve dysfunction and MR &gt; 2+ at the end of each follow-up interval.
Control group: Freedom from death, re-operation for mitral valve dysfunction and MR &gt; 2+ at the end of each follow-up interval.</description>
        <time_frame>18-24 months</time_frame>
        <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Device Group (MitraClip Device)</title>
            <description>Percutaneous mitral valve repair using MitraClip implant.</description>
          </group>
          <group group_id="O2">
            <title>Control Group (Mitral Valve Surgery)</title>
            <description>Mitral valve repair or replacement surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Durability of the MitraClip Device and Surgery.</title>
          <description>Device group: Freedom from death, surgery for mitral valve dysfunction and MR &gt; 2+ at the end of each follow-up interval.
Control group: Freedom from death, re-operation for mitral valve dysfunction and MR &gt; 2+ at the end of each follow-up interval.</description>
          <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Deaths</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Surgeries</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patients with MR &gt; 2+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Withdrawn/ Censored</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Durability of the MitraClip Device and Surgery.</title>
        <description>Device group: Freedom from death, surgery for mitral valve dysfunction and MR &gt; 2+ at the end of each follow-up interval.
Control group: Freedom from death, re-operation for mitral valve dysfunction and MR &gt; 2+ at the end of each follow-up interval.</description>
        <time_frame>24 months-3 year</time_frame>
        <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Device Group (MitraClip Device)</title>
            <description>Percutaneous mitral valve repair using MitraClip implant.</description>
          </group>
          <group group_id="O2">
            <title>Control Group (Mitral Valve Surgery)</title>
            <description>Mitral valve repair or replacement surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Durability of the MitraClip Device and Surgery.</title>
          <description>Device group: Freedom from death, surgery for mitral valve dysfunction and MR &gt; 2+ at the end of each follow-up interval.
Control group: Freedom from death, re-operation for mitral valve dysfunction and MR &gt; 2+ at the end of each follow-up interval.</description>
          <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="87"/>
                <count group_id="O2" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Deaths</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Surgeries</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patients with MR &gt; 2+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Withdrawn/ Censored</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52"/>
                    <measurement group_id="O2" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Freedom From Death, Mitral Valve Surgery/Re-operation and MR &gt; 2+</title>
        <description>Durability estimates: Freedom from Death, Mitral Valve Surgery/Re-operation and MR &gt; 2+</description>
        <time_frame>12 months</time_frame>
        <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Device Group (MitraClip Device)</title>
            <description>Percutaneous mitral valve repair using MitraClip implant.</description>
          </group>
          <group group_id="O2">
            <title>Control Group (Mitral Valve Surgery)</title>
            <description>Mitral valve repair or replacement surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Freedom From Death, Mitral Valve Surgery/Re-operation and MR &gt; 2+</title>
          <description>Durability estimates: Freedom from Death, Mitral Valve Surgery/Re-operation and MR &gt; 2+</description>
          <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="178"/>
                <count group_id="O2" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="110"/>
                    <measurement group_id="O2" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Freedom From Death, Mitral Valve Surgery/Re-operation and MR &gt; 2+</title>
        <description>Durability estimates: Freedom from Death, Mitral Valve Surgery/Re-operation and MR &gt; 2+</description>
        <time_frame>24 months</time_frame>
        <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Device Group (MitraClip Device)</title>
            <description>Percutaneous mitral valve repair using MitraClip implant.</description>
          </group>
          <group group_id="O2">
            <title>Control Group (Mitral Valve Surgery)</title>
            <description>Mitral valve repair or replacement surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Freedom From Death, Mitral Valve Surgery/Re-operation and MR &gt; 2+</title>
          <description>Durability estimates: Freedom from Death, Mitral Valve Surgery/Re-operation and MR &gt; 2+</description>
          <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="178"/>
                <count group_id="O2" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="101"/>
                    <measurement group_id="O2" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Freedom From Death, Mitral Valve Surgery/Re-operation and MR &gt; 2+</title>
        <description>Durability estimates: Freedom from Death, Mitral Valve Surgery/Re-operation and MR &gt; 2+</description>
        <time_frame>3 years</time_frame>
        <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Device Group (MitraClip Device)</title>
            <description>Percutaneous mitral valve repair using MitraClip implant.</description>
          </group>
          <group group_id="O2">
            <title>Control Group (Mitral Valve Surgery)</title>
            <description>Mitral valve repair or replacement surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Freedom From Death, Mitral Valve Surgery/Re-operation and MR &gt; 2+</title>
          <description>Durability estimates: Freedom from Death, Mitral Valve Surgery/Re-operation and MR &gt; 2+</description>
          <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="178"/>
                <count group_id="O2" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96"/>
                    <measurement group_id="O2" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Freedom From Mitral Valve Surgery/Re-operation</title>
        <description>Durability estimates: Freedom from Mitral Valve Surgery/Re-operation</description>
        <time_frame>12 months</time_frame>
        <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Device Group (MitraClip Device)</title>
            <description>Percutaneous mitral valve repair using MitraClip implant.</description>
          </group>
          <group group_id="O2">
            <title>Control Group (Mitral Valve Surgery)</title>
            <description>Mitral valve repair or replacement surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Freedom From Mitral Valve Surgery/Re-operation</title>
          <description>Durability estimates: Freedom from Mitral Valve Surgery/Re-operation</description>
          <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="178"/>
                <count group_id="O2" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="141"/>
                    <measurement group_id="O2" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Freedom From Mitral Valve Surgery/Re-operation</title>
        <description>Durability estimates: Freedom from Mitral Valve Surgery/Re-operation</description>
        <time_frame>24 months</time_frame>
        <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Device Group (MitraClip Device)</title>
            <description>Percutaneous mitral valve repair using MitraClip implant.</description>
          </group>
          <group group_id="O2">
            <title>Control Group (Mitral Valve Surgery)</title>
            <description>Mitral valve repair or replacement surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Freedom From Mitral Valve Surgery/Re-operation</title>
          <description>Durability estimates: Freedom from Mitral Valve Surgery/Re-operation</description>
          <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="178"/>
                <count group_id="O2" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="140"/>
                    <measurement group_id="O2" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Freedom From Mitral Valve Surgery/Re-operation</title>
        <description>Durability estimates: Freedom from Mitral Valve Surgery/Re-operation</description>
        <time_frame>3 years</time_frame>
        <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Device Group (MitraClip Device)</title>
            <description>Percutaneous mitral valve repair using MitraClip implant.</description>
          </group>
          <group group_id="O2">
            <title>Control Group (Mitral Valve Surgery)</title>
            <description>Mitral valve repair or replacement surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Freedom From Mitral Valve Surgery/Re-operation</title>
          <description>Durability estimates: Freedom from Mitral Valve Surgery/Re-operation</description>
          <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="178"/>
                <count group_id="O2" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="139"/>
                    <measurement group_id="O2" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Freedom From Mitral Valve Surgery/Re-operation</title>
        <description>Durability estimates: Freedom from Mitral Valve Surgery/Re-operation</description>
        <time_frame>4 years</time_frame>
        <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Device Group (MitraClip Device)</title>
            <description>Percutaneous mitral valve repair using MitraClip implant.</description>
          </group>
          <group group_id="O2">
            <title>Control Group (Mitral Valve Surgery)</title>
            <description>Mitral valve repair or replacement surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Freedom From Mitral Valve Surgery/Re-operation</title>
          <description>Durability estimates: Freedom from Mitral Valve Surgery/Re-operation</description>
          <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="178"/>
                <count group_id="O2" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="137"/>
                    <measurement group_id="O2" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Freedom From Mitral Valve Surgery/Re-operation</title>
        <description>Durability estimates: Freedom from Mitral Valve Surgery/Re-operation</description>
        <time_frame>5 years</time_frame>
        <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Device Group (MitraClip Device)</title>
            <description>Percutaneous mitral valve repair using MitraClip implant.</description>
          </group>
          <group group_id="O2">
            <title>Control Group (Mitral Valve Surgery)</title>
            <description>Mitral valve repair or replacement surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Freedom From Mitral Valve Surgery/Re-operation</title>
          <description>Durability estimates: Freedom from Mitral Valve Surgery/Re-operation</description>
          <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="178"/>
                <count group_id="O2" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="135"/>
                    <measurement group_id="O2" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Freedom From Death and Mitral Valve Surgery/Re-operation</title>
        <description>Durability estimates: Freedom from Death and Mitral Valve Surgery/Re-operation</description>
        <time_frame>12 months</time_frame>
        <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Device Group (MitraClip Device)</title>
            <description>Percutaneous mitral valve repair using MitraClip implant.</description>
          </group>
          <group group_id="O2">
            <title>Control Group (Mitral Valve Surgery)</title>
            <description>Mitral valve repair or replacement surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Freedom From Death and Mitral Valve Surgery/Re-operation</title>
          <description>Durability estimates: Freedom from Death and Mitral Valve Surgery/Re-operation</description>
          <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="178"/>
                <count group_id="O2" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="133"/>
                    <measurement group_id="O2" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Freedom From Death and Mitral Valve Surgery/Re-operation</title>
        <description>Durability estimates: Freedom from Death and Mitral Valve Surgery/Re-operation</description>
        <time_frame>24 months</time_frame>
        <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Device Group (MitraClip Device)</title>
            <description>Percutaneous mitral valve repair using MitraClip implant.</description>
          </group>
          <group group_id="O2">
            <title>Control Group (Mitral Valve Surgery)</title>
            <description>Mitral valve repair or replacement surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Freedom From Death and Mitral Valve Surgery/Re-operation</title>
          <description>Durability estimates: Freedom from Death and Mitral Valve Surgery/Re-operation</description>
          <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="178"/>
                <count group_id="O2" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="127"/>
                    <measurement group_id="O2" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Freedom From Death and Mitral Valve Surgery/Re-operation</title>
        <description>Durability estimates: Freedom from Death and Mitral Valve Surgery/Re-operation</description>
        <time_frame>3 years</time_frame>
        <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Device Group (MitraClip Device)</title>
            <description>Percutaneous mitral valve repair using MitraClip implant.</description>
          </group>
          <group group_id="O2">
            <title>Control Group (Mitral Valve Surgery)</title>
            <description>Mitral valve repair or replacement surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Freedom From Death and Mitral Valve Surgery/Re-operation</title>
          <description>Durability estimates: Freedom from Death and Mitral Valve Surgery/Re-operation</description>
          <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="178"/>
                <count group_id="O2" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="122"/>
                    <measurement group_id="O2" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Freedom From Death and Mitral Valve Surgery/Re-operation</title>
        <description>Durability estimates: Freedom from Death and Mitral Valve Surgery/Re-operation</description>
        <time_frame>4 years</time_frame>
        <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Device Group (MitraClip Device)</title>
            <description>Percutaneous mitral valve repair using MitraClip implant.</description>
          </group>
          <group group_id="O2">
            <title>Control Group (Mitral Valve Surgery)</title>
            <description>Mitral valve repair or replacement surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Freedom From Death and Mitral Valve Surgery/Re-operation</title>
          <description>Durability estimates: Freedom from Death and Mitral Valve Surgery/Re-operation</description>
          <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="178"/>
                <count group_id="O2" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="116"/>
                    <measurement group_id="O2" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Freedom From Death and Mitral Valve Surgery/Re-operation</title>
        <description>Durability estimates: Freedom from Death and Mitral Valve Surgery/Re-operation</description>
        <time_frame>5 years</time_frame>
        <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Device Group (MitraClip Device)</title>
            <description>Percutaneous mitral valve repair using MitraClip implant.</description>
          </group>
          <group group_id="O2">
            <title>Control Group (Mitral Valve Surgery)</title>
            <description>Mitral valve repair or replacement surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Freedom From Death and Mitral Valve Surgery/Re-operation</title>
          <description>Durability estimates: Freedom from Death and Mitral Valve Surgery/Re-operation</description>
          <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="178"/>
                <count group_id="O2" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="111"/>
                    <measurement group_id="O2" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With MitraClip Device Embolization/Single Leaflet Device Attachment</title>
        <description>Device Embolization is defined as the complete detachment of the MitraClip Device from one or both mitral leaflets. Single leaflet device attachment (SLDA) is defined as attachment of one mitral valve leaflet to the MitraClip device. The control group did not receive the MitraClip device.</description>
        <time_frame>12 months</time_frame>
        <population>The number of participants analyzed in device group includes subjects who had available follow up data at that time frame. Not applicable for Mitral valve surgery patients as device was not implanted.</population>
        <group_list>
          <group group_id="O1">
            <title>Device Group (MitraClip Device)</title>
            <description>Percutaneous mitral valve repair using MitraClip implant.</description>
          </group>
          <group group_id="O2">
            <title>Control Group (Mitral Valve Surgery)</title>
            <description>Mitral valve repair or replacement surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With MitraClip Device Embolization/Single Leaflet Device Attachment</title>
          <description>Device Embolization is defined as the complete detachment of the MitraClip Device from one or both mitral leaflets. Single leaflet device attachment (SLDA) is defined as attachment of one mitral valve leaflet to the MitraClip device. The control group did not receive the MitraClip device.</description>
          <population>The number of participants analyzed in device group includes subjects who had available follow up data at that time frame. Not applicable for Mitral valve surgery patients as device was not implanted.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="158"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Device Embolization</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Single Leaflet Device Attachment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With MitraClip Device Embolization/Single Leaflet Device Attachment</title>
        <description>Device Embolization is defined as the complete detachment of the MitraClip Device from one or both mitral leaflets. Single leaflet device attachment (SLDA) is defined as attachment of one mitral valve leaflet to the MitraClip device. The control group did not receive the MitraClip device</description>
        <time_frame>12 months to 3 years</time_frame>
        <population>The number of participants analyzed in device group includes subjects who had available follow up data at that time frame. Not applicable for Mitral valve surgery patients as device was not implanted.</population>
        <group_list>
          <group group_id="O1">
            <title>Device Group (MitraClip Device)</title>
            <description>Percutaneous mitral valve repair using MitraClip implant.</description>
          </group>
          <group group_id="O2">
            <title>Control Group (Mitral Valve Surgery)</title>
            <description>Mitral valve repair or replacement surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With MitraClip Device Embolization/Single Leaflet Device Attachment</title>
          <description>Device Embolization is defined as the complete detachment of the MitraClip Device from one or both mitral leaflets. Single leaflet device attachment (SLDA) is defined as attachment of one mitral valve leaflet to the MitraClip device. The control group did not receive the MitraClip device</description>
          <population>The number of participants analyzed in device group includes subjects who had available follow up data at that time frame. Not applicable for Mitral valve surgery patients as device was not implanted.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="158"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Device Embolization</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Single Leaflet Device Attachment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With MitraClip Device Embolization/Single Leaflet Device Attachment</title>
        <description>Device Embolization is defined as the complete detachment of the MitraClip Device from one or both mitral leaflets. Single leaflet device attachment (SLDA) is defined as attachment of one mitral valve leaflet to the MitraClip device. The control group did not receive the MitraClip device</description>
        <time_frame>12 months to 4 years</time_frame>
        <population>The number of participants analyzed in device group includes subjects who had available follow up data at that time frame. Not applicable for Mitral valve surgery patients as device was not implanted.</population>
        <group_list>
          <group group_id="O1">
            <title>Device Group (MitraClip Device)</title>
            <description>Percutaneous mitral valve repair using MitraClip implant.</description>
          </group>
          <group group_id="O2">
            <title>Control Group (Mitral Valve Surgery)</title>
            <description>Mitral valve repair or replacement surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With MitraClip Device Embolization/Single Leaflet Device Attachment</title>
          <description>Device Embolization is defined as the complete detachment of the MitraClip Device from one or both mitral leaflets. Single leaflet device attachment (SLDA) is defined as attachment of one mitral valve leaflet to the MitraClip device. The control group did not receive the MitraClip device</description>
          <population>The number of participants analyzed in device group includes subjects who had available follow up data at that time frame. Not applicable for Mitral valve surgery patients as device was not implanted.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="158"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Device Embolization</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Single Leaflet Device Attachment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With MitraClip Device Embolization/Single Leaflet Device Attachment</title>
        <description>Device Embolization is defined as the complete detachment of the MitraClip Device from one or both mitral leaflets. Single leaflet device attachment (SLDA) is defined as attachment of one mitral valve leaflet to the MitraClip device. The control group did not receive the MitraClip device</description>
        <time_frame>12 months to 5 years</time_frame>
        <population>The number of participants analyzed in device group includes subjects who had available follow up data at that time frame. Not applicable for Mitral valve surgery patients as device was not implanted.</population>
        <group_list>
          <group group_id="O1">
            <title>Device Group (MitraClip Device)</title>
            <description>Percutaneous mitral valve repair using MitraClip implant.</description>
          </group>
          <group group_id="O2">
            <title>Control Group (Mitral Valve Surgery)</title>
            <description>Mitral valve repair or replacement surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With MitraClip Device Embolization/Single Leaflet Device Attachment</title>
          <description>Device Embolization is defined as the complete detachment of the MitraClip Device from one or both mitral leaflets. Single leaflet device attachment (SLDA) is defined as attachment of one mitral valve leaflet to the MitraClip device. The control group did not receive the MitraClip device</description>
          <population>The number of participants analyzed in device group includes subjects who had available follow up data at that time frame. Not applicable for Mitral valve surgery patients as device was not implanted.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="158"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Device Embolization</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Single Leaflet Device Attachment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Non-cerebral Thromboembolism.</title>
        <description>Defined as any thrombus or thromboembolism in the vasculature (excluding central nervous system events) or on the investigational device or any commercially available implant used during surgery confirmed by standard clinical and laboratory testing and which requires treatment.</description>
        <time_frame>12 months</time_frame>
        <population>ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>Device Group (MitraClip Device)</title>
            <description>Percutaneous mitral valve repair using MitraClip implant.</description>
          </group>
          <group group_id="O2">
            <title>Control Group (Mitral Valve Surgery)</title>
            <description>Mitral valve repair or replacement surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Non-cerebral Thromboembolism.</title>
          <description>Defined as any thrombus or thromboembolism in the vasculature (excluding central nervous system events) or on the investigational device or any commercially available implant used during surgery confirmed by standard clinical and laboratory testing and which requires treatment.</description>
          <population>ITT population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="184"/>
                <count group_id="O2" value="95"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With MR Severity</title>
        <description>MR Severity of 0: None,1+: Mild, 2+: Moderate, 3+: Moderate-to-Severe, 4+: Severe.
“Discharge” refers to each individual patient’s date of hospital discharge. The discharge date varies for each patient, but in general, discharge occurs before 30-days follow-up. A 30-day echocardiogram will be used if the discharge echocardiogram is unavailable or otherwise uninterpretable.</description>
        <time_frame>30 days</time_frame>
        <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Device Group (MitraClip Device)</title>
            <description>Percutaneous mitral valve repair using MitraClip implant.</description>
          </group>
          <group group_id="O2">
            <title>Control Group (Mitral Valve Surgery)</title>
            <description>Mitral valve repair or replacement surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With MR Severity</title>
          <description>MR Severity of 0: None,1+: Mild, 2+: Moderate, 3+: Moderate-to-Severe, 4+: Severe.
“Discharge” refers to each individual patient’s date of hospital discharge. The discharge date varies for each patient, but in general, discharge occurs before 30-days follow-up. A 30-day echocardiogram will be used if the discharge echocardiogram is unavailable or otherwise uninterpretable.</description>
          <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="173"/>
                <count group_id="O2" value="76"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>0: None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1+:Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89"/>
                    <measurement group_id="O2" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2+: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3+: Moderate-to-Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4+: Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With MR Severity</title>
        <description>MR Severity of 0: None,1+: Mild, 2+: Moderate, 3+: Moderate-to-Severe, 4+: Severe</description>
        <time_frame>12 months</time_frame>
        <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Device Group (MitraClip Device)</title>
            <description>Percutaneous mitral valve repair using MitraClip implant.</description>
          </group>
          <group group_id="O2">
            <title>Control Group (Mitral Valve Surgery)</title>
            <description>Mitral valve repair or replacement surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With MR Severity</title>
          <description>MR Severity of 0: None,1+: Mild, 2+: Moderate, 3+: Moderate-to-Severe, 4+: Severe</description>
          <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="149"/>
                <count group_id="O2" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>0: None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1+:Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55"/>
                    <measurement group_id="O2" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2+: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3+: Moderate-to-Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4+: Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With MR Severity</title>
        <description>MR Severity of 0: None,1+: Mild, 2+: Moderate, 3+: Moderate-to-Severe, 4+: Severe</description>
        <time_frame>24 months</time_frame>
        <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Device Group (MitraClip Device)</title>
            <description>Percutaneous mitral valve repair using MitraClip implant.</description>
          </group>
          <group group_id="O2">
            <title>Control Group (Mitral Valve Surgery)</title>
            <description>Mitral valve repair or replacement surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With MR Severity</title>
          <description>MR Severity of 0: None,1+: Mild, 2+: Moderate, 3+: Moderate-to-Severe, 4+: Severe</description>
          <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="127"/>
                <count group_id="O2" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>0: None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1+: Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                    <measurement group_id="O2" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2+: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3+: Moderate-to-Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4+: Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With MR Severity</title>
        <description>MR Severity of 0: None,1+: Mild, 2+: Moderate, 3+: Moderate-to-Severe, 4+: Severe</description>
        <time_frame>3 years</time_frame>
        <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Device Group (MitraClip Device)</title>
            <description>Percutaneous mitral valve repair using MitraClip implant.</description>
          </group>
          <group group_id="O2">
            <title>Control Group (Mitral Valve Surgery)</title>
            <description>Mitral valve repair or replacement surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With MR Severity</title>
          <description>MR Severity of 0: None,1+: Mild, 2+: Moderate, 3+: Moderate-to-Severe, 4+: Severe</description>
          <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="122"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>0: None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1+:Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45"/>
                    <measurement group_id="O2" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2+: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3+: Moderate-to-Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4+: Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With MR Severity</title>
        <description>MR Severity of 0: None,1+: Mild, 2+: Moderate, 3+: Moderate-to-Severe, 4+: Severe</description>
        <time_frame>4 years</time_frame>
        <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Device Group (MitraClip Device)</title>
            <description>Percutaneous mitral valve repair using MitraClip implant.</description>
          </group>
          <group group_id="O2">
            <title>Control Group (Mitral Valve Surgery)</title>
            <description>Mitral valve repair or replacement surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With MR Severity</title>
          <description>MR Severity of 0: None,1+: Mild, 2+: Moderate, 3+: Moderate-to-Severe, 4+: Severe</description>
          <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="105"/>
                <count group_id="O2" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>0: None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1+:Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41"/>
                    <measurement group_id="O2" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2+: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3+: Moderate-to-Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4+: Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With MR Severity</title>
        <description>MR Severity of 0: None,1+: Mild, 2+: Moderate, 3+: Moderate-to-Severe, 4+: Severe</description>
        <time_frame>5 years</time_frame>
        <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Device Group (MitraClip Device)</title>
            <description>Percutaneous mitral valve repair using MitraClip implant.</description>
          </group>
          <group group_id="O2">
            <title>Control Group (Mitral Valve Surgery)</title>
            <description>Mitral valve repair or replacement surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With MR Severity</title>
          <description>MR Severity of 0: None,1+: Mild, 2+: Moderate, 3+: Moderate-to-Severe, 4+: Severe</description>
          <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="106"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>0: None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1+:Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49"/>
                    <measurement group_id="O2" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2+: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3+: Moderate-to-Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4+: Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Non-cerebral Thromboembolism.</title>
        <description>Defined as any thrombus or thromboembolism in the vasculature (excluding central nervous system events) or on the investigational device or any commercially available implant used during surgery confirmed by standard clinical and laboratory testing and which requires treatment.</description>
        <time_frame>30 days</time_frame>
        <population>ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>Device Group (MitraClip Device)</title>
            <description>Percutaneous mitral valve repair using MitraClip implant.</description>
          </group>
          <group group_id="O2">
            <title>Control Group (Mitral Valve Surgery)</title>
            <description>Mitral valve repair or replacement surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Non-cerebral Thromboembolism.</title>
          <description>Defined as any thrombus or thromboembolism in the vasculature (excluding central nervous system events) or on the investigational device or any commercially available implant used during surgery confirmed by standard clinical and laboratory testing and which requires treatment.</description>
          <population>ITT population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="184"/>
                <count group_id="O2" value="95"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Incidence of Mitral Valve Replacement</title>
        <time_frame>12 months</time_frame>
        <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Device Group (MitraClip Device)</title>
            <description>Percutaneous mitral valve repair using MitraClip implant.</description>
          </group>
          <group group_id="O2">
            <title>Control Group (Mitral Valve Surgery)</title>
            <description>Mitral valve repair or replacement surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Incidence of Mitral Valve Replacement</title>
          <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="158"/>
                <count group_id="O2" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Incidence of Mitral Valve Replacement</title>
        <time_frame>24 months</time_frame>
        <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Device Group (MitraClip Device)</title>
            <description>Percutaneous mitral valve repair using MitraClip implant.</description>
          </group>
          <group group_id="O2">
            <title>Control Group (Mitral Valve Surgery)</title>
            <description>Mitral valve repair or replacement surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Incidence of Mitral Valve Replacement</title>
          <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="167"/>
                <count group_id="O2" value="84"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>5 years</time_frame>
      <desc>The EVEREST II RCT enrolled 279 patients (184 Device and 95 Control), of whom 21 patients (6 Device and 15 Control) did not undergo treatment per their randomized assignment, and are reported as &quot;randomized not treated&quot; (RNT). Therefore, the Adverse Event was evaluated in 178 patients in Device group and 80 patients in Control group.</desc>
      <group_list>
        <group group_id="E1">
          <title>Device Group (MitraClip Device)</title>
          <description>Percutaneous mitral valve repair using MitraClip implant.</description>
        </group>
        <group group_id="E2">
          <title>Control Group (Mitral Valve Surgery)</title>
          <description>Mitral valve repair or replacement surgery.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 11.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="127" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="54" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="20" subjects_affected="16" subjects_at_risk="178"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Coagulopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Infection/bacteremia/septicemia</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="178"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Hematologic:Other</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="178"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="178"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Hemolysis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA 10.0">Mitral Valve (MV) surgery</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>cardiac-single leaflet device attachment (SLDA)</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="178"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Tamponade</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="178"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Atrial arrhythmia</sub_title>
                <counts group_id="E1" events="37" subjects_affected="30" subjects_at_risk="178"/>
                <counts group_id="E2" events="12" subjects_affected="9" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Atrial septal defect</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="178"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Bradyarrhythmia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="178"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="178"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Cardiomyopathy</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="178"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Chest pain/angina</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="178"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Congestive heart failure</sub_title>
                <counts group_id="E1" events="31" subjects_affected="19" subjects_at_risk="178"/>
                <counts group_id="E2" events="23" subjects_affected="10" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Endocarditis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="178"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Heart block</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="178"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Lead displacement</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="178"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Left ventricular dysfunction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Mitral valve injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="178"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Cardiac:Other</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="178"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Cardiac:Other rhythm disorder</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="178"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="178"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Peripheral edema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Residual/recurrent mitral regurgitation (MR)</sub_title>
                <counts group_id="E1" events="21" subjects_affected="21" subjects_at_risk="178"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Supraventricular arrhythmia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="178"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Syncope/dizziness</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="178"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Thrombus</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="178"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Ventricular arrhythmia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="178"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Cardiogenic shock</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="178"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Gastro intestinal related:Bleed</sub_title>
                <counts group_id="E1" events="13" subjects_affected="10" subjects_at_risk="178"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Gastro intestinal related:Infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="178"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Gastro intestinal related:Other</sub_title>
                <counts group_id="E1" events="24" subjects_affected="20" subjects_at_risk="178"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="20" subjects_affected="20" subjects_at_risk="178"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Generalized weakness/fatigue:other</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="178"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" events="29" subjects_affected="23" subjects_at_risk="178"/>
                <counts group_id="E2" events="10" subjects_affected="7" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Incisional site pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection:Other</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="178"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Metabolic/endocrine disorders:Other</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="178"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Connective tissue disorders</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="178"/>
                <counts group_id="E2" events="7" subjects_affected="5" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA 10.0">Transient ischemic attack (TIA)</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="178"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Intracerebral hemorrhage</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="178"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Neurologic:Other</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="178"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Neurologic:Stroke</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="178"/>
                <counts group_id="E2" events="9" subjects_affected="3" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Ischemic stroke</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Mental disorders:Other</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="178"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal-Infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="178"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Renal-Other</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="178"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Renal insufficiency/failure</sub_title>
                <counts group_id="E1" events="13" subjects_affected="12" subjects_at_risk="178"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease (COPD)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Bronchial/lung disorders</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="178"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Respiratory:Other</sub_title>
                <counts group_id="E1" events="13" subjects_affected="8" subjects_at_risk="178"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="178"/>
                <counts group_id="E2" events="6" subjects_affected="4" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="178"/>
                <counts group_id="E2" events="10" subjects_affected="7" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Pulmonary edema</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="178"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="178"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="15" subjects_affected="13" subjects_at_risk="178"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Hemothorax</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin/mucosal/subcutaneous tissue disorders:other</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Arteriovenous (AV) fistula</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis (DVT)</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="178"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Peripheral Ischemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Bleeding complication</sub_title>
                <counts group_id="E1" events="17" subjects_affected="16" subjects_at_risk="178"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Blood pressure complication</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="178"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Bruise/contusion/ecchymosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Hematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Hemodynamic instability</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="178"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Vascular:Injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Vascular:Other</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="178"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Pseudoaneurysm</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="178"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="178"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Vascular:Shock</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 11.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="168" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="80" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="37" subjects_affected="32" subjects_at_risk="178"/>
                <counts group_id="E2" events="32" subjects_affected="28" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Hemolysis</sub_title>
                <counts group_id="E1" events="15" subjects_affected="11" subjects_at_risk="178"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="178"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Hematologic:Other</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA 10.0">Atrial arrhythmia</sub_title>
                <counts group_id="E1" events="37" subjects_affected="23" subjects_at_risk="178"/>
                <counts group_id="E2" events="33" subjects_affected="27" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Bradyarrhythmia</sub_title>
                <counts group_id="E1" events="16" subjects_affected="14" subjects_at_risk="178"/>
                <counts group_id="E2" events="8" subjects_affected="6" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Chest pain/angina</sub_title>
                <counts group_id="E1" events="41" subjects_affected="33" subjects_at_risk="178"/>
                <counts group_id="E2" events="14" subjects_affected="11" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Congestive heart failure</sub_title>
                <counts group_id="E1" events="22" subjects_affected="15" subjects_at_risk="178"/>
                <counts group_id="E2" events="13" subjects_affected="11" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Myocardial ischemia</sub_title>
                <counts group_id="E1" events="21" subjects_affected="19" subjects_at_risk="178"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Cardiac:Other rhythm disorder</sub_title>
                <counts group_id="E1" events="21" subjects_affected="19" subjects_at_risk="178"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="178"/>
                <counts group_id="E2" events="9" subjects_affected="5" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Peripheral edema</sub_title>
                <counts group_id="E1" events="28" subjects_affected="25" subjects_at_risk="178"/>
                <counts group_id="E2" events="26" subjects_affected="23" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Residual/recurrent mitral regurgitation (MR)</sub_title>
                <counts group_id="E1" events="34" subjects_affected="29" subjects_at_risk="178"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Syncope/dizziness</sub_title>
                <counts group_id="E1" events="51" subjects_affected="38" subjects_at_risk="178"/>
                <counts group_id="E2" events="18" subjects_affected="16" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Ventricular arrhythmia</sub_title>
                <counts group_id="E1" events="12" subjects_affected="9" subjects_at_risk="178"/>
                <counts group_id="E2" events="12" subjects_affected="10" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Cardiomyopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Left ventricular dysfunction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Cardiac:Other</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" events="15" subjects_affected="12" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>mitral stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA 10.0">Gastrointestinal:Other</sub_title>
                <counts group_id="E1" events="119" subjects_affected="79" subjects_at_risk="178"/>
                <counts group_id="E2" events="81" subjects_affected="48" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Gastrointestinal-Bleed</sub_title>
                <counts group_id="E1" events="13" subjects_affected="10" subjects_at_risk="178"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="19" subjects_affected="17" subjects_at_risk="178"/>
                <counts group_id="E2" events="14" subjects_affected="13" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Generalized weakness/fatigue</sub_title>
                <counts group_id="E1" events="43" subjects_affected="32" subjects_at_risk="178"/>
                <counts group_id="E2" events="30" subjects_affected="25" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Incisional site pain</sub_title>
                <counts group_id="E1" events="60" subjects_affected="49" subjects_at_risk="178"/>
                <counts group_id="E2" events="53" subjects_affected="49" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" events="133" subjects_affected="78" subjects_at_risk="178"/>
                <counts group_id="E2" events="60" subjects_affected="35" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Metabolic/endocrine disorders:other</sub_title>
                <counts group_id="E1" events="73" subjects_affected="49" subjects_at_risk="178"/>
                <counts group_id="E2" events="58" subjects_affected="38" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Connective tissue disorders:other</sub_title>
                <counts group_id="E1" events="114" subjects_affected="76" subjects_at_risk="178"/>
                <counts group_id="E2" events="44" subjects_affected="26" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Transient ischemic attack (TIA)</sub_title>
                <counts group_id="E1" events="12" subjects_affected="11" subjects_at_risk="178"/>
                <counts group_id="E2" events="10" subjects_affected="9" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Neurologic:Other</sub_title>
                <counts group_id="E1" events="21" subjects_affected="16" subjects_at_risk="178"/>
                <counts group_id="E2" events="17" subjects_affected="14" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Mental disorders:other</sub_title>
                <counts group_id="E1" events="35" subjects_affected="28" subjects_at_risk="178"/>
                <counts group_id="E2" events="32" subjects_affected="25" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal:Infection</sub_title>
                <counts group_id="E1" events="16" subjects_affected="10" subjects_at_risk="178"/>
                <counts group_id="E2" events="12" subjects_affected="9" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Renal-Other</sub_title>
                <counts group_id="E1" events="22" subjects_affected="19" subjects_at_risk="178"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Renal insufficiency/failure</sub_title>
                <counts group_id="E1" events="15" subjects_affected="10" subjects_at_risk="178"/>
                <counts group_id="E2" events="11" subjects_affected="9" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bronchial/lung disorders</sub_title>
                <counts group_id="E1" events="21" subjects_affected="19" subjects_at_risk="178"/>
                <counts group_id="E2" events="24" subjects_affected="22" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Respiratory:Infection</sub_title>
                <counts group_id="E1" events="22" subjects_affected="18" subjects_at_risk="178"/>
                <counts group_id="E2" events="11" subjects_affected="10" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Respiratory:Other</sub_title>
                <counts group_id="E1" events="115" subjects_affected="79" subjects_at_risk="178"/>
                <counts group_id="E2" events="45" subjects_affected="30" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="25" subjects_affected="19" subjects_at_risk="178"/>
                <counts group_id="E2" events="31" subjects_affected="27" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Pulmonary edema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" events="8" subjects_affected="6" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Pulmonary hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin/mucosal/subcutaneous tissue disorders:other</sub_title>
                <counts group_id="E1" events="19" subjects_affected="14" subjects_at_risk="178"/>
                <counts group_id="E2" events="7" subjects_affected="5" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Bleeding complication</sub_title>
                <counts group_id="E1" events="73" subjects_affected="62" subjects_at_risk="178"/>
                <counts group_id="E2" events="18" subjects_affected="17" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Blood pressure complication</sub_title>
                <counts group_id="E1" events="23" subjects_affected="19" subjects_at_risk="178"/>
                <counts group_id="E2" events="18" subjects_affected="14" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Bruise/contusion/ecchymosis</sub_title>
                <counts group_id="E1" events="32" subjects_affected="26" subjects_at_risk="178"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Hematoma</sub_title>
                <counts group_id="E1" events="29" subjects_affected="26" subjects_at_risk="178"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Hemodynamic instability</sub_title>
                <counts group_id="E1" events="55" subjects_affected="45" subjects_at_risk="178"/>
                <counts group_id="E2" events="31" subjects_affected="27" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Vascular:Other</sub_title>
                <counts group_id="E1" events="11" subjects_affected="9" subjects_at_risk="178"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Blood transfusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chithra Sangli</name_or_title>
      <organization>Abbott Vascular Structural Heart (formerly Evalve, Inc.)</organization>
      <phone>650-421-6994</phone>
      <email>chithra.sangli@av.abbott.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

